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This thesis details the current methods for meta-selective C-H functionalisation and 
contains three chapters relating to the area of ruthenium catalysed meta selective 
functionalisation by σ-activation. 
 
The first of which contains a published manuscript entitled “Catalytic meta-selective C-H 
functionalization to construct quaternary carbon centres” and describes a meta selective 
tertiary alkylation procedure on 2-phenylpyridine substrates. Key findings from this work 
provide good evidence for a radical based mechanism and proposes a catalytic cycle 
involving two distinct roles for the ruthenium catalyst; both in the activation of the substrate 
molecule and in the formation of a tertiary radical coupling partner.  
 
The second chapter contains another published manuscript entitled “Mechanistic insight 
into ruthenium catalysed meta-sulfonation of 2-phenylpyridine” and provides mechanistic 
analysis for the meta selective sulfonation of 2-phenylpyridine. Key findings from this work 
show through stoichiometric experiments that sulfonation occurs at the position para to the 
C-Ru bond formed following cyclometalation with a radical addition being implied. The work 
also shows that the catalytic species involved do not require an arene ligand and deuterium 
labelling studies identified a likely rate limiting radical sulfonation step. 
 
The final chapter contains additional work relating to the use of α-halo carbonyl coupling 
reagents to enable meta selective primary, secondary and tertiary alkylations. The use of a 
triphenylphosphine ligand source was necessary for the coupling of primary α-halo carbonyl 
coupling partners at the meta position. Crucially, this transformation was not possible with 
simple, straight-chain alkyl halides, highlighting the privileged reactivity of α-halo carbonyl 
coupling reagents. This work also contains experimental and computational mechanistic 
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1.1 Overview of C-H Functionalisation  
1.1.1 What? Why? and challenges 
The direct selective activation and functionalisation of C-H bonds within an organic molecule 
has challenged synthetic chemists for decades. Whereas traditional synthetic 
methodologies for the construction of complex organic molecules rely predominantly on 
employing two complimentary reactive functional groups to generate new C-C or C-X 
bonds, direct C-H functionalisation instead utilises one (or more) C-H bonds as functional 
groups. There are a number of benefits of such an approach to synthetic chemistry. From 
a green chemistry perspective, step and atom economy can be significantly improved by 
negating the need to prepare two functionalised reagents or perform functional group 
interconversions. This can lead to particularly efficient processes as step economy is 
usually the dominant measure of synthetic efficiency.1 In the context of target orientated 
synthesis and drug discovery, selective C-H bond functionalisation can also create new 
synthetic disconnections, leading to new strategies for preparing complex molecules and 
developing libraries of structurally analogous compounds. 
 
While the benefits are apparent, there are intrinsic challenges associated with the selective 
functionalisation of C-H bonds. These challenges stem predominantly from the fact that C-
H bonds are both ubiquitous within an organic molecule, and generally unreactive when 
compared to other functional groups. As such, functionalising one C-H bond selectively in 
the presence of many C-H bonds and functional groups in a molecule has been at the 
forefront of research into the area over the last decade.2–7 Overcoming these challenges is 
not straightforward. Nevertheless, there exist many examples in both traditional and modern 
synthetic methodology whereby a C-H bond can be directly functionalised. These strategies 
can be broadly categorised by utilising either “innate” or “chelate assisted” reactivity.  
1.1.2 How? innate reactivity 
The innate reactivity of a C-H bond depends on both its electronic environment as well as 
any steric influences within the molecule. Early examples of selective C-H functionalisation 
via its innate reactivity include electrophilic aromatic substitution on both simple aromatics 
and heteroaromatics, free radical additions and deprotonations of acidic C-H bonds. 
Functionalised products can therefore be achieved through direct reaction with common 




A number of modern transformations have also been achieved that exploit the innate 
reactivity of C-H bonds by homogeneous insertion of a transition metal. Again, these 
strategies rely on the most reactive C-H bond being either the one that is the most sterically 
available, the most electron rich, electron poor, or the most acidic. This approach to C-H 
functionalisation has been covered in a number of recent reviews and has been shown to 
be an effective strategy for the synthesis of complex organic molecules and natural 
products.2,8,9 
1.1.3 How? chelate assisted 
The chelation assisted approach to C-H functionalisation overcomes the molecules innate 
reactivity by utilising pre-existing functional groups (directing groups) within a molecule to 
coordinate to a transition metal complex and position it for selective C-H bond cleavage. 
This type of reactivity overcomes the issues with reactivity and selectivity associated with 
multiple C-H bonds in a molecule by increasing the effective concentration of the transition 
metal complex in the vicinity of a particular C-H bond. This approach typically results in the 
formation of a conformationally stable 5 or 6 membered cyclometalated species that can be 
subsequently functionalised as part of a catalytic cycle to form new C-C and C-X bonds. 
The key mechanistic step of these reactions involves initial coordination of the directing 
group to a transition metal complex followed by a metal mediated C-H bond cleavage.  
 
There are a number of pathways by which a transition metal complex can cleave a C-H 
bond. These include oxidative addition, concerted metalation−deprotonation (CMD), σ bond 
metathesis, electrophilic addition to a π system or abstraction of a hydrogen atom.10 Of 
these, oxidative additions and CMD mechanisms have become the most widely applicable 
for further functionalisation (Scheme 1-1). 
 
 
Scheme 1-1: Cyclometalation via an oxidative addition or CMD pathway. 
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 An oxidative addition is a process that increases both the oxidation state and coordination 
number of a metal centre and is typical for electron rich, low valent complexes of late 
transition metals. In C-H activation reactions this proceeds in a concerted manner with the 
oxidation state and coordination number of the metal increasing by 2. The active catalyst 
for this type of mechanism must be coordinatively unsaturated and is usually unstable. 
Therefore, they are often formed in situ from a stable precatalyst. In a concerted metalation-
deprotonation pathway, both the metal and a base are implicated in the abstraction of the 
C-H proton. This occurs via a simultaneous metalation / intramolecular deprotonation with 
no net oxidation state change of the metal. The base implicit in the deprotonation can be a 
pre-existing ligand of the catalyst or can become coordinated under the reaction conditions 
and are typically carboxylates or carbonates.  
  
These mechanisms result in conformationally stable metallacycles and have been proven 
to activate sp2 aryl and vinyl C-H bonds as well as sp3 alkyl C-H bonds. The following review 
will focus on the activation and functionalisation of aryl C-H bonds. 
 
1.2 Ortho functionalisation 
The utilisation of a directing group in a molecule to direct reactions to an ortho C-H bond 
has now been demonstrated with a wide range of transformations. These types of reactions 
have been covered extensively in a number of recent reviews7,6,5,4,3,2 so the following 
sections will show selected examples of some typical mechanisms associated with ortho 
selective C-H functionalisation reactions as well as a summary of many of the 
transformations performed to date.  
1.2.1 Mechanisms for catalysis 
Although transition metal mediated C-H bond cleavage and cyclometalation is a 
fundamental step in directed C-H functionalisation, a number of other conditions must be 
met for it to be developed into a synthetically useful catalytic methodology. A balance must 
be struck between a cyclometalated intermediate that is both stable enough to form in the 
first instance; which is usually governed by geometry; and yet must also be reactive enough 
to react further with a coupling partner.  
 
Despite these requirements, a great number of catalytic transformations have been reported 
in recent years. These reactions often draw upon contemporary knowledge of 
organometallic mechanisms to generate closed catalytic cycles where the substrate is 
functionalised. In most cases a cyclometalated intermediate formed by one of the 
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mechanisms summarised in section 1.1.2 forms an integral part of the mechanism. These 
processes may also require the use of stoichiometric oxidants in order for them to be 
catalytic and depends on the nature of the cyclometalation step and the manner in which 
the coupling partner interacts with the metal centre. Some common catalytic mechanisms 
are summarized in Figure 1-1 however new transformations are continuing to challenge 




Figure 1-1: Some common catalytic mechanisms for ortho C-H bond functionalisation. 
1.2.2 Summary of ortho selective transformations 
The resurgence of interest into the area of C-H functionalisation in recent years has led to 
a vast number of new chemical transformations. Many of these utilise a directing group 
strategy, the majority of which leading to ortho and di-ortho substituted products. These 
transformations have been achieved using a range of metals whereby the most extensively 
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studied metals have been precious metals such as palladium,11,12 rhodium13 and 
ruthenium,14,15,16 however an ever growing number of transformations are beginning to be 
made using earth abundant metals such as cobalt,17 nickel18 and copper.19 The 
transformations achieved to date include a number of C-C bond forming reactions including 
acylations, arylations, alkylations, alkenyations, annulations and cyanations as well as a 
number of C-Heteroatom tranformations including aminations, silylations, nitrations, 




Figure 1-2: Summary of ortho C-H functionalisations. 
 
A range of directing groups have also been widely demonstrated. Traditionally, these have 
been achieved using strongly Lewis basic functional groups which facilitate the 
cyclometalation step common to many directed C-H functionalisation reactions. Many 
examples of these include strongly coordinating heterocycles, however it is the stability of 
these complexes that can make them synthetically restrictive. Coordination via weaker, 
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more common directing groups such as carboxylic acids, alcohols or amines has therefore 




Figure 1-3: Examples of commonly used strong and weak directing groups. 
 
Much contemporary research into developing new broadly useful C-H functionalisations has 
been associated with the design of new directing groups that are readily removed or 
converted into useful functionality. This has led to strategies that incorporate directing group 
auxiliaries which can be readily installed and removed, or traceless directing groups that 
achieve the same result under the reaction conditions with no additional synthetic steps. 





1.3 Overcoming ortho selectivity: meta selective C-H functionalisation 
The application of the directing group strategy for C-H functionalisation has led to enormous 
success in the ortho functionalisation of arenes. Key to this success is the facile formation 
of 5 or 6 membered metallacycles for subsequent transformations as these intermediates 
are energetically and conformationally stable. However, when devising strategies to activate 
more remote C-H bonds, for example the position meta to a directing group, this approach 
becomes increasingly challenging as ring size increases and conformational stability 
decreases. As a result, existing approaches have adapted and new strategies have 
emerged to enable new reactions with complementary meta selectivity. 
 
1.3.1 Intrinsic control: Steric and electronic 
Among the first examples of meta selective C-H functionalisation were cases where the 
regioselectivity was governed by intrinsic properties of the substrate. Direct meta 
substitution by steric control was first reported by Hartwig et al.20,21 and Smith et al.22 who 
demonstrated a one pot Ir catalysed meta C-H borylation / functionalisation procedure for 
1,3-disubstituted arenes. This approach demonstrated the selective borylation of sterically 
unhindered C-H bonds within substituted aromatics by iridium(III) catalysis with the capacity 




Scheme 1-2: Concept for sterically controlled C-H functionalisation.  
 
Since this seminal work, a number of other transformations have been reported that utilise 
this sterically controlled iridium catalysed borylation / palladium catalysed coupling 
procedure to achieve one pot arylations,22 alkylations23 (Scheme 1-3) and iodinations.24 In 
addition to this, direct sterically controlled functionalisations have also been achieved using 
palladium25 and rhodium26 catalysis. Selectivity for the meta position in these reactions is 
governed by the steric bulk of the prefunctionalised substrate and therefore usually limits 







Scheme 1-3: Sterically controlled C-H borylation / alkylation.  
 
Exploiting the intrinsic electronic effects of a substrate has also led to a number of direct 
functionalisations with high meta selectivity. An early example of this was reported by Yu et 
al. who demonstrated a directing group free olefination of electron deficient arenes27 
(Scheme 1-4). Key to this reactivity was the use of branched 2,6 disubstituted pyridine 
ligands which the authors proposed could promote reoxidation of palladium(0) by O2 whilst 





Scheme 1-4: Electronic controlled C-H olefination.  
 
Since this work, a number of electronically governed palladium catalysed transformations 
have been achieved, including acetoxylations,28 olefinations29 and imidations.30 
Furthermore, gold31 and rhodium32 catalysis has enabled meta selective arylations by 
similar electronic biases. An interesting example has also been achieved using copper 
catalysis by Gaunt et al. who reported on the first meta selective copper catalysed C-H 
arylation.33 This was initially proposed to go via a mechanism as per Scheme 1-5. However, 
a more recent mechanistic study has cast doubt on this hypothesis, as this reaction works 
in the absence of copper albeit at higher temperatures.34 This suggests that this is more 
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likely an intrinsic electronic property of the substrates used and the authors now propose 




Scheme 1-5: Initial proposed mechanism for Cu catalysed meta selective direct C-H 
arylation. 
  
Exploiting intrinsic properties of a molecule has enabled a range of transformations to be 
achieved on a number of different structural motifs. Because of their intrinsic bias, selectivity 
can be high, although this approach is fundamentally limited in substrate scope. The search 
for a more general methodology to access meta C-H bonds has therefore attracted 
significant interest. 
1.3.2 Directing group assisted: Extended template approach 
One of the major issues in developing directed C-H functionalisation reactions beyond the 
ortho position to a directing group is that the corresponding cyclometalated intermediates, 
which are paramount to their reactivity, are considerably less likely to form and be 
sufficiently stable to react. Among the first solutions to this issue came from Yu et al. who 
were the first to develop removable “templates” that could be installed to common functional 
groups and that would result in a conformationally stable cyclometalated complex akin to 
those demonstrated in ortho selective reactions. These templates were rationally designed 
with end-on nitrile containing coordinating groups (Figure 1-4). Weak coordination could 
therefore alleviate the ring strain of the resulting cyclophane-like pre-transition state and 
can hence form conformationally stable metallacycles. This pioneering work enabled 
access to meta alkenylated toluene and hydrocinammic acid derivatives following removal 









Scheme 1-6: Template assisted meta olefination and subsequent recovery.35 
 
Since this initial report, a number of research groups including those headed by Yu, Tan, Li 
and Maiti have further utilised nitrile containing templates for the synthesis of meta 
substituted aromatic alcohol,36,37,38 amine,39,40,41 tolyl,35,38 phosphonate,42 aldehyde,38 
sulfonic acid,43,44 and carboxylic acid35,45,46,47,48 derivatives by a range of cleavable linkages 
to enable direct meta selective olefinations,35,36,37,46,39,40,43,47,41,42,48 arylations,45,40 
acetoxylations39,40,48 and hydroxylations42,44 with the potential for further synthetic 
elaborations. A summary of the transformations by this approach achieved to date is given 





Figure 1-5: Removable “templates” developed for meta functionalisation. 
 
Nitrile containing templates have therefore enabled an ever growing number of meta 
selective transformations. However, the use of such a weakly coordinating directing group 
does have some intrinsic limitations. These include competing coordination from other 
functional groups or solvents as well as the variable binding modes of nitrile groups, 
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affording potentially undesired switches in selectivity.41 In response to this, Yu et al.49 have 
developed templates that incorporate more strongly coordinating pyridine groups. These 
templates overcome some of the limitations of nitrile groups and have successfully enabled 
alkenylations and iodinations on benzyl alcohol and phenylethyl alcohol derivatives via a 




Figure 1-6: Template using coordinating pyridine group. 
 
The “covalent template” approach to direct meta functionalisation offers an elegant solution 
for accessing distal C-H bonds, an approach which has also been demonstrated on the 
functionalisation of para C-H bonds.50 However, despite the growing success in the area, 
this approach suffers from intrinsic drawbacks, particularly when step and atom economy 
are considered. Many of the templates reported to date have relatively elaborate structures 
and may require a multistep synthesis. When coupled with the synthetic steps necessary 
for the installation and removal of the template, the overall atom and step economy, that 
makes C-H functionalisation an attractive methodology in the first instance, is considerably 
diminished. Furthermore, this approach also suffers from drawbacks common to ortho 
functionalisation whereby potentially undesired di-meta substituted products can be formed. 
Nevertheless, this approach serves as a useful tool for accessing previously unknown 
disconnections by utilising common functional groups. 
 
1.3.3 Removable and “traceless” directing group approach 
An alternative approach to accessing meta substituted arenes is by using directing groups 
that can be readily removed following a transformation. Initially, this was demonstrated on 
substituted arenes in two step processes such that meta substituted products resulted 






Figure 1-7: Concept for removable directing group approach. 
 
This strategy has been demonstrated on sulfoxide directed lithiation processes where the 
directing group can be removed under fairly forcing conditions using raney nickel,51 but 
more recently carboxylic acids have also been demonstrated. Carboxylic acid directing 
groups have advantages of being well established in transition metal catalysed ortho C-H 
funcitonalizations as well as benefiting from recent advances in transition metal proto-
decarboxylation processes. This can allow the transformation to be achieved in a one pot 
manner52 and hence, a number of examples utilising removable carboxylic acid directing 
groups on prefunctionalised substrates to access meta substituted products have been 
recently reported. These include olefinations,53,54 arylations,55 heteroarlyations,56 
acylations,57 amidations58 and aminations.59 A representative decarboxylative arylation 




Scheme 1-7: Decarboxylative arylation of substituted benzoic acids.55 
 
This concept was further expanded by the Larrosa group to also include the installation of 
the carboxylate group in a “traceless” directing group strategy. This was achieved using a 
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modified Kolbe-Schmitt reaction to install the carboxylate ortho to a phenol directing group, 
which could then be coupled with a decarboxylative arylation process to yield meta arylated 




Scheme 1-8: Meta arylation of phenols by traceless carboxylic acid directing group.60 
 
The concept of using a removable directing group is a potentially synthetically versatile 
method for C-H functionalisation and the formation of meta substituted products. This 
method has been particularly successful for easily removable directing groups such as 
carboxylic acids. Furthermore, the elegant “traceless” directing group strategy employed by 
Larrosa introduced a conceptually new strategy for achieving meta functionalisation. 
However, the selective installation and complete removal of a directing group from an 
aromatic substrate is not typically straightforward so this early example suffers from a lack 
of generality.  
1.3.4 Traceless directing groups: norbornene mediated  
The “traceless” directing group approach to meta functionalisation has become an 
increasingly attractive strategy, and recent advances in this area have drawn inspiration 
from the Catellani reaction whereby aryl iodides can be used to perform bi or tri 
functionalisation utilising palladium catalysis and norbornene as a mediator (Figure 1-8). 
The key reaction mechanisms for this transformation are initial oxidative addition of an aryl 
halide, carbopalladation of the norbornene mediator, palladacycle formation, oxidative 
addition of the coupling partner to the palladacycle, reductive elimination from the 
palladacycle, norbornene extrusion and finally termination by a number of means including 






Figure 1-8: Catalytic cycle for Catellani reaction. 
 
This was initially adapted in  removable directing group fashion by Lautens et al.61 who 
utilised aryl iodides in an adapted Catellani reaction to form meta substituted products 
(Scheme 1-9). In this case, proto-termination could occur following transmetallation with 
isopropyl boronic acid, β-hydride elimination and subsequent reductive elimination of the 




Scheme 1-9: Palladium catalysed alkylation / hydride reduction sequence.61 
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Later this was adapted in a “traceless” fashion by Yu et al. incorporating the initial installation 
of the palladium through an ortho metalation strategy followed by application of the Catellani 
reaction and proto-demetalation.62 The authors recognised the potential for unwanted site 
reactions, however these could be minimised with the use of specialised pyridine ligands 
(Figure 1-9). This early example enabled direct meta alkylation and arylation on a range of 
substituted aromatics bearing an amide directing group (Scheme 1-10).62  
 
 








Scheme 1-10: Norbornene mediated meta alkylation and arylation.62 
 
Soon after, a similar example was reported by Dong et al.63 to include meta arylations on 
aromatic substrates bearing simple benzyl amine directing groups. AsPh3 as a ligand and 




Scheme 1-11: Norbornene mediated meta arylation using acetate cocktail.63 
 
These seminal contributions did however suffer from a limited coupling partner scope. For 
example, alkylation procedures were only possible on alkyl halides with no β-hydrogen, and 
arylations were only possible using aryl iodides bearing an ortho electron withdrawing 
group. These drawbacks were addressed by Yu et al.64 who expanded the coupling partner 
scope significantly on phenyl acetamide substrates to include a significantly wider range of 
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alkyl and aryl halide coupling partners. Key to this success was a modified norbornene 
coupling partner and quinolone type ligand. Zhao et al.65 also achieved significantly 
improved aryl iodide scope with the assistance of a bidentate directing group.  
 
Yu et al. have also utilised this norbornene assisted arylation procedure on aniline, phenol 
and heterocycle substrates66 and the same group has also recently expanded the coupling 
partner scope to include meta selective amination,67 alkynylation67 and chlorination.68 In all 
cases, specialised pyridine ligands are essential for this reactivity. 
1.3.5 Utilising non-covalent interactions 
Whereas most meta selective borylations are governed by steric factors in the absence of 
directing groups, the groups of Singleton, Malekzka and Smith69 observed that borylation 
on 3 substituted N-Boc anilines gave mixtures of ortho and meta regioisomers, despite the 
meta position being sterically more accessible. Here, selectivity could be attributed to a 
hydrogen bonding interaction between the substrate N-H and a hydrogen bond acceptor on 




Scheme 1-12:Ortho borylation of N-Boc anilines governed by non-covalent interaction.69 
 
In a complementary approach, Kanai et al.70 reported on a meta selective C-H borylation 
directed by non-covalent interactions between the ligand and the substrate on 
monosubstituted and 1,2 disubstituted arenes bearing amide or phosphonate groups. This 
strategy incorporates hydrogen bond donor groups onto a bipyridine ligand backbone so 
that hydrogen bond acceptor groups on the substrate molecule can interact with the ligand 






Scheme 1-13: Meta borylation governed by hydrogen bonding interaction with the 
ligand.70  
 
A similar strategy was later demonstrated by Phipps et al. who reported an ion pairing 
interaction between ligand and substrate to achieve meta selective borylations on arenes 
bearing quaternary ammonium salts.71 In this case, bipyridine ligands with an ionic sulfonate 
group could interact with quaternary ammonium salts derived from aniline and benzylamine 








Utilising non-covalent interactions has led to a unique and elegant strategy for direct meta 
selective C-H borylations of arenes. This methodology has however only been 
demonstrated on borylation reactions, transformations which are compatible with mild 
conditions, effectiveness in non-polar solvents and lack of requirement for acidic additives. 
These requirements may limit this methodology as non-covalent interactions may be easily 
disrupted by more aggressive reaction conditions. 
1.4 Ruthenium catalysed σ-activation 
1.4.1 Sulfonation 
An interesting new approach to achieve meta C-H functionalisation by ruthenium catalysis 
is through remote C-H bond activation through catalytic σ-activation processes. This was 
first demonstrated by Frost et al. in the ruthenium catalysed meta sulfonation of 2-
phenylpyridines.72 This finding was in contrast to an ortho selective sulfonation reaction 




Scheme 1-15: Palladium(II) catalysed ortho sulfonation73 and ruthenium(II) catalysed 
meta C-H sulfonation.72 
 
In this reaction, the authors proposed that initial formation of a σ-Ru-Caryl bond activates the 
C-H bond para to the ruthenium metal centre by inductive and mesomeric effects. 
Subsequent reaction with aromatic sulfonyl chlorides results in electrophilic aromatic 
substitution (SEAr) at this activated position to yield net meta substituted products (Scheme 
1-16). This was in contrast to mechanistic studies on the corresponding ortho selective 
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sulfonation  where strong evidence for an oxidative addition / reductive elimination to a 




Scheme 1-16: Proposed mechanism for ruthenium catalysed meta sulfonation of                
2-phenylpyridines.72  
 
As justification for this mechanism, the authors cited previous stoichiometric transformations 
on ruthenium complexes bearing cyclometalated phenylpyridine ligands.75 The metal atom 
of these complexes exert mesomeric and inductive effects such that they display increased 
electron density on the σ-bonded aryl ligand. This enabled organic transformations including 
nitrations and halogenations onto these complexes (Figure 1-10). The cyclometalated 
ruthenium(II) species shown in Figure 1-11, formed by the reaction of [Ru(p-cymene)Cl2]2 
with 2-phenylpyridine was also shown to be an effective catalyst, indicating the likely 












Figure 1-11: Cyclometalated ruthenium(II) species and active catalyst for meta 
sulfonation reaction. 
 
Substrate scope for this reaction is limited to 2-phenylpyridine derivatives and only aromatic 
sulfonyl chloride derivatives were reported. The notion of substrate activation para to the          
C-Ru bond was also substantiated by the fact that blocking off one meta (C3) position 
resulted in no sulfone product being generated (Scheme 1-17). This was rationalised due 
to cyclometalation occurring at the least hindered ortho C-H bond resulting in a complex 
where the methyl substituent is para to the Ru-Caryl bond. With this position blocked, no 




Scheme 1-17: Meta sulfonation reaction with C3 methylated substrate.72 
 
The meta selective sulfonation reaction of 2-phenylpyridines was the first example reported 
that utilised a ruthenium catalysed σ-activation strategy. Since this seminal work, a number 




1.5 Aims and Objectives 
At the outset of this investigation, just one example of a meta selective C-H functionalisation 
had been reported by a ruthenium catalysed σ-activation strategy: the meta sulfonation of        
2-phenylpyridines. Given its benefits of being very operationally simple and highly selective, 
an overall goal was established to develop it into a broadly useful methodology for meta 
selective C-H functionalisation. 
 
In order to achieve these eventual goals, our group approached the task with a number of 
complementary strategies. One of these strategies was mechanistically focused. This would 
include full mechanistic elucidation of the meta sulfonation reaction in order to identify the 
catalytic species and the rate limiting step of the catalytic cycle. With this additional insight, 
improved catalyst design could achieve the reaction with improved efficiency and could 
enable new reactions of this type. 
 
Another strategy was to expand the substrate and coupling partner scope through the 
development of new catalytic reactions. This would have the impact of both making this 
methodology more synthetically useful as well as providing valuable mechanistic insight 
and exposing its limitations. 
 
The work described herein details the use of these strategies to achieve new meta selective 
transformations and gain greater mechanistic understanding of meta selective ruthenium 
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2.0 Catalytic meta selective C-H functionalisation to 
construct quaternary carbon centres 
2.1 Introduction and commentary  
At the outset of our investigation, there was only one example of ruthenium catalysed meta 
C-H functionalisation; the meta sulfonation reaction first reported within the Frost group 
(Scheme 1-15). At this time our research was focused into two interconnected areas: 
mechanistic studies of the sulfonation reaction (which is discussed in detail in Chapter 3) 
and the development of new meta selective reactions.  
 
In order to develop new meta selective reactions, many previous attempts within the group 
had focused on the screening of new electrophilic coupling partners. This was because the 
working theory was that cyclometalation with ruthenium activated the position para to the 
newly formed C-Ru bond towards SEAr type reactivity. Within the group this led to limited 
success in finding new meta selective reactions. 
 
In 2013, a second example of meta selective functionalisation promoted by ruthenium 
catalysed σ-activation was reported by Ackermann et al., who achieved a direct meta C-H 
alkylation process using secondary alkyl halides.1 This was in contrast to other work 
conducted within the same group which reported ortho selective alkylation with primary alkyl 




Scheme 2-1: Meta alkylation with secondary alkyl halides1 and ortho alkylation with 




This process was achieved on substrates directed by pyridine, pyrazole, pyrimidine, 
imidazole and benzimidazole derivatives. The use of catalytic carboxylic acid additives was 
also necessary for optimum yields, with 1-AdCO2H and MesCOOH proving to be especially 
effective. It was determined that the ruthenium species shown in Figure 2-1 was generated 
in situ and this complex was subsequently isolated and shown to be catalytically active. It 
was also noted that the complex given in Figure 1-11 was not catalytically active in the 




Figure 2-1: Active catalytic species generated in situ under the conditions in Scheme 2-1. 
 
As per the meta sulfonation reaction, this reaction was proposed to occur due to initial σ-
Ru-Caryl bond formation activating the position para to the ruthenium centre for SEAr. 
However, unlike the meta sulfonation, C2-substituted substrates yielded a mixture of the 
two possible meta regioisomers resulting from electrophilic attack at the ortho and para 
positions with respect to the ruthenium centre. A clear preference for the least hindered 




Scheme 2-2: meta alkylation reaction using C2-substituted substrates.1 
 
Some additional mechanistic studies were also carried out on this reaction. KIE experiments 
were conducted and were indicative of a reversible ortho C-H activation and a non-
kinetically relevant meta C-H bond cleavage step. Reaction with an enantiomerically pure 
alkyl halide showed that racemisation occurred under the reaction conditions              
(Scheme 2-3) and it was also noted that in the presence of stoichiometric amounts of 
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TEMPO, no alkylation of the substrate was observed. Nevertheless, the authors proposed 








Figure 2-2: Proposed mechanism for meta alkylation with secondary alkyl halides. 
 
While this second example of ruthenium catalysed σ-activation provided valuable new 
insight into this class of reaction, it was not immediately apparent why sulfonyl chlorides 
32 
 
and secondary alkyl halides would react with overall meta selectivity while many more 
examples in the literature reacted with ortho selectivity under analogous conditions. 
However, the crucial result shown in Scheme 2-3 began to narrow our search of effective 
coupling partners. Reaction with an enantiomerically enriched secondary alkyl halide 
resulted in a racemic product, showing that this reaction could not be reacting via an SN2 
type mechanism. Instead a planar intermediate consistent with either an SN1 or a radical 
mechanism must have been operative. As a result of this, our focus changed to testing 
coupling partners that could readily react via one of these two mechanisms and it was soon 
found that tert-butyl bromide was a successful coupling partner. This was the first result in 
the paper entitled: “Catalytic meta selective C-H functionalisation to construct quaternary 
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A catalytic meta-selective C-H functionalization of 2-phenylpyridines using a range 
of tertiary halides is described. The protocol is simple to perform and uses 
commercially available reagents to construct challenging quaternary carbon centres 
in a regioselective manner. Preliminary studies suggest the C-H functionalization 
proceeds through a radical process directed via a remote -activation. 
 
The transition-metal catalyzed cleavage and functionalization of inert C-H bonds is evolving 
into a fundamental methodology for the design of atom economical approaches to useful 
organic molecules.1 While the direct functionalization at the ortho position of aromatic 
compounds by chelation assisted C-H bond cleavage has become well established in recent 
years, developing reactions with complementary regioselectivity continues to challenge 
contemporary catalytic methodology.2 In this context, examples of meta selective catalytic 
C-H functionalization have been reported offering diversity in molecular design through 
alternative reaction strategies (Scheme 1a). These include substrate controlled systems,3 
transient mediators such as a carboxylic acid4 or norbornene5 and covalent template 
strategies for remote activation.6 We first reported a novel catalytic σ-activation protocol for 
C-H functionalization that allows the meta sulfonation of 2-phenylpyridines via 
cyclometalated ruthenium intermediates.7 Interestingly, the catalytic σ-activation strategy 
proved effective for meta-alkylations with secondary alkyl halides8 whilst acyl halides and 
primary alkyl halides afford only the ortho-functionalized products consistent with a 
mechanism involving oxidative addition of the organohalide.9 
 
Here we report a new catalytic meta-selective C-H functionalization of 2-phenylpyridines to 
construct quaternary carbon centres (Scheme 1b). The transition-metal catalyzed coupling 
of tertiary alkyl halides and aromatic C-H bonds is an especially challenging reaction due to 
the difficult oxidative addition of a metal complex into a bulky C–X bond.10 We hypothesized 
that a catalytic σ-activation strategy would therefore be amenable to establishing quaternary 





Scheme 1 Catalytic meta-directed C-H functionalization 
 
In preliminary experiments, 2-phenylpyridine 1a was treated under conditions analogous to 
those developed in our meta-sulfonation reaction: [RuCl2(p-cymene)]2 (5 mol%) K2CO3 (2 
equiv), t-BuBr 2a (3 equiv) using MeCN as the solvent.7 Unfortunately no coupled products 
were formed under these conditions however the desired meta-substituted product was 
observed in 12% conversion when the reaction solvent was changed to 1,4-Dioxane (Table 
1: Entries 1-2). By simply changing the base from K2CO3 to various acetate salts, a 
significant increase in conversion was observed with KOAc proving the most effective (Entry 
6). In the absence of ruthenium complex, no product was observed (Entry 11). This catalytic 
system was found to perform well in a range of solvents as well as under solvent free 
conditions and was completed in as little as 4 hours (Entry 14). When t-BuCl 2b was used 
as the coupling reagent, a significant drop in conversion was observed, however by using 
a combination of K2CO3 and KOAc, the reaction performed competitively (Entry 17). For full 




Table 1 Optimization of catalytic meta tertiary alkylation 
 
Entry t-Bu-X Base Solvent Conversion                      
(%)a 
1 2a K2CO3 MeCN 0 
2 2a K2CO3 1,4-Dioxane 12 
3 2a KOAc neat 69 
4 2a KOAc 2-Me-THF 68 
5 2a KOAc 2-Butanone 61 
6 2a KOAc 1,4-Dioxane 74 
7b 2a K2CO3 1,4-Dioxane 60 
8 2a NaOAc 1,4-Dioxane 31 
9 2a CsOAc 1,4-Dioxane 64 
10 2a Bu4NOAc 1,4-Dioxane 13 
11c 2a KOAc 1,4-Dioxane 0 
12d 2a KOAc 1,4-Dioxane 25 
13e 2a KOAc 1,4-Dioxane 50 
14f 2a KOAc 1,4-Dioxane 72 
15 2b KOAc 1,4-Dioxane 20 
16 2b K2CO3 1,4-Dioxane 27 
17 2b KOAc (0.5 equiv) K2CO3 
(1.5 equiv) 
1,4-Dioxane 63 
18b 2b K2CO3 1,4-Dioxane 62 
a Conversion of 1a to 3a by 1H NMR. b With 30 mol% MesCOOH c Without [RuCl2(p-
cymene)]2. d Reaction in air. e [RuCl2(p-cymene)]2 (1 mol%). f Reaction time 4 h. 
 
With optimized catalytic systems in hand, we then investigated how reaction conversions 
were affected when substituents at the 4-position of the aryl ring were varied (Scheme 2). 
It was found that electron donating substituents favoured the reaction whereas strongly 
electron withdrawing groups shut the reaction down entirely. The reaction was tolerant of 
halogen and ester substituents which is useful for further synthetic transformations. The 
reactions led to the sole formation of the mono substituted meta products with no 
37 
 
decomposition or by-products observed although quantitative separation by conventional 
methods was not always possible (see supporting information for full analysis). Intriguingly, 
1-bromoadamantane was found to be an effective coupling partner and product 4c was 
characterised by X-ray analysis confirming the regioselective meta substitution (Figure 1).11  
 
 
Scheme 2 Catalytic meta functionalization using tertiary alkyl bromides. Numbers quoted 





Figure 1 The asymmetric unit in the crystal structure of 4c. Ellipsoids are illustrated at 30% 
probability. 
 
Our procedure also effectively coupled a range of tertiary alkyl chlorides, reagents which 
are readily available and generally considered to be less reactive (Scheme 3). In these 
examples, it was found that the incorporation of longer alkyl chain lengths maintained high 





Scheme 3 Catalytic meta functionalization using alkyl chloride reagents. Numbers quoted 
are direct conversions to product by 1H NMR. a Numbers in brackets indicate isolated yields. 
 
In addition to the alkyl halide reagents outlined in Schemes 2 and 3, tertiary α-bromo ester 
2c was effectively coupled, generating meta-substituted products 8a, 8c and 8d, 
compounds with a useful functional handle, in reasonable isolated yields (Scheme 4). This 
result provided key insight into the reaction mechanism and strongly suggested a radical 
type pathway, rather an SEAr type mechanism previously proposed in our meta-sulfonation 
reaction.7 Heterolytic cleavage of the C-X bond of 2c in an SN1-type manner would result in 
a strongly disfavoured carbocation residing alpha to an electron withdrawing ester. It is 
therefore unlikely that reaction with the aromatic substrate would occur in this fashion. The 
possibility of SN2 type reactivity can also be effectively ruled out given the steric effects of 
the tertiary alkyl halides used. The generation of tertiary alkyl radicals has however been 
widely reported with a range of transition metal catalysts and shown to be effective in the 
substitution of aromatics, heteroaromatics and olefins.12 In contrast to the reactions with 
simple alkyl-halides outlined in Schemes 2 and 3 which led to the sole formation of one 
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product, reaction with 2c generated additional by-products. Compounds 9a, 9c and 9d were 
isolated along with spectroscopic evidence of trace higher oligomers and are consistent 
with a radical conjugate polymerisation pathway. We hypothesise that a tertiary carbon-
centered radical species can add onto elimination products formed under the reaction 
conditions, which can in turn propagate onto a cyclometalated (σ-activated) substrate 
molecule to afford the observed by-products. Furthermore, the addition of radical scavenger 
TEMPO proved detrimental to the reaction with no desired product observed when 
stoichiometric quantities were used (See Supporting Information). 
 
 
Scheme 4 Catalytic meta functionalization with α-bromo ester 2c. Numbers quoted are 
isolated yields. 
 
Further mechanistic work was conducted to provide additional insight into the interesting 
meta selectivity displayed by this reaction (Scheme 5). It has previously been proposed that 
initial ruthenium insertion into an ortho C-H bond to generate a cyclometalated complex is 
key to this type of reactivity.7,8 In support of this, reaction of the ortho, ortho dimethyl 
substrate 1i resulted in no conversion to the desired meta substituted product. The 
importance of ruthenium σ-activation is also highlighted with the successful meta-selective 
reaction using pre-formed complex A. No meta-substituted product was observed when 
substrate 1j bearing a methyl group at the 3-position of the aromatic ring was used. Instead, 
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the only product isolated was dimer 10 suggesting a competing reductive elimination of two 
coordinated substrate molecules when the site para to the C-Ru bond is blocked.13 
Conformationally locked benzoquinoline 1k was however effectively alkylated generating 
11 as the only isolated product. Together these results suggest that substitution occurs 
preferentially at a position para to the C-Ru bond formed following cyclometalation. 
Interestingly, analogous reactivity has also recently been reported in a stoichiometric 
process on iridium complexes.14  
 
 




In light of this work we now propose the following mechanism (Scheme 6). Initial ortho C-H 
insertion generates a cyclometalated complex, a process shown to be reversible and aided 
by carboxylate ligands.15 Substitution at the position para to the newly installed C-Ru bond 
then most likely occurs via a radical process whereby single-electron transfer (SET) from a 
ruthenium(II) species can generate a tertiary alkyl radical and the corresponding 
ruthenium(III)X species. The carbon-centered radical then adds to the aromatic ring to 
generate a cyclohexadienyl radical intermediate. Rearomatisation could occur via single-
electron oxidation and deprotonation to regenerate a ruthenium(II) complex and furnish the 
meta alkylated product after proto-demetalation. 
 
 
Scheme 6 Proposed Catalytic Cycle. 
 
In summary, we have developed a novel meta selective catalytic C-H functionalisation of 2-
phenylpyridine substrates for the installation of quaternary carbon centres. The procedure 
is operationally simple and was found to couple a useful range of tertiary alkyl bromides 
and more challenging tertiary alkyl chlorides. Mechanistic studies indicate that site selective 
radical addition occurs at the position para to the C-Ru bond formed following 
cyclometalation to afford products with net meta substitution. More detailed mechanistic 
studies are underway to determine the precise nature of the organometallic species and 
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2.4 Post-commentary  
Since being published, this paper has received a number of citations and was selected 
among the top 25 most downloaded by Chemical Communications July-September 2015. 
Crucially this work gave significant evidence for a radical type mechanism, particularly from 
the results obtained using the α-halo carbonyl reagents and the associated polymer type 
products. Furthermore, this work was the first to propose a potential dual role of the 
ruthenium catalyst, both as an activator for the substrate and the coupling partner. 
 
In the months following, an analogous tertiary alkylation from the Ackermann group, was 
reported which supported many of the propositions made by the title manuscript and also 
provided additional scope and insight.4 In addition to enabling meta tertiary alkylations with 
alkyl bromides on phenylpyridine, pyrimidine and pyrazole containing substrates, a 
removable pyrimidine based auxiliary was also demonstrated, enabling a range of meta 
functionalised aniline derivatives (Scheme 2-4). The authors also reported on the 




Scheme 2-4: Tertiary alkylation on aniline derivatives with removable auxiliary.4  
 
Additional mechanistic work was also conducted on phenylpyridine derivatives. This 
revealed the importance of the alkyl bromide in the demetallation step and deuterium 
labelling studies identified the meta C-H bond cleavage as being kinetically relevant. The 
authors also proposed a radical addition of the alkyl halide onto the substrate. This was 
substantiated by epimerisation of bromo-4-phenylcyclohexanes as well as radical clock 
experiments. Furthermorethe authors also proposed a dual role of the ruthenium, for 
activation of the substrate molecule and for the generation of an alkyl radical, and led to an 
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3.0 Mechanistic insight into ruthenium catalysed meta 
sulfonation of 2-phenylpyridine 
3.1 Introduction and commentary 
Following publication of the meta sulfonation of 2-phenylpyridines,1 work was conducted 
within our group to accurately elucidate the mechanism in order to better understand the 
reaction and to develop more reactions of this type. There were several reasons to 
undertake this approach and several goals were sought. One was to identify the catalytic 
species and the rate limiting step of the reaction in order to aid in future catalyst design. It 
was hoped that the eventual development of a second generation catalyst or set of 
conditions that minimised the rate limiting step could achieve the reaction with increased 
efficiency and could enable future reactions. A greater understanding of the privileged 
reactivity of sulfonyl chlorides was also sought. 
 
At the outset of this investigation, the working theory was that cyclometalation of a substrate 
molecule with a ruthenium complex activated the position para to the newly formed carbon-
ruthenium bond for electrophilic aromatic substitution (SEAr). However, during the 
preparation of this manuscript, a number of other contributions in the field challenged this 
theory. As well as contributions to meta selective alkylations detailed in Chapter 2, a 
number of other meta selective C-Heteroatom transformations were successfully achieved. 
 
The groups of Greaney et al. reported on the ruthenium(II) catalysed meta selective 
bromination of 2-phenylpyridine derivatives using (NBu4)(Br3) as the halogenating reagent.2 
Soon after Huang et al. reported a similar system utilising NBS as the brominating reagent 
while extending the substrate scope to also include phenylpyrimidine and phenylpyrazole 
derivatives.3 Both works also demonstrated subsequent synthetic elaborations by palladium 
cross coupling chemistry. These meta selective bromination reactions were complementary 
to an ortho selective halogenation reported by Ackermann et al. using ruthenium(0) 
catalysis4, as well as numerous other examples of ortho halogenations using copper,5–7 





Scheme 3-1: Ruthenium(II) catalysed meta bromination with (NBu4)(Br3),2 ruthenium(II) 
catalysed meta bromination with NBS,3 ruthenium(0) catalysed ortho bromination with 
NBS.4 
 
Both authors suggested the likely involvement of cycloruthenation for the meta selectivity 
observed and additional mechanistic analysis conducted by Huang et al. suggested a 
kinetically relevant radical based bromination step based on KIE studies and the shutdown 
of the reaction by a radical scavenger. Furthermore, the authors noted the likelihood of 
coordination by multiple substrates based on deuterium labelling experiments. These 





Figure 3-1: Proposed mechanism for meta bromination with NBS.3 
 
Soon after, Zhang et al. demonstrated a meta nitration directed by a range of pyridine, 
pyrimidine, pyrazole, isoquinoline, quinoxaline, pyridazinone, oxime and benzimidazole 
containing substrates.14 Key to the success of this transformation was the use of Cu(NO3)2 
as the nitrate source as well as the addition of co-catalytic silver salts in combination with 
an oxidant, which the authors proposed promoted radical formation. The use of the phase 




Scheme 3-2: Ruthenium catalysed meta nitration.14 
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The authors also demonstrated that the nitro group could be further elaborated into a wide 
range of other functional groups including amines, aniline derivatives, sulfonamides, 
indoles, thiazoles, and the nitro group itself could be used as a directing group for a 
subsequent ortho arylation procedure. 
 
Additional mechanistic studies were also conducted. These revealed the importance of 
ortho ruthenation and deuterium labelling studies showed that this was a reversible process. 
In contrast, the meta C-H cleavage was found to be irreversible and was also found to be a 
kinetically relevant step. Radical scavengers TEMPO and BHT were found to shut down the 
reaction, prompting the authors to suggest that a radical nitration step was likely involved. 
On the basis of these observations and the isolation of a potential catalytic intermediate, 






Figure 3-2 : proposed mechanism for ruthenium catalysed meta nitration.14 
 
These contributions to the field were very valuable to our ongoing work into the mechanism 
of the meta sulfonation reaction and supported many of our own observations. Suggestions 
that radical mechanisms were likely to be involved were consistent with our previously 
reported alkylation procedure.15 In addition to this, suggestions that the catalytic species 
involved did not require an arene ligand and the likely coordination of multiple substrate 
molecules supported many of our own observations. The following manuscript outlines our 
approach to gain greater mechanistic understanding of the meta sulfonation reaction and 
was achieved through reaction monitoring, stoichiometric experiments and deuterium 
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Mechanistic Insight into Ruthenium Catalysed Meta-Sulfonation of 2-Phenylpyridine  
 
Patricia Marcé, Andrew J. Paterson, Mary F. Mahon and Christopher G. Frost. 
 
The catalytic meta-functionalization of arenes has emerged as important synthetic 
methodology in the last decade. We report herein structural and mechanistic studies of the 
meta-sulfonation of phenylpyridine using ruthenium complexes.  Furthermore, we disclose 
that the catalytically active species does not require the presence of a -arene ligand. 
Furthermore, the novel cycloruthenated phenylpyridine complex tosylated at the para 
position to the metal has been isolated and fully characterised. Protodemetallation studies 
suggest that a concerted C-H activation-demetallation process may be involved. Overall, 
this study provides fundamental insight into the meta-sulfonation phenylpyridine reaction 
pathway and uncovers new reaction intermediates that will guide the design of new catalytic 
systems for remote meta-functionalization. 
 
Introduction 
The functionalization of arenes catalysed by a metal complex via C-H activation has 
attracted great attention in the last decade.1,2 This transformation requires the presence of 
a directing group (DG) that coordinates to the metal centre to facilitate the C-H activation at 
the ortho position to form a metallacycle. Once the metallacycle is formed the introduction 
of a functional group can be achieved at the ortho1,2 and meta positions.3 The ortho-
functionalization of arenes has been widely studied and there are many transformations 
reported in the literature such as arylations,4 alkylations,5 olefinations6 and amidations7,2a 
among others.1,2 Despite the great achievements in this area, the direct introduction of a 
functional group at the meta position remains a challenge. We reported the first example of 
catalytic meta-functionalization by remote electronic activation using ruthenium catalysis.8,9 
This important switch of regioselectivity in the sulfonation of phenylpyridines from the ortho10 
to the meta position was realised by changing the catalyst from Pd(II) to Ru(II). The 
innovative template assisted direct meta-C–H bond activation first reported by Yu et al. 
involves the use of a removable tethered directing group capable of coordinating to the 
catalyst and directing it to the meta position.11 Other strategies involve transient mediators 
such as a carboxylic acid12 or norbornene13 that direct ortho but reveal meta-arylated 
products after their removal (Scheme 1a).  
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Recently, new examples of meta selective catalytic C-H functionalization controlled by the 
catalyst have been achieved  using secondary14 or tertiary15,16 alkyl halides and bromination 
reagents.17 To account for the switch in regioselectivity in the meta-sulfonation, we 
hypothesized that the chelating group facilitates the formation of a stable Ru-Caryl σ-bond 
that induces a strong para directing effect.8 Although the σ-activation of aromatics has been 
studied for a range of stoichiometric processes such as electrophilic halogenation,18 
acylation,19 and nitration,18b,18c,20 a catalytic σ-activation process invokes a novel 
mechanistic pathway for C-H functionalization processes.15 Recent studies have revealed 




Scheme 1 Strategies for meta-selective C-H functionalization. 
 
Herein, we present mechanistic studies to establish important steps and intermediates in 
the meta-sulfonation of phenylpyridines. We also demonstrate that the presence of a p-
cymene ligand is not essential for catalytic turnover. Moreover, this is the first time that the 
cycloruthenated tosylpyridine complex has been isolated and fully characterised confirming 
the σ-activation pathway in the catalytic meta-sulfonation process (Scheme 1b). This study 
provides fundamental insight into the reaction pathway and contributes to the broader 





Results and discussion 
The catalytic species. The C-H activation step of heteroarenes is crucial for further 
functionalization at the ortho position21 and has been thoroughly investigated.22 Recent 
studies carried out by Dixneuf and Jutand have revealed that C-H activation is an 
autocatalytic process which goes through a SE3 mechanism when [Ru(O2CR)(p-cymene)] 
complexes are employed.23,24 In contrast, DFT calculations carried out by Dixneuf and 
Maseras postulated that the C-H activation with Ru(II)-NHC complexes goes through a 
concerted metalation-deprotonation (CMD) mechanism.25  
 
Intrigued by the nature of the active species involved in the catalytic cycle for meta-
functionalization, a number of ruthenium complexes were synthesised. Based on previous 
studies in which ruthenium cyclometallated complexes were shown to be key intermediates, 
complexes 3, 4 and 5 were initially investigated (Table 1).23,24,26 As we have previously 
reported, complex 3 selectively delivered the sulfonated phenylpyridine in good yield.8 
Preformed cationic complex 4 was also found to perform competitively. Remarkably, Ru(II) 
complex 5 with no p-cymene coordinated was also catalytically competent. This is in 
contrast to the work of Jutand et al. who showed that this ligand was essential for catalytic 
turnover in ortho arylation reactions catalysed by Ru(II).24 It is worth noting that ortho 
arylations employing Ru(III) and Ru(IV) complexes did not require the presence of a p-
cymene ligand to achieve high reaction conversions.27   
 
In order to observe the evolution of the ruthenium intermediates during the catalytic process, 
a series of reactions were followed by in situ 1H-NMR. [RuCl2(p-cymene)]2 as well as 
complexes 3 and 4 were employed as the precatalysts. When [RuCl2(p-cymene)]2 was 
used, it was converted into cyclometalled complex 4 within 40 min at 393 K (Figure 1). The 
presence of a new doublet at 9.22 ppm (J = 5.82 Hz, H12) along with two doublets at 0.95 
ppm and 0.92 ppm (J = 6.92 Hz, H17, H18) confirmed the formation of complex 4. A new 
doublet at 1.23 ppm (J = 6.93 Hz, H17, H18) was also observed and assigned to free p-
cymene (6). After 2 h, signals from complex 4 and free p-cymene (6) were also identified 
along with characteristic signals from the tosylated phenylpyridine (2). After 4 h, only traces 
of ruthenium complex 4 remained with a significant increase in the signals corresponding 
to free p-cymene. The fact that complex 4 was detected along with the formation of the final 
product indicates that the Ru(II) species 4 is not involved in the catalytic cycle. Additionally, 
the increase of the signals of the free p-cymene together with the formation of the final 
product suggests that the active catalytic species does not contain p-cymene as ligand. 
Similar behaviour was observed when complex 3 was employed. In this case, in the initial 
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stages of the reaction the characteristic signals of 3 appeared at 9.32 ppm (d, J = 5.79 Hz, 
H12), 0.92 ppm and 0.82 ppm (d, J = 6.92, H17, H18). 
 
Table 1 Catalytic sulfonation using Ru(II) complexes potentially involved in the reaction 
 
Entry Catalyst loading (mol%) Ru Catalyst Yield (%)a 










a) Isolated yields. 
 
After 40 min at 393 K these signals disappeared to give new peaks which were assigned to 
complex 4 and free p-cymene (Figure S2, see ESI†). When the reaction was performed with 
complex 4, no changes in the ruthenium complex were observed after 1 h at 393 K (Figure 
S3, see ESI†). These results were consistent with previous observations. 
 
In order to know whether the chloride anion was involved in a coordination-discoordination 
equilibrium, complex 4 was treated with 15 equivalents of KCl in CD3CN and heated at 363 
K overnight. Changes in the 1H-NMR splitting pattern showed the formation of 5 along with 
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the dissociation of the p-cymene, but no evidence for the formation of 3 was detected. This 
experiment supported the fact that when the chloride dissociates from the metal centre it is 
very unlikely to re-coordinate under these reaction conditions (Figure S4, see ESI†). In 
recent work published by Dixneuf and Jutand,22 the attempt to isolate [Ru(OAc)(PhPy)(p-
cymene)] by flash chromatography using a chloroform as eluent failed and gave 3 instead, 
showing that chloride is a better ligand for the Ru(II) centre than acetate. Although under 
Dixneuf conditions the re-coordination of the chloride was evident, the ruthenium species 
detected by 1H-NMR in our experiment confirms that the ruthenium precatalyst does not 




Figure 1 1H NMR meta-sulfonation of phenylpyridine using [RuCl2(p-cymene)]2 
 
Tosylation step. The tosylation step was also subjected to investigation. The 
cycloruthenated complex 3 was placed in a NMR tube and treated with 1.5 equivalents of 











































t = 40 min
t = 2 h
t = 4 h
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the reaction overnight only the formation of 5 was observed. Taking into account that during 
the tosylation step a proton has to be abstracted, the presence of a base would favour the 
substitution. Thus, complex 3 was treated with TsCl and 2 equivalents of K2CO3. When the 
NMR tube was heated at 373 K the dissociation of the p-cymene ligand started taking place 
and, after 2 h the formation of a new complex was observed. 
 
The appearance of a new doublet at 8.92 ppm with a coupling constant of 5.5 Hz and a new 
doublet at 8.14 ppm with a small coupling constant of 1.8 Hz prompted us to think that the 
formation of the cycloruthenated tosylpyridine complex 7 was occurring. An analogous 
stoichiometric experiment was also performed on complex 4 and similar reactivity to 3 was 
observed (Scheme 2). The treatment of 4 with TsCl afforded complex 5 with concomitant 
dissociation of the p-cymene. Subsequent addition of K2CO3 was also necessary to detect 









To prove that this new ruthenium complex was indeed 7, the tosylation on 5 was carried out 
under the same reaction conditions. After purification of the reaction mixture and full 
spectroscopic and X-ray analysis of the product, compound 7 was unequivocally assigned 
to the tosylated phenylpyridine complex with the tosyl group located at the para position to 
the Ru(II) (Figure 2). In light of these results, it could be confirmed that the meta-tosylation 
reaction proceeds by the activation of the para position to the Ru(II). This evidence 
corroborates the role of Ru(II) acting as a para directing group.28 Finally, complex 7 was 
also used as precatalyst in the sulfonation reaction. Gratifyingly, it was found to be 
catalytically active, indicating the likelihood of sulfonated complexes involved in the catalytic 
cycle (Scheme 2). Interestingly, it has recently been demonstrated that similar ruthenium 
complexes such as [Ru(tBuCN)6][BF4]2 can catalyse the C-H arylation of fluoroarenes and 




Figure 2 Single crystal X-ray structure of the cation in complex 7.29 Ellipsoids are 
represented at 30% of probability. 
 
Dissociation of p-cymene. In all previous experiments it was impossible to detect the 
tosylated Ru(II) complex with the p-cymene coordinated. This indicated that the dissociation 
of the p-cymene is faster than the tosylation reaction under stoichiometric conditions. 
At this point, we decided to investigate the nature of the p-cymene dissociation. In order to 
study the stability of the cyclometallated Ru complex 3, a NMR tube was charged with 3 in 
CD3CN. The sample was heated at 343 K for one hour, showing no modification of the 
splitting pattern. Then, 1.5 equivalents of tosyl chloride were added and the sample was 
kept at 343 K. After 24 min the dissociation of p-cymene was observed showing that TsCl 
promotes the dissociation of the p-cymene ligand The mechanism of this process is still 
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uncertain. However, it is worth noting that the dissociation of p-cymene can be 
accomplished by a thermal process but longer reaction times are required.31 
 
Nature of the meta-functionalization. Having confirmed that sulfonation occurs at the 
para position to the newly installed C-Ru bond, we became intrigued by the nature of this 
process. We had previously proposed that cyclometallation increases the electron density 
of the aromatic ring, activating it for SEAr type reactivity. However, recent studies have 
shown the likelihood of a radical mechanism in meta-selective alkylation reactions.14,15,16 
  
In order to investigate a possible SEAr pathway, the effect of various sulfonating reagents 
were subjected to study (Table 2). Sulfonating reagents more susceptible to react with 
nucleophiles such as tosylimidazole, TsOBt and p-toluenesulfonic anhydride were 
employed in this transformation. Analysis of the crude reaction mixture did not show any 
evidence for the formation of 2 indicating that a simple SEAr pathway was doubtful. 
  
We also noted that the use of the radical scavenger TEMPO caused a detrimental effect on 
the reaction conversions (see ESI†). Other mechanistic studies carried out on meta- 
functionalization catalysed by ruthenium have also shown inhibition when TEMPO was 
employed as radical scavenger.14,15   In this context, we have previously proposed a 
mechanism involving a distinct Ru(II)/Ru(III)Cl redox cycle whereby a Ru(II) species can 
cause homolytic cleavage of a C-X bond to generate reactive radical species. Upon site 
selective addition to the aromatic substrate, the newly formed Ru(III)Cl species can 
reoxidise the resulting cyclohexadienyl radical intermediate. 
 
This proposal was independently supported by Ackermann in analogous meta-selective 
alkylation reactions.16 It is therefore possible that the meta-selective sulfonation reaction 
follows analogous reactivity. This is supported by the precedence for the generation of 





Table 2 Effect of various sulfonating reagents on the meta-sulfonationa 
 
Entry X Yield (%)b 










a) Reaction conditions: 2-phenylpyridine (1.0 mmol), sulfonating reagent (3.0 
mmol), [RuCl2(p-cymene)]2 (5 mol%), CH3CN (3 mL), 120 oC, 15 h. b) Isolated 
yield. 
Protodemetallation. The protodemetallation of the cyclometallated ruthenium 
tosylphenylpyridine is the process responsible of the release of the product with the 
concomitant regeneration of the catalyst. Precedent in the literature has hypothesized that 
the proton coming from the C-H activation is involved in the demetallation step.22 The 
demetallation of product 2 from complex 7 was subjected to study (Table 3). Since KHCO3 
is generated during the reaction we thought that this was a plausible proton source. Thus, 
complex 7 was treated with 10 equivalents of KHCO3 in CD3CN. However after heating the 
mixture at 393 K overnight the release of 2 was not detected (Table 3, entry 1). A number 
of other acid sources were tested in the same manner yet none resulted in the release of 
product 2 (Table 3, entries 2-4), nor did the addition of 1 equivalent of phenylpyridine (Table 
3, entry 5).  
 
Treatment of 7 with p-toluenesulfonic acid (p-TSA) afforded a new product. The 
spectroscopic analysis revealed that the carbon (Ru-C) was no longer coordinated to the 
Ru(II), but the nitrogen from the pyridyl unit was still coordinated (Figure S7, see ESI†). In 
order to study the influence of TsCl and phenylpyridine on the reaction turnover, complex 7 
was treated with 4.5 equivalents of TsCl. After heating the reaction mixture at 363 K 
overnight, 23% of the demetallated tosyl phenylpyridine was observed (Table 3, entry 7). A 
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parallel experiment was carried out using 10 equivalents of phenylpyridine and 26% of the 
final product was detected (Table 3, entry 8). These results demonstrated that both TsCl 
and phenylpyridine16 are important in facilitating the demetallation process and that KHCO3 
does not play a significant role. A concerted C-H activation-demetallation step cannot be 
ruled out which would also explain the formation of dimers as by-products during the 
reaction.33,34 
 
Table 3 Study of the protodemetallation of the TsPhPy from the metal centre. 
 
Entry Additives 2 (%) 
1 10 equiv KHCO3 -- 
2 
1 equiv MesCO2H 
2 equiv K2CO3 
-- 
3 1.5 equiv MesCO2H -- 
4 10 equiv MesCO2H -- 
5 
1 equiv PhPy 
2 equiv K2CO3 
-- 
6 1.5 equiv p-TSA --a 
7 
4.5 equiv TsCl 
2 equiv K2CO3 
23 
8 
10 equiv PhPy 
2 equiv K2CO3 
26 
 
a) Demetallation of the sulfone was observed but the pyridyl moiety was still coordinated to 
the Ru. b) 1.5 equivalents of tosyl chloride were added for the formation of the sulfone. The 
reaction was performed at 363 K in an NMR tube. 
 
Deuterium labelled experiments. In order to determine the C-H bonds involved in 
kinetically relevant steps, deuterium labelled experiments were performed. Competitive 
reaction of [D5]-1 and [D0]-1 showed a kinetic preference to react with unlabelled [D0]-1 
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(Scheme 3a) similar to that demonstrated in previous studies.8,14 In order to ascertain 
whether it was the ortho or meta C-H protons causing this effect, [D2]-1 and [D3]-1 were 
studied. A competitive reaction between [D2]-1 and 1 was carried out and the mixed product 
fraction was analysed. This revealed a product ratio of almost 1:1 of the deuterated and 
non-deuterated 2 when the H2 protons were considered. This is consistent with no 
kinetically relevant ortho C-H bond cleavage. Comparison of H2 and H6 in [Dn]-2 showed 
a different ratio of deuterium incorporation. This may reflect the involvement of 2 in a 
reversible C-H activation reaction35 which could cause this proton enrichment at the less 
hindered position. In contrast, the competitive reaction between [D3]-1 and 1 showed a 
higher percentage of the non-labelled product indicating a clear isotopic effect (Scheme 3c). 
 
 
Scheme 3 Studies with isotopically labelled compounds. 
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Single Turnover Experiment. To provide further insight into the mechanism of catalyst 
turnover, a stoichiometric experiment was performed using an isotopically labelled 
ruthenium complex [D4]-4 and unlabelled 2-phenylpyridine. The deuterium incorporation of 
the resulting organic and inorganic components was then analysed by 1H-NMR (Scheme 
4). In recovered fractions [Dn]-1, [Dn]-2 and [Dn]-7, 50% deuteration was observed at the 
meta and para positions to the pyridine ring. These results indicate that 1 and the labelled 
phenylpyridine ligand exchange multiple times before a slower tosylation step. Analysis of 
the ortho positions in [Dn]-1 and [Dn]-2 also revealed proton enrichment at the less hindered 
positions. This evidence supports the fact that tosylphenylpyridine is also involved in a 
reversible C-H activation. 
 
 
Scheme 4 Single turnover experiment with isotopically labelled ruthenium complex [D4]-4. 
 
We propose that the catalytic cycle starts by the breaking of the dimer followed by C-H 
activation of phenylpyridine with concomitant dissociation of the chloride to give complex 4. 
Once complex 4 is formed, the presence of CH3CN favours the dissociation of the p-cymene 
ligand generating 5 which is the active Ru(II) species involved in the catalytic cycle. This 
cycloruthenated species 5 activates the phenyl ring from the phenylpyridine towards a 
radical addition of tosyl chloride at the para position. The tosylation step has been 
determined as a kinetically relevant step. The demetallation step has been proved to be 
promoted by the presence of TsCl and phenylpyridine. The latter is believed to proceed 










The mechanism of the meta-sulfonation catalysed by Ru(II) complexes has been subjected 
to study. This is the first time in which the meta-sulfonylated Ru(II) complex 7 has been 
isolated and fully characterized. This proves that this new catalytic C-H functionalization 
goes unequivocally via the activation of the para position to the Ru(II) complex. It has also 
been demonstrated that complexes 5 and 7 are the active catalytic species which has been 
shown to be inactive in other catalytic processes. This study reveals that the presence of a 
p-cymene ligand is not crucial for the meta-sulfonation of phenylpyridines and it is 
postulated that the meta-sulfonation follows a radical mechanism.  
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4.0 α-halo carbonyls enable meta primary, secondary and 
tertiary C-H alkylations 
4.1 Introduction  
Shortly after publication of our groups Chemical Communications article entitled “Catalytic 
meta selective C-H functionalisation to construct quaternary carbon centres”1, a similar 
piece of work was reported by Ackermann et al. to achieve similar tertiary alkylation2 
(Chapter 2). The work was largely in agreement with our own and included a number of 
extra experiments which helped draw light to the mechanism. It was of particular interest 
that the authors also supported our original proposition that there was a dual role of the 
ruthenium; for both the activation of the substrate molecule and for the generation of the 
tertiary alkyl radical. It was therefore apparent that the possibility of a dual catalytic system 
could enable new meta selective reactions, a concept which was exemplified in ruthenium 
catalysed meta selective nitrations.3  
 
4.2 Optimisation of primary α-halo carbonyl coupling partner 
During the development of our tertiary alkylation procedure, we had attempted to utilise 
primary α-halo carbonyls to achieve meta selective primary alkylations, transformations that 
had not been reported at the time. Using our previously developed system, this led to 
disappointing yields with mixtures of regioisomers. We rationalised that homolytic C-Br 
cleavage was less easily achieved on the primary substrates due to lack of captodative 
stabilisation of the resulting radical and that ortho substituted by-products were being 
formed by competing oxidative addition / reductive elimination pathways. We therefore 
envisaged that the addition of a co-catalyst to generate a radical would favour a meta 
selective radical addition over the ortho selective oxidative addition / reductive elimination 
pathway (Table 4-1).  
 
We initially began our investigation using conditions known in the field, a ruthenium(II) 
precatalyst with carboxylate ligands.4,5 However, these resulted in low combined yields of 
inseparable regioisomers. Due to our theory that there was a dual role of ruthenium in 
tertiary alkylation reactions; activation of the substrate by cyclometalation, and a single 
electron redox catalyst to generate an alkyl radical, we tried a number of catalysts capable 
of acting as single electron redox catalysts. A number of copper systems were first 
employed given their natural abundance and precedence to form alkyl radicals in single 
electron processes6–9 however no products were observed. Similarly, photocatalytic 
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ruthenium complexes were also ineffective, providing no benefit over the monocatalytic 
system. However, the addition of Pd(PPh3)4 significantly improved reactions yields, with 10 
mol% loading resulting in near complete selectivity to the meta substituted product. Other 
palladium(II) precatalysts were ineffective whereby Pd2(dba)3 and Pd(OAc)2 yielded no 
additional benefit however PdCl2(PPh3)2 was somewhat more effective. Gratifyingly, ethyl 
chloroacetate showed comparable reactivity with high selectivity, expanding the range of 
potential commercial coupling partners available. Crucially when no ruthenium complex was 





Table 4-1. Optimisation of meta primary alkylation. 
 
Entry Ligand Co-Catalyst Yield (%)a m:ob 
1 No ligand - 21 2.5:1 
2 KOAc - 24 2:1 
3 MesCOOH - 26 2.3:1 
4 AdCOOH - 15 2:1 
6 MesCOOH CuCl (20%), 1,10-Phen (20%) 0 0 
7 MesCOOH CuCl (20 mol%)  PMETA (1eq) 0 0 
8 MesCOOH Cu2O (10 %) 1,10-Phen (12%) 0 0 
9c MesCOOH Ru(bpy)3Cl2 21 1:1 
10c MesCOOH Ru(Phen)3Cl2 19 0.6:1 
11 MesCOOH Pd(PPh3)4 (5%) 47 3.3:1 
12 MesCOOH Pd(PPh3)4 (10%) 58 20:1 
13 MesCOOH Pd2(dba)3 (5%) 17 2.5:1 
14 MesCOOH Pd(OAc)2 (10%) 17 1.5:1 
15 MesCOOH PdCl2(PPh3)2 (10%) 46 10:1 
15 MesCOOH Pd(PPh3)4 (12.5%) 54 20:1 
16 MesCOOH Pd(PPh3)4 (15%) 55 19:1 
17 AcOH Pd(PPh3)4 (10%) 55 15:1 
18 AdCOOH Pd(PPh3)4 (10%) 44 12:1 
19 MesCOOH Pd(PPh3)4 (No Ru) 0 0 
20d MesCOOH Pd(PPh3)4 (10%) 54 10:1 
21e MesCOOH Pd(PPh3)4 (10%) 46 2.9:1 
aCombined yield for both regiosiomers. bmeta:ortho ratio calculated by 1H NMR. cIrradiated 




4.3 Scope of primary α-halo carbonyl coupling partner 
With optimised catalytic conditions in hand, we aimed to explore the substrate scope with 
respect to the directing group. In all cases, near complete selectivity (>20:1) to the meta 
substituted product was observed. Substitution on the pyridine ring was generally well 
tolerated although significantly increasing or decreasing electron density had a negative 
effect on reaction yields. Pyrazole and a range of substituted pyrimidines were also effective 
directing groups affording the meta alkylated products in good yields. Substitution at the 3 
or the 6 position of the pyridine ring completely shut down reactivity, likely due to hindering 
the ability of the substrate to form a planar cyclometalated complex. Meanwhile 
conformationally locked benzoquinoline afforded exclusively alkylated product 6aa. X-Ray 
analysis could unequivocally confirm this regiosectivity (Figure 4-1) and supports the 













Figure 4-1. X-Ray crystal structure of compound 6aa. Ellipsoids are depicted at 30% 
probability.10 
 
Next, substitution on the aryl component was considered (Scheme 4-3). Whereas 
unsubstituted substrates afforded nearly exclusively the meta substituted products, some 
regioisomeric products were formed when the electronic properties of the aromatic ring 
were altered. Generally, electron donating groups at the para position yielded either 
exclusively the meta product or high selectivity towards this product in modest yields. In 
contrast, electron withdrawing groups yielded a higher proportion of regiosiomeric by-
products but with improved combined yield. Dimethylated substrate 3u afforded none of the 
meta alkylated product 3ua, likely due to its inability to form a cyclometalated complex. 
Similarly, incorporating methyl substituents at the ortho or meta position also shut down 







Scheme 4-3. Scope of substituted arenes aYields quoted are combined yields of both 
regioisomers. bMinor isomer could be assigned as ortho substituted product. 
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4.4 Scope of secondary and tertiary α-halo carbonyl coupling partners 
Next we saw the potential for other α-halo carbonyls to be used to install other useful 
functionality at the meta position (Scheme 4-4). When simple secondary and tertiary α-halo 
carbonyl reagents were used, the addition of palladium had a negligible effect on the yield 
of the corresponding meta substituted products. Thus, in agreement with previous work 
conducted in the field, a range of secondary and tertiary alkylated products could be 
achieved using solely a ruthenium compex.11,1,2 In agreement with the reactions carried out 
in Scheme 4-2, changing the electronics on pyridine ring generally had a detrimental effect 
on reaction yields with a 4-Me substituent again proving to be the most effective directing 
group. We have previously proposed that the key to this type of reactivity when tertiary α-
halo carbonyl 2b was employed was the facile generation of an alkyl radical.1 Captodative 
stabilization by the electron donating geminal dimethyl substituent along with the electron 
withdrawing effect of the ester could allow facile homolytic cleavage of the C-Br bond. Thus, 
coupling partners with solely electron withdrawing groups bound to the α-carbon did not 
result in alkylated products (3ag, 3ah) whereas the corresponding coupling partners with 
short alkyl chains introduced could furnish the meta substituted products (3ai). α-halo 
ketones could also be effectively coupled (3ae) however α-halo amides were ineffective 
(3af), again highlighting the importance of captodative stabilization in the coupling partner.
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Scheme 4-4. Scope of α-bromo carbonyl coupling reagents. aReaction with co-catalytic Pd(PPh3)4 (10 mol%). bReaction with 
corresponding α-chloro carbonyl. 
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4.5 Mechanistic considerations: Computational 
We previously proposed a dual metallic radical based mechanism for meta alkylation reactions 
involving initial cyclometalation, which activates the position para to the newly installed C-Ru 
bond for site selective addition.1 Recently, we also showed that substitution happens at the 
para position of the newly formed C-Ru bond in stoichiometric reactions with cyclometalated 
complexes in analogous meta sulfonation reactions.14 In order to investigate this further, we 
applied computational methods to model the electronic properties of the cyclometalated 
intermediates based on the work of Ritter and co-workers.15  This approach accurately predicts 
reaction regioselectivity using relative nucleophilic Fukui indices calculated from carbon NBO 
values and was applied to four substituted phenylpyridines (1a, 1k, 1n and 1r) and their 
equivalent cyclometalated complexes, Aa, Ak, An and Ar, [Ru(OMes) (p-cymene)] (1x). The 
relative Fukui indices in Figure 4-2 show that if the organic substrate alone was the active 
species, then reaction with an electrophile would most likely occur at C4, para to the phenyl 
group, or in the case of 1a (when X = H), at C10; para to the pyridine ring due to increased 
electron density at these positions. However, the regioselectivity of the substrate is altered after 
cyclometalation (Ax), with the most reactive (electron rich) carbon site for functionalisation now 
indicating addition at C11; the C-H position para to the new Ru-C bond. The analysis conducted 
on substituted arenes (1n, 1r) that had previously displayed significant regioisomeric 
byproducts (Scheme 3), did not show significantly enhanced reactivity at the free ortho position 
(C8/C12). This suggests that these products are formed via an alternative mechanism, likely an 
oxidative addition / reductive elimination pathway as has previously been proposed in 








Figure 4-2. Relative nucleophilicity Fukui indices (𝑓𝐴
−) calculated for computed substrates 1a, 
1k, 1n, 1r and the corresponding cyclometalated complexes, Ax, [(p-cymene)Ru(OMes)(1x)]. 
Calculations were performed at the BP86/6-31G**&SDD(Ru) level of theory. Fukui indices were 
calculated with NBO total atomic charges from the optimised neutral structure. The most 
reactive C-H position is highlighted in red. 
 
4.6 Mechanistic considerations: Role of Pd(PPh3)4 
Given the effectiveness of palladium(0) assistance in the above procedure, we had initially 
believed that the role of this additive was to assist in the activation of the α-halo carbonyl 
reagent via an oxidative addition pathway. However, during the preparation of this work, the 
groups of Ackermann16 and Wang17 reported on a procedure for ruthenium catalysed meta 
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selective mono and difluoromethylation reactions using α-bromo ester reagents and cast 
significant doubt onto this hypothesis (Scheme 4-6). 
 




In a similar manner to our previously developed procedure, the Wang group reported co-
catalytic palladium as being necessary to achieve this transformation. However, the Ackermann 
group reported that only phosphine assistance was necessary with P(4-C6H4CF3)3 performing 
as the optimum ligand and simpler phosphines such as PPh3 performing nearly as well. Other 
phosphine sources were significantly less effective, including a range of bisphosphines, trialkyl 
phosphines, phosphites and electron rich triaryl phosphines such as P(pTol)3 and P(Mes)3.  
When applied to our procedure, the addition of PPh3 instead of Pd(PPh3)4 led to comparable 




Table 4-2. Control experiments. 
 
Entry Additive  Yield (%) m:o 
1 none  24 0.4:1 
2 Pd(PPh3)4 (10 mol%)  55 20:1 
3 PPh3 (20 mol%)  58 18:1 
4 PPh3 (40 mol%)  57 19:1 
5 Pd(PPh3)4 (10 mol%) and PPh3 (20 mol%)  56 18:1 
6a PPh3a (20 mol%)  16 1:1 
a Using Na2CO3, [Ru(OMes)2(p-cymene)] at 60oC, 24 h16 
 
These results strongly indicated that the addition of Pd(PPh3)4 serves only as a source of PPh3. 
It therefore seems likely that PPh3 becomes de-coordinated from the palladium center under 
the reaction conditions and serves as a ligand for the ruthenium. This could provide additional 
electron density at the position para to the C-Ru bond formed after cyclometalation. 
Furthermore, the additional steric bulk of the phosphine ligand could also serve to block the 
coordination sphere of the ruthenium metal and disfavor oxidative addition of the alkyl halide 
which could lead to ortho substitution. These properties can help to explain the increased 
reaction yields and selectivity when compared with reactions with no phosphine assistance. 
 
The privileged reactivity of α-halo carbonyls was further highlighted when reaction with 
unactivated alkyl bromide 7 resulted in no meta alkylated products (Scheme 4-5) and led to 
ortho substituted products in agreement with other work in the field.12,13 No disubstituted 
products were isolated. The use of Pd(PPh3)4 led to no alkylated products and could be due to 






Scheme 4-5. Reaction with unactivated alkyl halide 7. 
 
4.7 Mechanistic considerations: Addition to cyclometalated complex 
We were then interested to discover the manner in which the alkyl halide coupling partners 
reacted with the activated arene. In our previous work with meta selective tertiary alkylation 
reactions, we proposed a second distinct single electron redox cycle that can generate the 
tertiary alkyl radical, which can add to the cyclometalated complex in a site selective manner.1 
To investigate this further, a series of experiments were conducted using radical coupling 




Table 4-3. Reactions with ABCN 
 
Entry Catalyst Yield 
1 No catalyst 0% 
2 [Ru(OMes)2(p-cymene)] (10 mol%) 9% 
3 [Ru(OMes)2(p-cymene)] (50 mol%) 26% 
4 PPh3 0% 
5 [Ru(OMes)2(p-cymene)] (10 mol%) + PPh3 (20 mol%) 8% 
 
Thermal generation of a tertiary radical through loss of nitrogen resulted in no conversion to 
the meta product when no ruthenium complex was used however when 10 mol% preformed 
complex [Ru(OMes)2(p-cymene)] was employed, meta alkylated product 1an was formed in a 
9% yield showing that ruthenium is essential for the activation of the substrate molecule. 
Increasing the catalyst loading increased the yield somewhat showing that this is a 
stoichiometric process. The sole use of PPh3 led to no product formation and did not provide 
any additional benefit when used with a ruthenium complex. These results support the 
proposition that cyclometalation activates the position para to the C-Ru bond and external 
activation of the coupling partner and generation of a tertiary alkyl radical can then result in 
addition to this complex. 
 
We were then interested to determine whether primary α-halo carbonyls reacted in the same 
manner as the corresponding secondary and tertiary coupling partners. Reactions with 
stoichiometric amounts of radical scavenger TEMPO led to no product formation (Scheme 4-
6) however this does not necessarily imply a radical mechanism when primary coupling partner 
2a was used. Unlike the secondary or tertiary α-halo carbonyl coupling partners that were 
shown to be effective in Scheme 4 or the thermally generated tertiary radical formed from 
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ABCN, the radical formed from homolytic cleavage of the C-Br bond in 2a would not benefit 
from any captodative stabilization and attempts to trap this radical with TEMPO were 
unsuccessful. It is possible still that this coupling partner could react via an electrophilic 




Scheme 4-7. Reactions with TEMPO aOnly added for reaction with 2a b2a (R1 = R2 = H) 2b (R1 
= H R2 = Me) 2c (R1 = R2 = Me) 
4.8 Conclusions and overall mechanism 
Based on our most recent mechanistic observations and on previous work conducted by 
ourselves1 and others11,2 in the field, we propose the following mechanism for meta selective 
alkylations with primary, secondary and tertiary α-halo carbonyls (Scheme 4-8). Reaction of a 
substrate molecule with ruthenium results in a cyclometalated complex activated with additional 
electron density at the position para to the C-Ru bond. Reaction of this complex with secondary 
or tertiary radicals externally generated by a single electron Ru(II)/Ru(III)X process then leads 
to the formation of a cyclometalated arene radical.  Single electron oxidation, rearomatization 
and demetallation then leads to the meta substituted products. When primary α-halo carbonyl 
radicals are instead utilised, phosphine coordination to the ruthenium catalyst further promotes 
activation of the substrate molecule for meta selectivity. Addition then occurs at the position 
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5.0 Overall conclusions and future work 
The field of selective catalytic C-H functionalisation has grown substantially in recent years and 
is still a topic of great importance in synthetic research. The benefits of improved step and atom 
economy over traditional approaches, as well as generating new synthetic disconnections, means 
that developing broadly useful methodologies remains as attractive as ever.  
 
The strategies devised to tackle the significant challenge of achieving selective functionalisation 
of a C-H bond within a molecule rely largely on either exploiting its innate reactivity or by utilising 
a directing group approach. In the best case scenario, these methodologies can result in the 
highly efficient coupling of two molecules in a catalytic cycle without the use of stoichiometric 
additives or the need for pre or post synthetic modifications. However, due to the complexity of 
molecular systems, it is difficult to develop a one-size-fits-all strategy for direct C-H 
functionalisation. 
 
The field of ortho functionalisation has become sufficiently developed such that most common 
Lewis basic functional groups can now be recognised for their potential to direct a transition metal 
catalyst to a C-H bond in a predictable manner. Conceptually, the use of a directing group strategy 
has largely prevailed, and through appropriate choice of catalyst and reaction conditions a great 
number of transformations have been made possible. In contrast, the field of meta selective C-H 
functionalisation has been less developed whereby a simple directing group strategy cannot 
always be as readily applied. 
 
Several approaches have nevertheless come into recent prominence, each with their own 
advantages and limitations. Early examples which relied solely on a molecules innate reactivity 
through electronic or steric biases afford reactions with excellent selectivity however are 
inherently limited in scope. Directing group strategies such as those utilising extended templates 
or transient mediators effectively address issues of scope by converting common functional 
groups into meta selective directing groups however often come at the expense of overall step 
and atom economy. The work in this thesis has described the development of another strategy 
for meta selective C-H functionalisation by ruthenium catalysed σ-activation, which can be viewed 
as a hybrid method between innate and directed functionalisation. It benefits from being 
operationally simple and highly selective, however at present is somewhat limited in scope. 
  
At the outset of this work, just one example had been reported: the meta sulfonation of 2-
phenylpyridines with aryl sulfonyl chlorides. The mechanism and scope of this reaction was not 
immediately clear but recent work conducted in the field has led to significant advances in 
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understanding with the work described in this thesis making valuable contributions to this. The 
manuscript entitled “Catalytic meta selective C-H functionalization to construct quaternary carbon 
centres” was the second contribution to the field from our group and crucially this work gave 
significant insight into the reaction mechanism and potential scope. Specifically, this work gave 
good evidence for a radical based mechanism, especially because of the effective coupling of α-
halo carbonyl reagents and the associated polymer type products which were consistent with a 
radical mechanism. Furthermore, this work was the first to propose a potential dual role of the 
ruthenium catalyst, activating both the substrate and the coupling partner, and this proposition 
was independently supported by similar work conducted in the field. Other work reported in this 
thesis using α-halo carbonyls expanded the scope of the meta alkylation procedure and enabled 
meta selective primary alkylations. This work also provided additional mechanistic insight into the 
substrate activation pathway, with experimental and computational support showing that 
cyclometalation activates the position para to the newly installed C-Ru bond for reaction with an 
externally activated coupling partner. 
 
The manuscript entitled “Mechanistic insight into ruthenium catalysed meta sulfonation of 2-
phenylpyridine” provided additional mechanistic analysis to the meta sulfonation reaction, with a 
focus on the catalytic species and mechanisms involved. A key result from this work was a 
stoichiometric experiment with a ruthenium complex, showing that sulfonation occurred para to 
the C-Ru bond, in agreement with previous mechanistic propositions. The work also showed that 
the catalytic species involved did not require an arene ligand and deuterium labelling studies 
identified a likely rate limiting radical tosylation step. 
 
Now, ruthenium catalysed σ-activation has been extended to include meta selective alkylations, 
brominations and nitrations. In most cases, generation of radical coupling partners are implied 
and could be key to the development of new meta selective transformations. This methodology 
has also been demonstrated on a range of substrates with directing groups including pyridine, 
pyrimidine, pyrazole, isoquinoline, quinoxaline, pyridazinone, imine, oxime and benzimidazole. 
This strategy for meta functionalisation usually also benefits from being very operationally simple, 
utilising cheap and readily available materials. 
  
However, despite the successes so far, we have not yet achieved our original ambitious goal of 
developing ruthenium catalysed σ-activation into a broadly useful methodology for meta selective 
C-H functionalisation. While the coupling partner scope is continually growing, a significant 
limitation is that to date, the methodology has only been demonstrated on substrates containing 
strongly coordinating nitrogen containing directing groups. While the use of removable auxiliaries 
has been demonstrated, this methodology likely requires a stable cyclometalated complex for 
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functionalisation and could hence be fundamentally limited in scope. This limitation in scope is 
however largely true of all of the current meta selective C-H functionalisation methodologies and 
represents a significant challenge to the field.  
 
In order to tackle these challenges in the context of ruthenium catalysed σ-activation, we have 
begun to show that new computational methods can be applied to predict the reactivity of the 
resulting complexes. This could be an effective tool for rapid and rational catalyst design and the 
use of appropriate ligands could be the key to enabling more substrates to react in a highly site 
selective manner, an approach that has recently enabled mono and difluoromethylations and 
primary alkylations. This, along with devising new ways of activating coupling partners by 
alternative methods, could be instrumental in developing this methodology into one that can be 
broadly synthetically useful. 
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6.0 Data and supporting information 
The following section contains the reformatted supporting information for each of the manuscripts 
in the previous sections. NMR Spectra for novel compounds have been omitted, however can be 
found online free of charge on the journal webpages. 
6.1 Supporting information and data for: Catalytic meta-selective C-H 
functionalisation to construct quaternary carbon centres. 
 
General Considerations:  
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were recorded on an Agilent 
Technologies spectrometer (1H NMR at 500 MHz, 13C NMR at 126 MHz, and 19F NMR at 470 
MHz). Chemical shifts for protons are reported downfield from tetramethylsilane and are 
referenced to residual protium in the solvent (1H NMR: CHCl3 at 7.26 ppm). Chemical shifts for 
carbons are reported in parts per million downfield from tetramethylsilane and are referenced to 
the carbon resonances of the solvent peak (13C NMR: CDCl3 at 77.0 ppm). Chemical shifts for 
fluorine resonances are reported in parts per million referenced to CFCl3. NMR data are 
represented as follows: chemical shift (integration, multiplicity [s = singlet, bs = broad singlet, d = 
double, dd = doublet of doublet, t = triplet, q = quartet, hept = heptet, m = multiplet], coupling 
constants (Hz)). IR spectra were recorded on a Perkin-Elmer 1600 FT IR spectrophotometer, with 
absorbencies quoted as ν in cm-1. High resolution mass spectrometry was performed on a Bruker 
Daltonik µTOF electrospray time-of-flight (ESI-TOF) mass spectrometer. HPLC analysis was 
conducted on an Agilent 1260 infinity quaternary LC instrument equipped with a Zorbax Eclipse 
XDB-C18 4.6 x 250 mm 5 μm analytical column. Analytical thin layer chromatography (TLC) were 
performed using aluminium-backed plates coated with Alugram® SIL G/UV254 purchased from 
Macherey-Nagel and visualised by UV light (254 nm) and/or KMnO4, staining. Silica gel column 




All reactions were carried out under an atmosphere of argon, in oven-dried glassware unless 
otherwise stated. Anhydrous solvents were used in all experiments and stored under an 
atmosphere of argon prior to use. [RuCl2 (p-cymene)]2 was purchased from Strem chemicals. 
Boronic acids were purchased from Fronteir Scientific. 2-chloro-2methylpropane, 2-bromo-
2methylpropane, 2-bromo-2methylbutane, 1-bromo adamantine and 3-chloro-3-ethyl pentane 
were purchased from sigma Aldrich. All other chemicals were bought from Alfa Aesar. All 





Reaction conversions were calculated using 1H NMR and confirmed using 19F NMR where 
possible. With the exception of those carried out using ethyl 2-bromoisobutrate (2c) all reactions 
formed one product exclusively and thus conversions represent conversion of the starting material 
to the desired product. Suitably resolved signals in the crude reaction mixture were used for these 
calculations. Orthogonal analysis using TLC and HPLC-MS revealed negligible by-products. This 
is exemplified below. 
 
Conversion by 1H NMR of Crude Reaction Mixture: Signal at 8.05 ppm  (dd, J = 1.8 Hz, 1H) from 




HPLC analysis of the crude reaction mixture showing the major components: starting material 1a 
(retention time 5.93 min) and product 3a (retention time 11.28 min). 
Sample prepared to approximate 10 μmol / mL in acetonitrile 
Column: Zorbax Eclipse XDB-C18 4.6 x 250 mm 5 μm analytical column 
Mobile Phase: Isocratic 70/30 acetonitrile/H2O with 0.1% formic acid 
Flow Rate: 0.5 mL / min 









To an oven dried, argon purged ampule equipped with magnetic stirrer was added 2-
phenylpyridine (1 mmol, 0.14 mL), a solvent (4 mL), 2-Bromo-2-methylpropane, [RuCl2(p-
cymene)]2 and a base in the amounts specified. The ampule was then sealed and refluxed on a 
carousel at 120 °C for the amount of time specified. After cooling to room temperature, aqueous 
NaHCO3 (saturated) and EtOAc were added. A sample of the organic phase was taken, 
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Methyl tert-butyl ether 55 
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Alkyl Halide Stoichiometry 
 






























Multiple reactions were set up in series and after the designated reaction time were immediately 
cooled in an ice bath, worked up and analysed as per the general procedure. 
 















































*No formation of 3a, starting material 1a completely destroyed. 
 
Optimisation for 2-Chloro-2-methylpropane 
 
KOAc Equivalents K2CO3 Equivalents Conversion (%) 
0 2 27 
0.5 1.5 63 
1 1 38 
1.5 0.5 0 








To an oven dried, argon purged flask equipped with magnetic stirrer and condenser was added 
Pd(PPh3)4 (1 mol%), K2CO3 (2 eq) and ethanol (1 M). A solution of the boronic acid (1.5 eq) in 
EtOH (1 M) was then added via a dropping funnel to the reaction vessel followed by the addition 
of 2-bromopyridine (1 eq). The reaction mixture was then heated to 100 °C and refluxed for 15 
hours. After cooling to room temperature, aqueous NaOH (1 M) was added and extracted three 
times with EtOAc. The organic extracts were then combined, washed with brine, dried with MgSO4 
and then concentrated under reduced pressure. The crude product was then purified by silica gel 




2-bromopyridine (25 mmol, 2.4 mL), 4-methoxyphenyl boronic acid (33 mmol, 5.0 g), Pd(PPh3)4 
(0.25 mmol, 289  mg), K2CO3 (50 mmol, 6.90 g) were reacted together in EtOH (25 mL) according 
to the general procedure to afford the title compound as a white solid (4.4 g, 95%). 1H NMR (500 
MHz, CDCl3) δ 8.65 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.76 – 7.64 (m, 2H), 
7.17 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 7.00 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 160.43, 157.08, 149.47, 136.67, 131.92, 128.15, 121.38, 119.79, 114.11, 55.34. 






2-bromopyridine (20 mmol, 1.9 mL), 4-fluorophenyl boronic acid (30 mmol, 4.20 g), Pd(PPh3)4 
(0.2 mmol, 231  mg), and K2CO3 (40 mmol, 5.52 g) were reacted together in EtOH (20 mL) 
according to the general procedure to afford the title compound as a yellow / white crystalline solid 
(3.20 g, 92%). 
 
1H NMR (500 MHz, CDCl3) δ 8.68 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.98 (dd, J = 8.9, 5.4 Hz, 2H), 
7.77 – 7.72 (m, 1H), 7.68 (dt, J = 8.0, 1.0 Hz, 1H), 7.22 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 7.16 (t, J 
= 8.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 163.51 (d, 1JC-F = 248.4 Hz), 135.51 (d, 4JC-F = 3.1 
Hz), 128.68 (d, 3JC-F = 8.4 Hz), 115.63 (d, 2JC-F = 21.6 Hz). 19F NMR (470 MHz, CDCl3) δ -113.14 
– -113.24 (m). 




2-bromopyridine (13 mmol, 1.2 mL), 4-chlorophenyl boronic acid (20 mmol, 3.04 g), Pd(PPh3)4 
(0.13 mmol, 150  mg), and K2CO3 (26 mmol, 3.58 g) were reacted together in EtOH (13 mL) 
according to the general procedure to afford the title compound as a pale yellow crystalline solid 
(1.20 g, 89%). 
 
1H NMR (500 MHz, CDCl3) δ 8.69 (dd, J = 4.8, 0.8 Hz, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.81 – 7.74 
(m, 1H), 7.71 (dd, J = 7.9, 0.9 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.29 – 7.24 (m, 1H). 
13C NMR (126 MHz, CDCl3) δ 155.97, 149.35, 137.31, 137.26, 135.30, 128.97, 128.23, 122.45, 
120.49. 






2-bromopyridine (13 mmol, 1.2 mL), 4-(methoxycarbonyl)phenyl boronic acid (20 mmol, 3.04 g), 
Pd(PPh3)4 (0.13 mmol, 150  mg), and K2CO3 (26 mmol, 3.58 g) were reacted together in EtOH (13 
mL) according to the general procedure to afford the title compound as a white solid (2.42 g, 
82%). 
 
1H NMR (500 MHz, CDCl3)  δ 8.73 (d, J = 4.6 Hz, 1H), 8.15 (d, J = 8.2 Hz, 2H), 8.07 (d, J = 8.3 
Hz, 2H), 7.87 – 7.71 (m, 2H), 7.29 (dd, J = 8.3, 4.8 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 
7.1 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 166.56, 156.38, 149.93, 143.42, 137.15, 130.90, 
130.16, 126.95, 123.00, 121.19, 77.16, 61.22, 14.50. 




2-bromopyridine (10 mmol, 0.92 mL), 4-(trifluoromethyl)phenyl boronic acid (15 mmol, 2.85 g), 
Pd(PPh3)4 (0.10 mmol, 115  mg), and K2CO3 (20 mmol, 2.76 g) were reacted together in EtOH (10 
mL) according to the general procedure to afford the title compound as an off white solid (1.38 g, 
62%). 
 
1H NMR (500 MHz, CDCl3)   δ 8.73 (d, J = 4.7 Hz, 1H), 8.11 (d, J = 8.2 Hz, 2H), 7.84 – 7.69 (m, 
4H), 7.33 – 7.27 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 155.98 (s), 150.03 (s), 142.77 (s), 137.13 
(s), 130.91 (q, 2JC-F = 32.5 Hz), 127.31 (s), 125.81 (q, 3JC-F = 3.8 Hz), 124.32 (q, 1JC-F = 272.0 Hz), 
123.09 (s), 121.00 (s). 19F NMR (470 MHz, CDCl3) δ -62.61 (s). 






2-bromopyridine (4.5 mmol, 0.43 mL), 4-nitrophenyl boronic acid (6 mmol, 1.0 g), Pd(PPh3)4 
(0.045 mmol, 52  mg), and K2CO3 (9 mmol, 1.24 g) were reacted together in EtOH (5 mL) 
according to the general procedure to afford the title compound as a yellow solid (609 mg, 68%). 
 
1H NMR (500 MHz, CDCl3) δ 8.76 (d, J = 4.7 Hz, 1H), 8.34 (d, J = 8.6 Hz, 2H), 8.19 (d, J = 8.6 
Hz, 2H), 7.89 – 7.74 (m, 2H), 7.35 (t, J = 5.6 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 155.03, 
150.30, 148.22, 145.41, 137.26, 127.83, 124.16, 123.66, 121.36 




2-bromopyridine (13 mmol, 1.2 mL), 2,6-dimethylphenylboronic acid (20 mmol, 3.0 g), Pd(PPh3)4 
(0.13 mmol, 150  mg), and K2CO3 (26 mmol, 3.59 g) were reacted together in EtOH (15 mL) 
according to the general procedure to afford the title compound as a red oil (1.96 g, 82%). 
 
1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 4.5 Hz, 1H), 7.82 (dd, J = 7.6 Hz, 1H), 7.34 – 7.30 (m, 
1H), 7.28 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.12 (d, J = 7.6 Hz, 2H).  13C NMR (126 
MHz, CDCl3) δ 159.56, 149.17, 139.76, 137.09, 135.93, 128.25, 127.72, 124.93, 122.02, 77.16, 
20.33. 






2-bromopyridine (5 mmol, 0.46 mL), 3-methylphenylboronic acid (7 mmol, 1.0 g), Pd(PPh3)4 (0.05 
mmol, 58  mg), and K2CO3 (10 mmol, 1.38 g) were reacted together in EtOH (7.5 mL) according 
to the general procedure to afford the title compound as a yellow oil (772 mg, 91%). 
 
1H NMR (500 MHz, CDCl3)  δ 8.73 (d, J = 4.7 Hz, 1H), 7.87 (s, 1H), 7.84 – 7.73 (m, 3H), 7.39 (dd, 
J = 7.6 Hz, 1H), 7.29 – 7.24 (m, 2H), 2.46 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.40, 149.18, 
138.81, 138.50, 137.16, 129.94, 128.69, 127.72, 124.09, 122.11, 120.86, 21.51. 




2-bromopyridine (20 mmol, 1.84 mL), 2-methylphenylboronic acid (30 mmol, 4.08 g), Pd(PPh3)4 
(0.2 mmol, 231  mg), and K2CO3 (40  mmol, 5.52 g) were reacted together in EtOH (30 mL) 
according to the general procedure to afford the title compound as a yellow oil (2.96 g, 88%). 
 
1H NMR (500 MHz, CDCl3) δ 8.71 (d, J = 3.9 Hz, 1H), 7.85 – 7.69 (m, 1H), 7.42 (dd, J = 13.6, 4.5 
Hz, 2H), 7.33 – 7.25 (m, 4H), 2.29 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.67, 148.75, 139.86, 
136.60, 135.77, 130.77, 129.64, 128.46, 125.91, 124.30, 121.76, 20.27. 






Synthesis of meta-Substituted 2-Phenylpyridine Derivatives. 
General Procedure A 
 
To an oven dried, argon purged ampule equipped with magnetic stirrer was added the 2-
phenylpyridine derivative (1 mmol), the alkyl halide (3mmol), [RuCl2(p-cymene)]2 (5 mol%, 30 mg), 
KOAc (2 mmol, 196 mg) and 1,4-Dioxane (4 mL). The ampule was then sealed and refluxed on a 
carousel at 120 °C for the amount of time specified. After cooling to room temperature, aqueous 
NaHCO3 (saturated) was added and then was extracted three times with EtOAc. The organic 
extracts were then combined, washed with brine, dried with MgSO4 and then concentrated under 
reduced pressure. The crude product was then purified by silica gel column chromatography 
(Hexane / EtOAc). 
 
General Procedure B 
 
To an oven dried, argon purged ampule equipped with magnetic stirrer was added the 2-
phenylpyridine derivative (1 mmol), the alkyl halide (3mmol), [RuCl2(p-cymene)]2 (5 mol%, 30 mg), 
KOAc (0.5 mmol, 49 mg), K2CO3 (1.5 mmol, 207 mg)  and 1,4-Dioxane (4 mL). The ampule was 
then sealed and refluxed on a carousel at 120 °C for the amount of time specified. After cooling 
to room temperature, aqueous NaHCO3 (saturated) was added and then was extracted three 
times with EtOAc. The organic extracts were then combined, washed with brine, dried with MgSO4 
and then concentrated under reduced pressure. The crude product was then purified by silica gel 






2-phenylpyridine (1 mmol, 0.14 mL), 2-bromo-2-methylpropane (3 mmol, 0.34 mL), [RuCl2(p-
cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-Dioxane 
(4 mL) according to general procedure A to afford the title compound as a yellow oil (15 mg, 7%). 
 
1H NMR (500 MHz, CDCl3) δ 8.71 (d, J = 4.8 Hz, 1H), 8.05 (dd, J = 1.8 Hz, 1H), 7.86 – 7.65 (m, 
3H), 7.47 (d, J = 7.9 Hz, 1H), 7.42 (t, J = 7.7 Hz, 1H), 7.22 (ddd, J = 6.7, 4.9, 1.9 Hz, 1H), 1.40 (s, 
9H).13C NMR (126 MHz, CDCl3) δ 158.19, 151.74, 149.75, 139.32, 136.78, 128.57, 126.20, 
124.30, 124.10, 122.04, 120.90, 77.16, 35.01, 31.54. HR-MS (ESI) m/z: calculated for C15H18N 




2-(4-methylphenyl)lpyridine (1 mmol, 0.17 mL), 2-bromo-2-methylpropane (3 mmol, 0.34 mL), 
[RuCl2(p-cymene)]2  (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-
Dioxane (4 mL) according to general procedure A to afford the title compound as a colourless oil 
(12 mg, 5%). 
 
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.0 Hz, 1H), 8.05 (s, 1H), 7.77 (dd, J = 7.4 Hz, 1H), 7.74 
– 7.68 (m, 2H), 7.24 (d, J = 7.6 Hz, 2H), 2.60 (s, 3H), 1.49 (s, 9H).13C NMR (126 MHz, CDCl3) δ 
157.83, 151.32, 149.12, 148.63, 137.41, 133.47, 125.07, 124.54, 122.86, 121.93, 120.90, 36.18, 
30.98, 23.27.HR-MS (ESI) m/z: calculated for C16H19N [M+H]+ 226.1596, found: 226.1594. νmax 






2-(4-methoxyphenyl)pyridine (1 mmol, 185 mg), 2-bromo-2-methylpropane (3 mmol, 0.34 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-
Dioxane (4 mL) according to general procedure A to afford the title compound as a colourless oil 
(100 mg, 42%). 
 
1H NMR (500 MHz, CDCl3) δ 8.67 (d, J = 4.7 Hz, 1H), 7.96 (d, J = 1.3 Hz, 1H), 7.83 (d, J = 8.4 
Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.68 (d, J = 7.9 Hz, 1H), 7.19 (br s, 1H), 6.98 (d, J = 8.5 Hz, 1H), 
3.90 (s, 3H), 1.44 (s, 9H).13C NMR (126 MHz, CDCl3) δ 159.84, 157.66, 149.06, 138.70, 137.25, 
126.05, 125.71, 121.40, 120.38, 111.84, 77.16, 55.29, 35.19, 29.84. HR-MS (ESI) m/z: calculated 




2-(4-fluorophenyl)pyridine (1 mmol, 173 mg), 2-bromo-2-methylpropane (3 mmol, 0.34 mL), 
[RuCl2(p-cymene)]2  (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) 
were reacted together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title 
compound as a colourless oil (140 mg, 61%). 
 
1H NMR (500 MHz, CDCl3) δ 8.68 (d, J = 4.6 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.79 – 7.74 (m, 
1H), 7.70 (dd, J = 7.1 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.22 – 7.16 (m, 1H), 7.08 (dd, J = 12.0, 
8.6 Hz, 1H), 1.46 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 162.83 (d, 1JC-F = 250.7 Hz), 157.14 (s), 
149.60 (s), 137.41 (d, 2JC-F = 12.1 Hz), 136.82 (s), 135.13 (d, 4JC-F = 3.0 Hz), 126.29 (d, 3JC-F = 6.4 
Hz), 126.25 (d, 3JC-F = 9.3 Hz), 121.89 (s), 120.43 (s), 116.64 (d, 2JC-F = 25.0 Hz), 34.53 (d, 3JC-F 
= 2.7 Hz), 29.97 (d, 4JC-F = 3.4 Hz). 19F NMR (470 MHz, CDCl3) δ -109.38 (s). HR-MS (ESI) m/z: 
calculated for C15H16NF [M+H]+  230.1345, found: 230.1342. νmax (neat) / cm-1; 2959, 1589, 





2-4-(chlorophenyl)pyridine (1 mmol, 190 mg), 2-bromo-2-methylpropane (3 mmol, 0.34 mL), 
[RuCl2(p-cymene)]2  (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-
Dioxane (4 mL) according to general procedure A to afford the title compound as a colourless oil 
(70 mg, 25%). 
 
1H NMR (500 MHz, CDCl3) δ 8.72 (d, J = 4.1 Hz, 1H), 8.10 (d, J = 2.2 Hz, 1H), 7.81 (td, J = 7.8, 
1.8 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 8.3 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.29 (ddd, 
J = 7.3, 4.9, 0.8 Hz, 1H), 1.55 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 156.47, 148.97, 146.95, 
137.60, 136.82, 135.08, 132.37, 126.67, 125.65, 122.36, 120.91, 36.31, 29.58. HR-MS (ESI) m/z: 
calculated for C15H16NCl [M+H]+ 246.1050, found: 246.1030. νmax (neat) / cm-1; 2960, 1586, 1459, 
1431. 
 
ethyl 2-tert-butyl-4-(pyridin-2-yl)benzoate (3f) 
 
2-(4-(ethoxycarbonyl)phenyl)pyridine (1 mmol, 190 mg), 2-bromo-2-methylpropane (3 mmol, 0.34 
mL), [RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 
1,4-Dioxane (4 mL) according to general procedure A to afford the title compound as a colourless 
oil (23 mg, 8%). 
 
1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 3.7 Hz, 1H), 8.17 (s, 1H), 7.85 – 7.78 (m, J = 13.6, 7.5 
Hz, 2H), 7.75 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 7.9 Hz, 1H), 7.33 – 7.28 (m, 1H), 4.39 (q, J = 7.1 
Hz, 2H), 1.48 (s, 9H), 1.40 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.75, 156.49, 
149.00, 148.31, 139.50, 137.64, 133.94, 129.34, 125.93, 124.05, 122.62, 121.26, 61.48, 36.20, 
31.36, 14.08. HR-MS (ESI) m/z: calculated for C18H21NO2 [M+H]+ 284.1651, found: 284.1645. νmax 








2-Phenylpyridine (1 mmol, 140 µL), 1-adamantyl bromide (3.00 mmol, 645 mg), [RuCl2(p-
cymene)]2 (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) were reacted 
together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title compound as 
a white solid (15 mg, 5%). 
 
1H NMR: (500 MHz, CDCl3) δ 8.75 (d, J = 4.6 Hz, 1H), 8.14 – 7.96 (m, 1H), 7.85 – 7.74 (m, 3H), 
7.50 – 7.42 (m, 2H), 7.31 – 7.24 (m, 1H), 2.14 (s, 3H), 2.02 (s, 6H), 1.85 – 1.76 (m, 6H). 13C NMR 
(126 MHz, CDCl3) δ 158.29, 152.00, 149.76, 139.35, 136.74, 128.60, 125.79, 124.36, 123.80, 
122.00, 120.87, 43.34, 36.95, 36.54, 29.13. HR-MS (ESI) m/z: calculated for C21H23NO [M+H]+ 




2-(4-Methoxyphenyl)pyridine (1 mmol, 185 mg), 1-adamantyl bromide (3.00 mmol, 645 mg), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) 
were reacted together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title 
compound as a white solid (114 mg, 36%). Crystals large enough for single crystal X-ray analysis 
were generated using CHCl3 / Hexane. 
1H NMR (500 MHz, CDCl3) δ 8.66 (ddd, J = 4.9, 1.7, 1.0 Hz, 1H), 7.92 (d, J = 2.3 Hz, 1H), 7.81 
(dd, J = 8.5, 2.3 Hz, 1H), 7.74 – 7.69 (m, 1H), 7.68 (ddd, J = 8.0, 1.2 Hz, 1H), 7.17 (ddd, J = 7.0, 
4.9, 1.4 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 3.89 (s, 3H), 2.20 – 2.15 (m, J = 2.9 Hz, 6H), 2.09 (s, 
3H), 1.79 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 159.99, 157.81, 149.31, 138.83, 136.95, 131.29, 
125.67, 125.64, 121.32, 120.22, 111.90, 55.24, 40.64, 37.29, 37.25, 29.22. HR-MS (ESI) m/z: 
calculated for C22H25NO [M+H]+ 320.2014, found: 320.2008 
112 
 
Crystal Data 4c, C22H25NO (M = 319.43 g/mol): monoclinic, space group P21/c (no. 14), a = 
12.82457(18), b = 6.61539(9), c = 20.0798(3) Å, β = 93.3829(13)°, U = 1700.59(4) Å3, Z = 4, T = 
150(2) K, μ(CuKα) = 0.581 mm-1, Dcalc = 1.248 g/cm3, 17596 reflections measured (8.82° ≤ 2θ 
≤ 143.96°), 3328 unique (Rint = 0.0403, Rsigma = 0.0297) which were used in all calculations. 
The final R1 was 0.0384 (I>2σ(I)) and wR2 was 0.0964 (all data).  
 
Crystallographic data have been deposited with Cambridge Crystallographic Data Centre; CCDC-
1064109.  Copies of these data can be obtained free of charge via 
http://www.ccdc.cam.ac.uk/conts/retrieving.html  (or from the Cambridge Crystallographic Data 





2-(4-Methoxyphenyl)pyridine (1 mmol, 185 mg), 2-chloro-2-methylbutane (367 µL, 3 mmol), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) 
were reacted together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title 
compound as a colourless oil (139 mg, 54%). 
 
1H NMR (500 MHz, CDCl3) δ 8.67 (ddd, J = 4.9, 1.7, 1.0 Hz, 1H), 7.90 (d, J = 2.3 Hz, 1H), 7.83 
(dd, J = 8.5, 2.3 Hz, 1H), 7.73 – 7.69 (m, 1H), 7.68 (ddd, J = 8.0, 1.2 Hz, 1H), 7.21 – 7.05 (m, 1H), 
6.96 (d, J = 8.5 Hz, 1H), 3.87 (s, 3H), 1.89 (q, J = 7.5 Hz, 2H), 1.41 (s, 6H), 0.66 (t, J = 7.5 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 159.68, 157.79, 149.33, 136.91, 136.87, 131.11, 126.92, 
125.89, 121.30, 120.20, 111.62, 55.28, 38.79, 33.22, 28.01, 9.78. HR-MS (ESI) m/z: calculated 






2-Phenylpyridine (1 mmol, 140 µL), 2-chloro-2-methylnonane (3 mmol, 530 mg), [RuCl2(p-
cymene)]2 (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) were reacted 
together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title compound as 
a colourless oil (146 mg, 43%). 
 
1H NMR: (500 MHz, CDCl3) δ 8.72 (d, J = 4.7 Hz, 1H), 8.00 – 7.96 (m, 1H), 7.83 – 7.71 (m, 3H), 
7.46 – 7.39 (m, 2H), 7.28 – 7.22 (m, 1H), 1.70 – 1.62 (m, 2H), 1.37 (s, 6H), 1.30 – 1.04 (m, 10H), 
0.84 (t, J = 7.1 Hz, 3H). 13C NMR: (126 MHz, CDCl3) δ 157.85, 150.47, 149.20, 138.55, 137.09, 
128.43, 126.85, 124.58, 124.14, 121.98, 120.95, 44.63, 37.90, 31.87, 30.31, 29.23, 29.01, 24.76, 
22.65, 14.09. HR-MS (ESI) m/z: calculated for C21H29NO [M+H]+ 296.2378, found: 296.2401. νmax 




2-(4-methoxyphenyl)pyridine (1 mmol, 185 mg), 2-chloro-2-methylnonane (3 mmol, 530 mg), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) 
were reacted together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title 
compound as a colourless oil (139 mg, 54%). 
 
1H NMR: (500 MHz, CDCl3) δ 8.67 (d, J = 4.6 Hz, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.84 (dd, J = 8.5, 
2.3 Hz, 1H), 7.74 – 7.65 (m, 2H), 7.20 – 7.12 (m, 1H), 6.95 (d, J = 8.5 Hz, 1H), 3.87 (s, 3H), 1.93 
– 1.78 (m, 2H), 1.44 (d, J = 6.7 Hz, 6H), 1.31 – 1.15 (m, 8H), 1.06 – 0.97 (m, 2H), 0.85 (t, J = 7.1 
Hz, 3H). 13C NMR: (126 MHz, CDCl3) δ 159.59, 157.64, 149.17, 137.12, 136.84, 130.93, 126.64, 
125.77, 121.20, 120.09, 111.51, 55.13, 40.80, 38.42, 31.89, 30.39, 29.21, 28.48, 25.26, 22.69, 
14.12.HR-MS (ESI) m/z: calculated for C22H31NO [M+H]+ 326.2484, found: 326.2521. νmax (neat) 






2-(4-methoxyphenyl)pyridine (1 mmol, 185 mg), 3-chloro-3-ethylpentane (1.70 mmol, 229 mg), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), KOAc (0.5 mmol, 49 mg) and K2CO3 (1.5 mmol, 207 mg) 
were reacted together in 1,4-Dioxane (4 mL) according to general procedure B to afford the title 
compound as a colourless oil (139 mg, 54%). 
 
1H NMR: (500 MHz, CDCl3) δ 8.69 (s, 1H), 7.95 – 7.68 (m, 4H), 7.22 (s, 1H), 6.97 (d, J = 6.2 Hz, 
1H), 3.86 (s, 3H), 1.88 (q, J = 7.2 Hz, 6H), 0.66 (t, J = 7.3 Hz, 9H). 13C NMR (126 MHz, CDCl3) δ 
160.11, 157.43, 148.85, 137.83, 135.10, 129.89, 128.57, 126.10, 121.57, 120.67, 111.80, 77.16, 
55.44, 44.78, 26.21, 8.65. HR-MS (ESI) m/z: calculated for C19H25NO [M+H]+ 284.1936, found: 




2-phenylpyridine (1 mmol, 0.14 mL), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), [RuCl2(p-
cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-Dioxane 
(4 mL) according to general procedure A. The crude mixture was purified by flash column 
chromatography to yield products 8a (125 mg, 46%) as a colourless oil and product 9a (25 mg, 





ethyl 2-methyl-2-[3-(pyridin-2-yl)phenyl]propanoate (8a) 
 
1H NMR (500 MHz, CDCl3) δ 8.69 (ddd, J = 4.9, 1.7, 1.0 Hz, 1H), 7.99 (dd, J = 1.9 Hz, 1H), 7.86 
– 7.83 (m, 1H), 7.77 – 7.74 (m, 1H), 7.71 (ddd, J = 8.0, 1.1 Hz, 1H), 7.43 (dd, J = 7.7 Hz, 1H), 
7.40 – 7.37 (m, 1H), 7.23 (ddd, J = 7.3, 4.9, 1.3 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 1.64 (s, 6H), 
1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.80, 157.50, 149.54, 145.50, 139.34, 
137.05, 128.87, 126.72, 125.45, 124.36, 122.27, 120.92, 60.96, 46.73, 26.70, 14.18. HR-MS (ESI) 
m/z: calculated for C17H19NO2 [M+H]+ 270.1494, found: 270.1533. νmax (neat) / cm-1; 2978, 1722, 
1584, 1461, 1433 
 
diethyl 2,2,3-trimethyl-3-[3-(pyridin-2-yl)benzyl]butanedioate (9a) 
 
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.8 Hz, 1H), 8.02 (s, 1H), 7.86 (d, J = 7.3 Hz, 1H), 7.77 
(dd, J = 7.6 Hz, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.26 – 7.23 (m, 1H), 4.24 – 
3.98 (m, 4H), 2.64 (d, J = 14.5 Hz, 1H), 2.56 (d, J = 14.5 Hz, 1H), 1.57 (s, 3H), 1.25 (t, J = 7.1 Hz, 
3H), 1.20 (t, J = 7.1 Hz, 3H), 1.20 (s, 3H), 1.13 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 178.44, 
176.08, 157.25, 149.16, 145.42, 137.59, 136.00, 128.97, 127.11, 125.76, 124.90, 122.43, 121.20, 
61.19, 60.69, 49.64, 48.05, 41.92, 29.35, 23.99, 21.04, 14.20, 14.09. HR-MS (ESI) m/z: calculated 
for C23H29NO4Na [M+Na]+ 406.1994, found: 406.1971 






2-(4-methoxyphenyl)pyridine (1 mmol, 185 mg), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-
Dioxane (4 mL) according to general procedure A. The crude mixture was purified by flash column 
chromatography to yield products 8c (170 mg, 57%) as a white amorphous solid and product 9c 
(45 mg, 12%) as a colourless oil. 
 
ethyl 2-[2-methoxy-5-(pyridin-2-yl)phenyl]-2-methylpropanoate (8c) 
 
1H NMR (500 MHz, CDCl3) δ 8.66 (d, J = 4.4 Hz, 1H), 7.99 (d, J = 2.1 Hz, 1H), 7.86 (dd, J = 8.4, 
1.9 Hz, 1H), 7.73 (dd, J = 7.5 Hz, 1H), 7.69 (d, J = 7.9 Hz, 1H), 7.21 – 7.14 (m, 1H), 6.94 (d, J = 
8.5 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.82 (s, 3H), 1.59 (s, 6H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 177.87, 157.87, 157.36, 149.31, 137.08, 134.68, 131.52, 126.70, 124.68, 
121.55, 120.28, 110.96, 60.44, 55.37, 44.55, 25.74, 14.32. HR-MS (ESI) m/z: calculated for 




diethyl 2-[2-methoxy-5-(pyridin-2-yl)phenyl]-2,3,3-trimethylbutanedioate (9c) 
 
1H NMR (500 MHz, CDCl3) δ 8.66 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.89 
(dd, J = 8.4, 2.2 Hz, 1H), 7.74 – 7.70 (m, 1H), 7.69 (ddd, J = 8.0, 1.3 Hz, 1H), 7.17 (ddd, J = 6.9, 
4.8, 1.5 Hz, 1H), 6.90 (d, J = 8.4 Hz, 1H), 4.11 – 4.02 (m, 2H), 3.87 – 3.82 (m, J = 7.2, 1.5 Hz, 
2H), 3.81 (s, 3H), 2.67 (d, J = 14.8 Hz, 1H), 2.50 (d, J = 14.8 Hz, 1H), 1.64 (s, 3H), 1.18 (s, 3H), 
1.12 (t, J = 7.1 Hz, 3H), 1.11 (t, J = 7.1 Hz, 3H), 0.88 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 177.98, 
177.32, 159.13, 156.04, 135.99, 132.74, 130.08, 128.28, 128.06, 127.10, 122.09, 121.53, 111.27, 
60.67, 60.43, 55.50, 48.06, 44.59, 41.47, 28.10, 27.38, 23.16, 14.21, 14.11. HR-MS (ESI) m/z: 






2-(4-fluorophenyl)pyridine (1 mmol, 173 mg), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-
Dioxane (4 mL) according to general procedure A. The crude mixture was purified by flash column 
chromatography to yield products 8c (135 mg, 47%) as a colourless oil, product 9c (50 mg, 13%) 
as a colourless oil and product 9d (15 mg, 3%). 
 
ethyl 2-[2-fluoro-5-(pyridin-2-yl)phenyl]-2-methylpropanoate (8d) 
 
1H NMR (500 MHz, CDCl3) δ 8.68 (d, J = 4.1 Hz, 1H), 8.03 (dd, J = 7.7, 2.2 Hz, 1H), 7.82 (ddd, J 
= 8.3, 4.8, 2.2 Hz, 1H), 7.77 (dd, J = 7.6 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 4.15 (q, J = 7.1 Hz, 
2H), 1.63 (s, 6H), 1.17 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.65 (s), 161.64 (d, 
1JC-F = 249.7 Hz), 156.59 (s), 149.40 (s), 137.32 (s), 135.14 (s), 133.31 (d, 2JC-F = 14.0 Hz), 127.19 
(d, 3JC-F = 9.2 Hz), 125.76 (d, 3JC-F = 5.2 Hz), 122.24 (s), 120.70 (s), 116.00 (d, 2JC-F = 23.2 Hz), 
61.03 (s), 44.37 (s), 25.84 (d, 4JC-F = 0.7 Hz), 14.14 (s). 
19F NMR (470 MHz, CDCl3) δ -112.82. HR-MS (ESI) m/z: calculated for C17H18FNO2Na [M+H]+ 











diethyl 2-[2-fluoro-5-(pyridin-2-yl)phenyl]-2,3,3-trimethylbutanedioate (9d) 
 
1H NMR (500 MHz, CDCl3) δ 8.69 (d, J = 4.1 Hz, 1H), 7.96 (dd, J = 7.7, 2.2 Hz, 1H), 7.89 (ddd, J 
= 8.2, 4.7, 2.2 Hz, 1H), 7.79 (dd, J = 7.1 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 7.31 – 7.23 (m, 1H), 
7.09 (dd, J = 11.3, 8.5 Hz, 1H), 4.19 – 4.07 (m, 2H), 3.98 – 3.80 (m, 2H), 2.61 (d, J = 14.9 Hz, 
1H), 2.58 (d, J = 14.9 Hz, 1H), 1.65 (s, 3H), 1.20 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H), 1.16 (t, J = 7.2 
Hz, 3H), 0.96 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 177.83 (s), 176.17 (s), 161.89 (d, 1JC-F = 249.9 
Hz), 156.36 (s), 149.19 (s), 137.60 (s), 131.69 (d, 2JC-F = 12.9 Hz), 127.63 (d, 3JC-F = 9.4 Hz), 
127.40 (d, 3JC-F = 5.0 Hz), 122.32 (s), 120.85 (s), 116.12 (d, 2JC-F = 23.9 Hz), 61.22 (s), 60.53 (s), 
47.98 (s), 45.44 (d, 3JC-F = 2.8 Hz), 41.49 (s), 27.63 (s), 27.13 (s), 22.48 (s), 14.04 (s), 14.03 (s). 
19F NMR (470 MHz, CDCl3) δ -110.60. HR-MS (ESI) m/z: calculated for C23H28FNO4Na [M+Na]+ 
424.1900, found: 424.1905. νmax (neat) / cm-1; 2980, 1723, 1589, 1463 
 
triethyl 2-[2-fluoro-5-(pyridin-2-yl)phenyl]-3,5-dimethylhexane-2,3,5-tricarboxylate (9e) 
 
1H NMR (500 MHz, CDCl3) δ 8.72 (s, 1H), 8.03 – 7.89 (m, J = 21.0, 11.2, 4.3 Hz, 2H), 7.86 (s, 
1H), 7.77 (s, 1H), 7.36 – 7.28 (m, J = 10.0, 5.7 Hz, 1H), 7.16 – 7.04 (m, 1H), 4.21 – 3.95 (m, 4H), 
3.73 – 3.56 (m, J = 46.8, 10.8, 7.2 Hz, 2H), 2.83 – 2.65 (m, 1H), 2.42 – 2.29 (m, J = 25.8, 13.9 
Hz, 1H), 2.21 – 2.09 (m, 1H), 2.09 – 1.95 (m, 1H), 1.71 – 1.59 (m, 3H), 1.31 – 1.05 (m, 15H), 1.03 
– 0.95 (m, 3H). 19F NMR (470 MHz, CDCl3) δ -109.10. HR-MS (ESI) m/z: calculated for 






Synthesis of Complex A 
 
Complex A was synthesised according to literature procedure.5 To an oven dried, argon purged 
round bottom flask was added [RuCl2(p-cymene)]2 (1.5 mmol, 918 mg), KOAc (6 mmol, 588 mg) 
followed by 2-phenylpyridine (3 mmol, 0.42 mL) and dry MeOH (30 mL). The reaction was stirred 
at room temperature for 48 h. The reaction was then concentrated to dryness, dissolved in a 
minimal amount of EtOAc and then purified through neutral alumina with EtOAc as the solvent to 
yield the title compound as a yellow solid (1.1 g, 86%). 
 
1H NMR (500 MHz, CDCl3) δ 9.23 (d, J = 5.5 Hz, 1H), 8.15 (d, J = 7.5 Hz, 1H), 7.70 (d, J = 7.9 
Hz, 1H), 7.65 (dd, J = 7.6 Hz, 1H), 7.60 (d, J = 7.6 Hz, 1H), 7.17 (dd, J = 7.3 Hz, 1H), 7.06 – 6.99 
(m, 2H), 5.58 (d, J = 5.8 Hz, 1H), 5.55 (d, J = 5.9 Hz, 1H), 5.17 (d, J = 5.9 Hz, 1H), 4.98 (d, J = 
5.8 Hz, 1H), 2.43 (hept, J = 6.8 Hz, 1H), 2.04 (s, 3H), 0.98 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 6.9 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 181.50, 165.44, 154.70, 143.41, 139.67, 136.70, 129.53, 
123.96, 122.57, 121.48, 118.87, 100.73, 100.59, 90.83, 89.72, 84.24, 82.27, 30.89, 22.61, 21.81, 
18.85. 
Data conforms to literature.5 
 
Catalytic Reaction using Complex A 
 
2-phenylpyridine (1 mmol, 0.14 mL), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), Complex A (10 
mol%, 41 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-Dioxane (4 mL) 
according to general procedure A. The crude mixture was purified by flash column 






Reactions with Substrates 1j-1l 
 
2-(2,6-dimethylphenyl)pyridine (1 mmol, 183 mg), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-




2-(3-methylphenyl)pyridine (1 mmol, 169 mg), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-





1H NMR (500 MHz, CDCl3) δ 8.34 (d, J = 2.7 Hz, 2H), 7.43 – 7.33 (m, 4H), 7.29 (d, J = 7.7 Hz, 
2H), 7.25 (t, J = 6.7 Hz, 2H), 7.06 (bs, 1H), 6.80 (d, J = 7.7 Hz, 2H), 2.40 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 157.80, 148.48, 138.98, 137.69, 136.81, 136.07, 131.42, 130.80, 
129.78, 124.80, 121.52, 21.17.HR-MS (ESI) m/z: calculated for C24H20N2 [M+Na]+ 359.1524, 
found: 359.1533 





Benzoquinoline (1 mmol, 179 mg), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), [RuCl2(p-
cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-Dioxane 
(4 mL) according to general procedure A. The crude mixture was purified by flash column 
chromatography to yield product 11 as a colourless oil (63 mg, 22%) 
 
ethyl 2-(benzo[h]quinolin-7-yl)-2-methylpropanoate (11) 
 
1H NMR (500 MHz, CDCl3) δ 9.38 (d, J = 8.0 Hz, 1H), 9.00 (dd, J = 4.4, 1.8 Hz, 1H), 8.15 (dd, J 
= 8.0, 1.7 Hz, 1H), 7.90 (d, J = 9.3 Hz, 1H), 7.77 (dd, J = 7.5, 1.4 Hz, 1H), 7.74 – 7.70 (m, 1H), 
7.66 (d, J = 9.3 Hz, 1H), 7.50 (dd, J = 8.0, 4.4 Hz, 1H), 4.10 (q, J = 7.1 Hz, 2H), 1.80 (s, 7H), 1.02 
(t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 178.85, 148.81, 146.83, 141.08, 135.81, 132.46, 
131.42, 126.65, 125.53, 125.22, 125.07, 124.07, 123.96, 121.96, 61.15, 46.58, 27.88, 14.05. HR-
MS (ESI) m/z: calculated for C19H19NO2 [M+H]+ 294.1494, found: 294.1517. νmax (neat) / cm-1; 
2979, 1718, 1592, 1428 
 
 
2-(2-methylphenyl)pyridine (1 mmol, 169 mg), ethyl 2-bromoisobutrate (3 mmol, 0.44 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 30 mg), and KOAc (2 mmol, 196 mg) were reacted together in 1,4-











1H NMR (500 MHz, CDCl3) δ 8.57 (d, J = 4.2 Hz, 2H), 7.55 (t, J = 7.1 Hz, 2H), 7.36 – 7.30 (m, J 
= 6.2 Hz, 2H), 7.10 – 7.06 (m, 2H), 7.04 (d, J = 7.5 Hz, 2H), 6.93 (t, J = 7.6 Hz, 2H), 6.77 (d, J = 
7.6 Hz, 2H), 2.10 (s, 6H). 13C NMR (126 MHz, CDCl3) δ 159.38, 148.63, 140.35, 139.62, 136.03, 
135.83, 128.89, 128.75, 126.83, 125.87, 121.40, 20.64. HR-MS (ESI) m/z: calculated for C24H20N2 
[M+Na]+ 359.1524, found: 359.1517 
Data conforms to literature.6  
 
Reactions with TEMPO 
Reactions were carried out as per general procedure A. 
 






Reaction with ethyl 2-bromoisobutrate carried out as per general procedure A. No trapped 
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6.2 Supporting information and data for: Mechanistic insight into ruthenium 
catalysed meta-sulfonation of 2-phenylpyridine 
 
General Considerations 
All chemicals used were reagent grade and used as supplied unless otherwise specified. HPLC 
grade acetonitrile (CH3CN), and diethyl ether were dried using a solvent purification system (PS-
400-7®). 1H and 13C NMR spectra were recorded on Bruker, AV 300, AV 400 or AV 500 
spectrometers in CD3CN as solvent. Chemical shifts (δ) were referenced internally to residual 
protic solvent signal for CD3CN (1.94 ppm 1H (q), 1.39 ppm 13C (sep)). 2D correlation spectra 
(gCOSY, gHSQC and gHMBC) were recorded to fully characterise the non-reported ruthenium 
complexes. Multiplicities are presented as: singlet (s), broad singlet (br s), doublet (d), apparent 
doublet (app d), doublet of doublets (dd), doublet of doublet of doublets (ddd), triplet (t), triplet of 
doublets (td), doublet doublet doublet of doublets (dddd), triplet of triplets (tt), quartet (q), quintet 
(quint.), and multiplet (m). Coupling constants (J) were expressed in Hertz (Hz).  
 
ESI MS were run on an Agilent® 1200 Series LC/MSD. Elemental analysis (C, H, N, S) was run 
in London Metropolitan University. Analytical thin layer chromatography (TLC) was performed on 
Merck® silica gel 60 F254 glass or aluminium plates. Organic Compounds were visualized by UV 
(254 nm) irradiation. Flash column chromatography was carried out using forced flow or by gravity 
of the indicated solvent on Fluka® silica gel 60 (230-400 mesh) or on Acros® neutral aluminium 
oxide (50-200 µm, 60 Å).  
 
All complexes were synthesised using standard Schlenck techniques under nitrogen atmosphere. 
The precursor catalyst [RuCl2(p-cymene)]2 was purchased from Strem Chemicals and used 
without further purification. [RuCl(PhPy)(p-cymene)],1 D5-2-phenylpyridine2 and D3-2-
phenylpyridine3 were prepared according literature methods. 
 
CCDC 1479685 contains the supplementary crystallographic data for this paper. These data can 






1. Synthesis of Ru Complexes 
1.1. Preparation of [Ru(PhPy)(p-cymene)(CH3CN)]PF6 (4) 
 
Dixneuf and Jutand method1 was used for the synthesis of 4 with modifications. 3 (0.5 g, 1.2 mmol) 
was dissolved in CH3CN (12 mL) and AgPF6 (0.44 g, 1.7 mmol) was added. The reaction mixture 
was stirred for 30 min at room temperature. An aliquot from the reaction mixture was taken and 
diluted into CD3CN and analysed by 1H NMR showing the complete consumption of the starting 
material. The reaction mixture was filtered over oven-dried neutral alumina and eluted with 
anhydrous CH3CN under nitrogen. The solvent was removed under vacuum and the solution 
poured into petroleum ether. After filtration and drying, 4 was obtained as green solid (0.66 g, 
98%). Spectroscopic data was in good agreement with those previously reported.1  
 
1.2. Preparation of [Ru(PhPy)(CH3CN)4]PF6 (5) 
 
Dixneuf and Jutand method1 was used for the synthesis of 5 with modifications. 4 (0.5 g, 0.87 
mmol) was dissolved in CH3CN (5.4 mL). The reaction mixture was stirred for 2 days at 70 oC. An 
aliquot from the reaction mixture was taken and diluted into CD3CN and analysed by 1H NMR 
showing the complete consumption of the starting material. The reaction mixture was purified by 
flash chromatography over oven-dried neutral alumina and eluted with anhydrous CH3CN under 
nitrogen. The solution was concentrated under vacuum and the solution poured into petroleum 
ether. After filtration and drying, 5 was obtained as yellow-green solid (0.37 g, 75%). 









1.3. Preparation of [Ru(TsPhPy)(CH3CN)4]PF6 (7) 
 
A dried Schlenck tube under argon was charged with molecular sieves 4 Å, complex 5 (0.1 g, 
0.18 mmol) and dry CH3CN (1.8 mL). Then, p-toluenesulfonyl chloride (TsCl) (67 mg, 0.35 mmol) 
and oven-dried K2CO3 (61 mg, 0.44 mmol) were added. After stirring the reaction mixture for 15 
h at 120 °C, the reaction crude was purified through oven-dried neutral alumina (Al2O3) and eluted 
with CH3CN. The solution was concentrated under reduced pressure and precipitated with diethyl 
ether. After filtration and drying, complex 7 was obtained as green solid (66 mg, 52%). Crystals 
of 7 were grown by vapour diffusion using CH3CN–Et2O. 
 
1H NMR (500 MHz, CD3CN) δ 8.92 (d, J = 5.5 Hz, 1H, H12), 8.22 (d, J = 8.0 Hz, 1H, H6), 8.14 (d, 
J = 1.8 Hz, 1H, H3), 8.04 (d, J = 8.1 Hz, 1H, H9), 7.88 (d, J = 8.3 Hz, 2H, Ts), 7.81 (td, J = 8.0, 
1.5 Hz, 1H, H10), 7.49 (dd, J = 8.0, 1.9 Hz, 1H, H5), 7.37 (d, J = 8.2 Hz, 2H, Ts), 7.25 (t, J = 6.5 
Hz, 1H, H11), 2.50 (s, 3H, CH3CN), 2.38 (s, 3H, Ts), 2.14 (s, 16H, CH3CN), 1.97 (s, 5H, CH3CN), 
1.96 (s, 3H, CH3CN). 13C NMR (126 MHz, CD3CN) δ 201.76 (C1), 167.73 (C7), 153.96 (C12), 
149.45 (C2), 145.40 (Ts), 141.64 (Ts), 140.55 (C6), 137.92 (C10), 135.27 (C4), 131.35 (Ts), 
128.44 (Ts), 125.52 (C5), 123.74 (C11), 121.56 (C3), 120.02 (C9), 118.69 (s), 21.89 (Ts), 4.75 
(CH3CN), 4.50 (CH3CN). HRMS-ESI Calcd for C24H23N4O2RuS: 533.0585 [M-CH3CN]+. Found 
533.0573. Elemental Analysis. Calcd for C26H26F6N5O2PRuS: C, 43.46; H, 3.65; N, 9.75; Found: 




1.4. Preparation of 1H-benzo[d][1,2,3]triazol-1-yl 4-methylbenzenesulfonate (8) 
 
Synthesis of 8 was carried out using the reported method.4 To a solution of 1-
hydroxybenzotriazole hydrate (0.99 g, 7.4 mmol) in dry dichloromethane (30 mL), imidazole (0.51 
g, 7.6 mmol) was added. The mixture was cooled to 0 oC under N2 and a solution of TsCl 
(recrystallized) (1.43 g, 7.5 mmol) in dichloromethane (4 mL) was added dropwise over a 10 min 
period. The reaction mixture was warmed to rt and stirred for a further 3 h. The reaction mixture 
was diluted with dichloromethane (30 mL) and filtered in a sintered funnel over MgSO4 under N2. 
The solvent was removed in vacuo and the resulting colourless residue was recrystallized from 
dry dichloromethane/hexane. The product was filtered to recover the pure final compound as a 
white crystalline solid (1.46 g, 69%). 1H NMR (300 MHz, CDCl3) δ 8.02 – 7.99 (m, 1H, Ar), 7.81 – 
7.75 (m, 2H, Ar), 7.65 (dt, J = 8.3, 1.0 Hz, 1H, Ar), 7.62 – 7.55 (m, 1H, Ar), 7.47 – 7.38 (m, 3H, 
Ar), 2.50 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3) δ 141.6 (q), 139.8 (q), 134.6 (q), 131.2, 129.8, 
129.2 (2 x ArCH), 128.9 (q), 125.9 (2 x ArCH), 114.6, 112.5, 21.4 (CH3). HRMS-ESI calculated 
for C13H11N3O3SNa:  312.0419 [M+Na]+. Found: 312.0399. 
 
1.5. Preparation of 1-tosyl-1H-imidazole (9) 
 
Synthesis of 9 was carried out with some modifications of the reported method.5 A solution of 
imidazole (1.38 g, 20.3 mmol) in dry dichloromethane (10 mL) was stirred at 0 oC for 1.5 h under 
N2. In a separate flask, a solution of TsCl (recrystallysed) (1.74 g, 9.1 mmol) in dry 
dichloromethane (10 mL) was stirred at rt for 1.5 h under N2. The p-toluenesulfonyl solution was 
added dropwise to the imidazole solution for 30 min at 0 oC. The reaction mixture was allowed to 
reach rt and stirred for a further 17 h. The resulting mixture was filtered through a pad of silica 
and washed with hexane (20 mL) followed by a mixture of EtOAc:hexane (1:1) (300 mL). The 
filtrate was concentrate in vacuo and the oil residue was dissolved in the minimum amount of 
EtOAc (1.5 mL) and crashed out with hexane (125 mL) to afford the pure compound as a white 
solid (1.39 g, 68%). 1H NMR (300 MHz, CDCl3) δ 8.01 (s, 1H, NCHN), 7.85 – 7.79 (m, 2H, Ar), 
7.35 (d, J = 8.1 Hz, 1H, Ar), 7.29 (t, J = 1.4 Hz, 1H, SO2NCH), 7.08 (s, 1H, Ar), 2.44 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3) δ 146.5 (q), 136.8, 135.1 (q), 131.6, 130.6, 127.5, 128.9 (q), 125.9, 
129 
 
114.6, 112.5, 21.4 (CH3). HRMS-ESI calculated for C10H11N2O2S:  223.0541 [M+H]+. Found: 
223.0535. 
 
2. Study of the Ru(II) complexes involved in the meta-sulfonation reaction 
2.1. Catalytic reactions  
To a nitrogen-purged ampule, [RuCl2(p-cymene)]2 (21 mg, 5 mol%), [RuCl(PhPy)(p-cymene)] (30 
mg, 10 mol%) or [Ru(PhPy)(p-cymene)(CH3CN)]PF6 (40 mg, 10 mol%) was dissolved in dry 
CH3CN (4 mL). Then, phenylpyridine (0.1 mL, 0.70 mmol), K2CO3 (0.193 g, 1.4 mmol) and TsCl 
(0.4 g, 2.1 mmol) were added and the reaction mixture was heated at 120 oC in an oil bath for 15 
h. The reaction crude was filtered over celite using EtOAc as eluent and the resulting mixture was 
purified by flash chromatography (from 20% EtOAc:hexane to 40% EtOAc) affording 2 as 
yellowish solid (0.11 g, 50%). 
 
2.2. Study of the catalyst behaviour during the meta-sulfonation of 2-phenypyridine  
Following the reaction conditions detailed above, the reaction using [RuCl2(p-cymene)]2, 
[RuCl(PhPy)(p-cymene)] and [Ru(PhPy)(p-cymene)(CH3CN)]PF6 were prepared in CD3CN and 




Figure S1. 1H NMR meta-sulfonation of phenylphyridine using [RuCl2(p-cymene)]2  
 
 












































t = 40 min
t = 2 h
t = 4 h
131 
 
Figure S2. 1H NMR meta-sulfonation of phenylphyridine using [ [RuCl(PhPy)(p-cymene)] 
 
 

























































































2.4. Reaction of [Ru(PhPy)(p-cymene)(CH3CN)]PF6 with KCl 
In a flame-dried NMR tube with a young cap, [Ru(PhPy)(p-cymene)(CH3CN)]PF6 (10 mg, 0.017 
mmol) was dissolved in CD3CN (0.5 mL) and KCl (20 mg, 0.27 mmol) was added. The NMR 
sample was heated for 15 h at 363 K. 
 
Figure S4. Reaction of [RuPhPy(p-cymene)]PF6 with KCl 
 
 
1H NMR (500 MHz, CD3CN) recorded at 298K a)1H-NMR of the reaction mixture after heating 4 
at 363 K; b) 1H-NMR of 5 for comparison; c) 1H-NMR of 4 for comparison. 
 
2.5. Study of the stability of [RuCl(PhPy)(p-cymene)] in the presence of TsCl 
In a flame-dried NMR tube with a young cap, [RuCl(PhPy)(p-cymene)] (34 mg, 0.08 mmol) was 
dissolved in CD3CN. The sample was placed in the NMR spectrometer which was previously 
heated at 343 K. 1H-NMR were recorded over time at this temperature. After 1 h TsCl (23 mg, 
0.12 mmol) was added and heated at the same temperature in the NMR spectrometer recording 


























Figure S5. Stability of [RuCl(PhPy)(p-cymene)] in the presence of TsCl 
a) [RuCl(PhPy)(p-cymene)] in CD3CN heated at 343 K 
1H 















b) [RuCl(PhPy)(p-cymene)] in CD3CN heated at 343 K in the presence of TsCl 
1H 
NMR (400 MHz, CD3CN) recorded at 343 K 
 
3. Study of the protodemetallation step 
3.1. Protodemetallation of 7 
In a flame dried NMR tube with a young cap [Ru(TsPhPy)(CH3CN)4]PF6 (7 mg, 0.01 mmol ) was 
dissolved in CD3CN (0.5 mL) and KHCO3 (9.7 mg, 0.1 mmol ), MesCO2H (1.6 mg, 0.01 mmol) 
and K2CO3 (2.7 mg, 0.02 mmol), MesCO2H (2.4 mg, 0.015 mmol), MesCO2H (16 mg, 0.1 mmol), 
p-toluenesulfonic acid (p-TSA) (18 mg, 0.094 mmol) or a mixture of PhPy (1.4 mL, 0.01 mmol) 
and K2CO3 (2.7 mg, 0.02 mmol) were added depending on the experiment. The sample was 





Table S1. Protodemetallation conditions of 7 
 
Entry Proton source 2 (%) 
1 10 equiv KHCO3 -- 
2 
1 equiv MesCO2H 











1 equiv PhPy 
2 equiv K2CO3 
-- 
6 1.5 equiv p-TSA Complex 10 
7 
4.5 equiv TsCl 
2 equiv K2CO3 
23% 
8 
10 equiv PhPy 






Figure S6. Formation of complex 10 
 
a) 1H-NMR for the compound obtained by treatment of 7 with p-TSA and assigned to complex 10; 
b) 1H-NMR of the tosylated phenylpyridine salt in CD3CN by its treatment with 1.5 equivalents of 
p-TSA; c) 1H-NMR of 2 for comparison; d) 1H-NMR of 7 for comparison.  
 
3.2. Protodemetallation of 4 
In a flame dried NMR tube with a young cap [Ru(PhPy)(p-cymene)(CH3CN)]PF6 (7 mg, 0.01 mmol 
) was dissolved in CD3CN (0.5 mL) and K2CO3 (8 mg, 0.06 mmol ), KHCO3 (12 mg, 0.12 mmol) 
or a mixture of PhPy (2.2 L, 0.015 mmol) and K2CO3 (8 mg, 0.06 mmol) and PhPy (5.7 L, 0.04 
mmol) and K2CO3 (8 mg, 0.06 mmol) were added depending on the experiment. The sample was 





Table S2. Protodemetallation conditions for 4 
 
Entry Proton source 2 (%) 
1 
1.5 equiv TsCl 
5 equiv K2CO3 
14 
2 
1.5 equiv TsCl 
10 equiv KHCO3 
11 
3 
1.5 equiv TsCl 
5 equiv K2CO3 
1.5 equiv PhPy 
33 
4 
1.5 equiv TsCl 
5 equiv K2CO3 
3.5 equiv PhPy 
46 
 
4. Experiments with isotopically labelled compounds 
4.1. Synthesis of 2-(2,6-dideuterophenyl)pyridine 
 
A suspension of [RuCl2(p‐cymene)]2 (76.5 mg, 0.124 mmol), AcOD (0.1 mL, 1.74 mmol), K2CO3 
(1.38 g, 10 mmol) and 1 (0.71 mL, 4.97 mmol) in degassed D2O (20 mL) was stirred under N2 for 
20 h at 100 °C. EtOAc (50 mL) and H2O (50 mL) were added to the reaction mixture at ambient 
temperature. The separated aqueous phase was extracted with EtOAc (2 × 50 mL). The combined 
organic layers were washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. 
The remaining residue was purified by column chromatography on silica gel (hexane:EtOAc 5:1) 







4.2. General procedure for the competitive experiments 
To a nitrogen-purged ampule, [RuCl2(p-cymene)]2 (11 mg, 5 mol%) was dissolved in dry CD3CN 
(4 mL). Then, phenylpyridine (50 L, 0.35 mmol), [D5]-1 (56 mg, 0.35 mmol), [D2]-1 (51 mg, 0.35 
mmol) or [D3]-1 (55 mg, 0.35 mmol) along with K2CO3 (97 mg, 0.7 mmol) and TsCl (0.2 g, 1 mmol) 
were added. The reaction mixture was heated at 120 oC in an oil bath. The reaction mixture was 
filtered through a pad of celite and the crude was purified by flash chromatography on silica gel 
(from 20% EtOAc:hexane to 40% EtOAc). 
 
4.2.1. Intramolecular competition experiment between 2-(2,3,4,5,6-
pentadeuterophenyl)pyridine and phenylpyridine 
 
 
Following the general procedure described above, a mixture of [Dn]-2 (1H NMR ratio H2/H6:D2/D6 
1.6:1 and H5:D5 2.3:1, 54 mg, 25%) and a mixture of the re-isolated [D0]-1 and [D5]-1 (1H NMR 
ratio 1:1, 83 mg, 75%) was obtained. 
 




Following the general procedure described above, a mixture of [Dn]-2 (1H NMR ratio H6:D6 1.6:1 
and H2/D2 1.1:1, 78 mg, 36%) and a mixture of the re-isolated [D0]-1 and [D2]-1 (1H NMR ratio 









Following the general procedure described above, a mixture of [Dn]-2 (1H NMR ratio H5:D5 2.1:1, 
43 mg, 20%) and a mixture of the re-isolated [D0]-1 and [D5]-1 (1H NMR ratio 1:1, 87 mg, 80%) 
was obtained. 
 
4.2. Single turnover experiment 
 
2-Phenyl pyridine was purified by distillation and dried using 4 Å molecular sieves before use. 
Tosyl chloride was purified by recrystalisation and thoroughly dried before use.  
 
To a flame dried ampule purged with argon, K2CO3 (69 mg, 0.5 mmol) and activated molecular 
sieves 4 Å (100 mg) were added. Ruthenium complex [D4]-5 (107 mg, 0.15 mmol), 2-phenyl 
pyridine (35 L, 0.25 mmol), tosyl chloride (143 mg, 0.75 mmol) and dry CH3CN (2.5 mL) were 
then added and the reaction mixture was heated at 120 °C for 15 h. Analysis of the crude reaction 
mixture by 1H-NMR was used to calculate reaction composition with respect to total pyridine 
content. The reaction mixture was purified through oven-dried neutral alumina (Al2O3) and eluted 
with CH3CN to separate the Ru complex [Dn]-7 and a mixture of [Dn]-1 and [Dn]-2. The fraction 
corresponding to the mixture of [Dn]-1 and [Dn]-2 was re-purified by flash chromatography over 
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6.3 Supporting information and data for: α-halo carbonyls enable meta 
primary, secondary and tertiary C-H alkylations 
 
General Considerations:  
1H, 13C and 19F nuclear magnetic resonance (NMR) spectra were recorded on an Agilent 
Technologies spectrometer (1H NMR at 500 MHz, 13C NMR at 126 MHz, and 19F NMR at 470 
MHz). Chemical shifts for protons are reported downfield from tetramethylsilane and are 
referenced to residual protium in the solvent (1H NMR: CHCl3 at 7.26 ppm). Chemical shifts for 
carbons are reported in parts per million downfield from tetramethylsilane and are referenced to 
the carbon resonances of the solvent peak (13C NMR: CDCl3 at 77.0 ppm). Chemical shifts for 
fluorine resonances are reported in parts per million referenced to CFCl3. NMR data are 
represented as follows: chemical shift (integration, multiplicity [s = singlet, bs = broad singlet, d = 
double, dd = doublet of doublet, t = triplet, q = quartet, hept = heptet, m = multiplet], coupling 
constants (Hz)). IR spectra were recorded on a Perkin-Elmer 1600 FT IR spectrophotometer, with 
absorbencies quoted as ν in cm-1. High resolution mass spectrometry was performed on a Bruker 
Daltonik µTOF electrospray time-of-flight (ESI-TOF) mass spectrometer. HPLC analysis was 
conducted on an Agilent 1260 infinity quaternary LC instrument equipped with a Zorbax Eclipse 
XDB-C18 4.6 x 250 mm 5 μm analytical column. Analytical thin layer chromatography (TLC) were 
performed using aluminium-backed plates coated with Alugram® SIL G/UV254 purchased from 
Macherey-Nagel and visualised by UV light (254 nm) and/or KMnO4, staining. Silica gel column 
chromatography was carried out using 60 Å, 200-400 mesh particle size silica gel purchased from 
Sigma-Aldrich. All reactions were carried out under an atmosphere of argon, in oven-dried 
glassware unless otherwise stated. Anhydrous solvents were used in all experiments and stored 
under an atmosphere of argon prior to use. Reagents were purchased from commercial sources 




Synthesis of 2-Aryl Pyridine Derivatives 
General Procedure 
 
To an oven dried, argon purged flask equipped with magnetic stirrer and condenser was added 
Pd(PPh3)4 (1 mol%), K2CO3 (2 eq) and ethanol (1 M). A solution of the boronic acid (1.5 eq) in 
EtOH (1 M) was then added to the reaction vessel followed by the addition of the 2-bromopyridine 
reagent (1 eq). The reaction mixture was then heated to 100 °C and refluxed for 15 hours. After 
cooling to room temperature, aqueous NaOH (1 M) was added and extracted three times with 
EtOAc. The organic extracts were then combined, washed with brine, dried with MgSO4 and then 
concentrated under reduced pressure. The crude product was then purified by silica gel column 






2-bromo,4-methoxy pyridine (5.3 mmol, 1g), phenyl boronic acid (7 mmol, 854 mg), Pd(PPh3)4 
(0.053 mmol, 65  mg), K2CO3 (10 mmol, 1.38 g) were reacted together in EtOH (5 mL) according 
to the general procedure to afford the title compound as a white solid (684 mg, 70%).  
1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 5.7 Hz, 1H), 8.05 – 7.92 (m, 2H), 7.50 – 7.38 (m, 3H), 
7.24 (d, J = 2.4 Hz, 1H), 6.78 (dd, J = 5.7, 2.4 Hz, 1H), 3.91 (s, J = 0.8 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 166.42, 159.20, 150.84, 139.38, 129.01, 128.67, 126.97, 108.11, 106.88, 55.17. 




2-bromo,4-methyl pyridine (6.8 mmol, 1.16g), phenyl boronic acid (8 mmol, 1 g), Pd(PPh3)4 (0.068 
mmol, 79  mg), K2CO3 (14 mmol, 1.9 g) were reacted together in EtOH (20 mL) according to the 
general procedure to afford the title compound as a colourless oil (1.08 g, 94%).  
1H NMR (500 MHz, CDCl3) δ 8.58 (d, J = 5.0 Hz, 1H), 8.04 – 7.98 (m, 2H), 7.56 (d, J = 0.7 Hz, 
1H), 7.52 – 7.46 (m, 2H), 7.45 – 7.39 (m, 1H), 7.07 (dd, J = 5.0, 0.8 Hz, 1H), 2.42 (s, 3H). 13C 
NMR (101 MHz, CDCl3) δ 157.40, 149.43, 147.76, 139.55, 128.83, 128.70, 126.96, 123.15, 
121.56, 21.22. 





2-chloro,4-fluorooopyridine (35 mmol, 4.6 g), phenyl boronic acid (42 mmol, 5.08 g), Pd(PPh3)4 
(0.35 mmol, 404  mg), and K2CO3 (70 mmol, 9.66 g) were reacted together in EtOH (100 mL) 
according to the general procedure to afford the title compound as a yellow / white crystalline solid 
(5.4 g, 90%). 
1H NMR (500 MHz, CDCl3) δ 8.65 (dd, J = 8.8, 5.6 Hz, 1H), 7.98 (dd, J = 8.2, 1.3 Hz, 2H), 7.54 – 
7.33 (m, 4H), 6.96 (ddd, J = 8.1, 5.5, 2.4 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 169.37 (d, J = 
261.1 Hz), 160.65 (d, J = 6.9 Hz), 151.93 (d, J = 7.2 Hz), 138.29 (d, J = 3.3 Hz), 129.60 (s), 128.83 
(s), 126.93 (s), 109.91 (d, J = 16.4 Hz), 108.10 (d, J = 17.3 Hz). 19F NMR (470 MHz, CDCl3) δ -
102.60 (ddd, J = 10.4, 8.6 Hz). 




2-bromo,4-chloro pyridine (5.2 mmol, 1g), phenyl boronic acid (7 mmol, 854 mg), Pd(PPh3)4 
(0.052 mmol, 60  mg), K2CO3 (10.4 mmol, 1.44 g) were reacted together in EtOH (10 mL) 
according to the general procedure to afford the title compound as a white solid (929 mg, 94%).  
1H NMR (500 MHz, CDCl3) δ 8.59 (d, J = 5.3 Hz, 1H), 8.03 – 7.91 (m, 2H), 7.74 (d, J = 1.8 Hz, 
1H), 7.54 – 7.39 (m, 3H), 7.26 – 7.23 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 159.01, 150.48, 
144.73, 138.13, 129.59, 128.85, 126.99, 126.97, 122.27, 120.85. 




methyl 2-phenylisonicotinate (1f) 
  
methyl 2-bromoisonicotinate (7 mmol, 1.5g), phenyl boronic acid (8.5 mmol, 1 g), Pd(PPh3)4 (0.07 
mmol, 81  mg), K2CO3 (28 mmol, 3.8 g) were reacted together in Toluene (20 mL), THF (10 mL) 
and H2O (20 mL) according to the general procedure to afford the title compound as a colourless 
oil (988 mg, 65%).  
1H NMR (500 MHz, CDCl3) δ 8.83 (dd, J = 5.0, 0.9 Hz, 1H), 8.30 (dd, J = 1.4, 1.0 Hz, 1H), 8.10 – 
8.01 (m, J = 4.2, 3.5, 1.9 Hz, 2H), 7.77 (dd, J = 5.0, 1.5 Hz, 1H), 7.54 – 7.41 (m, 3H), 3.98 (d, J = 
1.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 165.76, 158.45, 150.42, 138.49, 138.15, 129.45, 
128.84, 126.97, 121.10, 119.70, 52.71. 





1H NMR (500 MHz, CDCl3) δ 8.53 (d, J = 0.7 Hz, 1H), 7.98 (d, J = 8.3 Hz, 2-bromo,5-methyl 
pyridine (15 mmol, 2.6g), phenyl boronic acid (22.5 mmol, 2.7 g), Pd(PPh3)4 (0.15 mmol, 173  mg), 
K2CO3 (30 mmol, 4.2 g) were reacted together in EtOH (30 mL) according to the general 
procedure to afford the title compound as a colourless oil (2.28 g, 90%).  
1H NMR (500 MHz, CDCl3 ) δ 8.57 (s, 1H), 7.97 – 7.90 (m, 2H), 7.63 (d, J = 8.1 Hz, 1H), 7.56 
(dd, J = 8.0, 1.7 Hz, 1H), 7.47 (t, J = 7.5 Hz, 2H), 7.42 – 7.35 (m, 1H), 2.38 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 154.80, 150.04, 139.39, 137.30, 131.58, 128.68, 128.58, 126.68, 120.03, 18.15. 




   
2-bromo,5-fluorooopyridine (35 mmol, 6.2 g), phenyl boronic acid (42 mmol, 5.08 g), Pd(PPh3)4 
(0.35 mmol, 404  mg), and K2CO3 (70 mmol, 9.66 g) were reacted together in EtOH (100 mL) 
according to the general procedure to afford the title compound as a yellow / white crystalline solid 
(5.5 g, 91%). 
1H NMR (500 MHz, CDCl3) δ 8.55 (d, J = 2.9 Hz, 1H), 7.97 – 7.90 (m, 2H), 7.72 (ddd, J = 8.8, 4.3, 
0.6 Hz, 1H), 7.50 – 7.44 (m, 3H), 7.44 – 7.39 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 158.81 (d, J 
= 256.3 Hz), 153.77 (d, J = 3.8 Hz), 138.42, 137.73 (d, J = 23.5 Hz), 128.86, 128.78, 126.75, 
123.48 (d, J = 18.5 Hz), 121.28 (d, J = 4.2 Hz). 19F NMR (470 MHz, CDCl3) δ -129.88 (m). 
Data conforms to literature.5 
 
6-methyl-2-phenylpyridine (1i) 
   
2-bromo,6-methyl pyridine (6.8 mmol, 1.16g), phenyl boronic acid (8 mmol, 1 g), Pd(PPh3)4 (0.068 
mmol, 79  mg), K2CO3 (14 mmol, 1.9 g) were reacted together in EtOH (20 mL) according to the 
general procedure to afford the title compound as a colourless oil (1.14 g, 99%).  
1H NMR (400 MHz, CDCl3) δ 8.10 – 7.99 (m, 2H), 7.64 (t, J = 7.7 Hz, 1H), 7.58 – 7.48 (m, 3H), 
7.46 (dt, J = 9.6, 4.3 Hz, 1H), 7.12 (d, J = 7.6 Hz, 1H), 2.69 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 158.39, 157.00, 139.84, 136.92, 128.74, 127.20, 127.07, 121.65, 117.65, 24.80. 







2-bromo,3-methyl pyridine (6.8 mmol, 1.16g), phenyl boronic acid (8 mmol, 1 g), Pd(PPh3)4 (0.068 
mmol, 79  mg), K2CO3 (14 mmol, 1.9 g) were reacted together in EtOH (20 mL) according to the 
general procedure to afford the title compound as a colourless oil (1.1 g, 96%).  
1H NMR (400 MHz, CDCl3) δ 8.55 (dd, J = 4.7, 1.1 Hz, 1H), 7.59 (dd, J = 7.4, 1.1 Hz, 1H), 7.57 – 
7.52 (m, 2H), 7.50 – 7.43 (m, 3H), 7.18 (dd, J = 7.7, 4.8 Hz, 1H), 2.37 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 158.73, 147.00, 140.68, 138.46, 130.79, 128.95, 128.14, 127.90, 122.06, 20.06. 




2-bromopyridine (25 mmol, 2.4 mL), 4-methoxyphenyl boronic acid (33 mmol, 5.0 g), Pd(PPh3)4 
(0.25 mmol, 289  mg), K2CO3 (50 mmol, 6.90 g) were reacted together in EtOH (25 mL) according 
to the general procedure to afford the title compound as a white solid (4.4 g, 95%).  
1H NMR (500 MHz, CDCl3) δ 8.65 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 7.96 (d, J = 8.9 Hz, 2H), 7.76 – 
7.64 (m, 2H), 7.17 (ddd, J = 7.2, 4.8, 1.3 Hz, 1H), 7.00 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 160.43, 157.08, 149.47, 136.67, 131.92, 128.15, 121.38, 119.79, 114.11, 
55.34. 






2-bromo,4-methylpyridine (15 mmol, 1.66 mL), 4-methoxyphenyl boronic acid (22.5 mmol, 3.42 
g), Pd(PPh3)4 (0.15 mmol, 173  mg), K2CO3 (30 mmol, 4.14 g) were reacted together in Ethanol 
(25 mL) according to the general procedure to afford the title compound as a colourless oil (2.71 
g, 91%).  
1H NMR (500 MHz, CDCl3) δ 8.51 (d, J = 5.0 Hz, 1H), 7.98 – 7.90 (m, 2H), 7.49 (d, J = 0.4 Hz, 
1H), 7.05 – 6.92 (m, 3H), 3.87 (s, 3H), 2.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 160.33, 156.99, 
149.26, 147.57, 132.12, 128.14, 122.46, 120.73, 114.03, 55.31, 21.21. 




2-bromopyridine (20 mmol, 1.9 mL), 4-fluorophenyl boronic acid (30 mmol, 4.20 g), Pd(PPh3)4 
(0.2 mmol, 231  mg), and K2CO3 (40 mmol, 5.52 g) were reacted together in EtOH (20 mL) 
according to the general procedure to afford the title compound as a yellow / white crystalline solid 
(3.20 g, 92%). 
1H NMR (500 MHz, CDCl3) δ 8.68 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H), 7.98 (dd, J = 8.9, 5.4 Hz, 2H), 
7.77 – 7.72 (m, 1H), 7.68 (dt, J = 8.0, 1.0 Hz, 1H), 7.22 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 7.16 (t, J 
= 8.7 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 163.51 (d, 1JC-F = 248.4 Hz), 135.51 (d, 4JC-F = 3.1 
Hz), 128.68 (d, 3JC-F = 8.4 Hz), 115.63 (d, 2JC-F = 21.6 Hz). 19F NMR (470 MHz, CDCl3) δ -113.14 
– -113.24 (m). 






2-bromo,4-methylpyridine (15 mmol, 1.66 mL), 4-fluorophenyl boronic acid (22.5 mmol, 3.15 g), 
Pd(PPh3)4 (0.15 mmol, 173  mg), K2CO3 (30 mmol, 4.14 g) were reacted together in EtOH (25 mL) 
according to the general procedure to afford the title compound as a colourless oil (2.24 g, 80%).  
1H NMR (500 MHz, CDCl3) δ 8.52 (d, J = 5.0 Hz, 1H), 8.01 – 7.88 (m, 2H), 7.50 (s, J = 0.6 Hz, 
1H), 7.18 – 7.09 (m, 2H), 7.05 (ddd, J = 5.1, 1.4, 0.7 Hz, 1H), 2.41 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 164.41, 162.44, 156.36, 149.40, 147.84, 135.67, 128.72, 128.65, 123.06, 121.21, 
115.63, 115.46, 21.21. 19F NMR (470 MHz, CDCl3) δ -113.42 (m). 
Data conforms to literature.8 
 
ethyl 4-(pyridin-2-yl)benzoate (1p) 
 
2-bromopyridine (13 mmol, 1.2 mL), 4-(methoxycarbonyl)phenyl boronic acid (20 mmol, 3.04 g), 
Pd(PPh3)4 (0.13 mmol, 150  mg), and K2CO3 (26 mmol, 3.58 g) were reacted together in EtOH (13 
mL) according to the general procedure to afford the title compound as a white solid (2.42 g, 
82%). 
1H NMR (500 MHz, CDCl3)  δ 8.73 (d, J = 4.6 Hz, 1H), 8.15 (d, J = 8.2 Hz, 2H), 8.07 (d, J = 8.3 
Hz, 2H), 7.87 – 7.71 (m, 2H), 7.29 (dd, J = 8.3, 4.8 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 
7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.56, 156.38, 149.93, 143.42, 137.15, 130.90, 
130.16, 126.95, 123.00, 121.19, 77.16, 61.22, 14.50. 






2-bromopyridine (13 mmol, 1.2 mL), 4-chlorophenyl boronic acid (20 mmol, 3.04 g), Pd(PPh3)4 
(0.13 mmol, 150  mg), and K2CO3 (26 mmol, 3.58 g) were reacted together in EtOH (13 mL) 
according to the general procedure to afford the title compound as a pale yellow crystalline solid 
(1.20 g, 89%). 
1H NMR (500 MHz, CDCl3) δ 8.69 (dd, J = 4.8, 0.8 Hz, 1H), 7.95 (d, J = 8.4 Hz, 2H), 7.81 – 7.74 
(m, 1H), 7.71 (dd, J = 7.9, 0.9 Hz, 1H), 7.45 (d, J = 8.5 Hz, 2H), 7.29 – 7.24 (m, 1H). 13C NMR 
(126 MHz, CDCl3) δ 155.97, 149.35, 137.31, 137.26, 135.30, 128.97, 128.23, 122.45, 120.49. 




2-bromopyridine (10 mmol, 0.92 mL), 4-(trifluoromethyl)phenyl boronic acid (15 mmol, 2.85 g), 
Pd(PPh3)4 (0.10 mmol, 115  mg), and K2CO3 (20 mmol, 2.76 g) were reacted together in EtOH (10 
mL) according to the general procedure to afford the title compound as an off white solid (1.38 g, 
62%). 
1H NMR (500 MHz, CDCl3)   δ 8.73 (d, J = 4.7 Hz, 1H), 8.11 (d, J = 8.2 Hz, 2H), 7.84 – 7.69 (m, 
4H), 7.33 – 7.27 (m, 1H). 13C NMR (126 MHz, CDCl3) δ 155.98 (s), 150.03 (s), 142.77 (s), 
137.13 (s), 130.91 (q, 2JC-F = 32.5 Hz), 127.31 (s), 125.81 (q, 3JC-F = 3.8 Hz), 124.32 (q, 1JC-F = 
272.0 Hz), 123.09 (s), 121.00 (s). 19F NMR (470 MHz, CDCl3) δ -62.61 (s). 






2-bromopyridine (5 mmol, 0.46 mL), 3-methylphenylboronic acid (7 mmol, 1.0 g), Pd(PPh3)4 (0.05 
mmol, 58  mg), and K2CO3 (10 mmol, 1.38 g) were reacted together in EtOH (7.5 mL) according 
to the general procedure to afford the title compound as a yellow oil (772 mg, 91%). 
1H NMR (500 MHz, CDCl3)  δ 8.73 (d, J = 4.7 Hz, 1H), 7.87 (s, 1H), 7.84 – 7.73 (m, 3H), 7.39 (dd, 
J = 7.6 Hz, 1H), 7.29 – 7.24 (m, 2H), 2.46 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 157.40, 149.18, 
138.81, 138.50, 137.16, 129.94, 128.69, 127.72, 124.09, 122.11, 120.86, 21.51. 





2-bromopyridine (20 mmol, 1.84 mL), 2-methylphenylboronic acid (30 mmol, 4.08 g), Pd(PPh3)4 
(0.2 mmol, 231  mg), and K2CO3 (40  mmol, 5.52 g) were reacted together in EtOH (30 mL) 
according to the general procedure to afford the title compound as a yellow oil (2.96 g, 88%). 
1H NMR (500 MHz, CDCl3) δ 8.71 (d, J = 3.9 Hz, 1H), 7.85 – 7.69 (m, 1H), 7.42 (dd, J = 13.6, 4.5 
Hz, 2H), 7.33 – 7.25 (m, 4H), 2.29 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 159.67, 148.75, 139.86, 
136.60, 135.77, 130.77, 129.64, 128.46, 125.91, 124.30, 121.76, 20.27. 






2-bromopyridine (13 mmol, 1.2 mL), 2,6-dimethylphenylboronic acid (20 mmol, 3.0 g), Pd(PPh3)4 
(0.13 mmol, 150  mg), and K2CO3 (26 mmol, 3.59 g) were reacted together in EtOH (15 mL) 
according to the general procedure to afford the title compound as a red oil (1.96 g, 82%). 
1H NMR (500 MHz, CDCl3) δ 8.74 (d, J = 4.5 Hz, 1H), 7.82 (dd, J = 7.6 Hz, 1H), 7.34 – 7.30 (m, 
1H), 7.28 (d, J = 8.2 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.12 (d, J = 7.6 Hz, 2H). 13C NMR (126 
MHz, CDCl3) δ 159.56, 149.17, 139.76, 137.09, 135.93, 128.25, 127.72, 124.93, 122.02, 77.16, 
20.33. 
Data conforms to literature.6 
 
4-dimethylamino-2-phenylpyridine (1v) 
   
2-bromo,4-dimethylaminoopyridine (13.8 mmol, 2.7 g), phenyl boronic acid (20.7 mmol, 2.5 g), 
Pd(PPh3)4 (0.14 mmol, 160  mg), and K2CO3 (28 mmol, 3.8 g) were reacted together in EtOH (25 
mL) according to the general procedure to afford the title compound as a white crystalline solid 
(2.40 g, 86%). 
1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 5.9 Hz, 1H), 7.86 (dd, J = 8.3, 1.3 Hz, 2H), 7.41 – 7.23 
(m, 3H), 6.82 (d, J = 2.5 Hz, 1H), 6.40 (dd, J = 5.9, 2.6 Hz, 1H), 2.97 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 158.01, 155.07, 149.73, 140.77, 128.50, 127.05, 105.45, 103.65, 39.25. MP 84-85 oC 






2-bromo,4-trifluoromethyl pyridine (12 mmol, 2.74g), phenyl boronic acid (18 mmol, 2.2 g), 
Pd(PPh3)4 (0.12 mmol, 140  mg), K2CO3 (24 mmol, 1.44 g) were reacted together in EtOH (30 mL) 
according to the general procedure to afford the title compound as a colourless oil (2.54 g, 95%).  
1H NMR (500 MHz, CDCl3) δ 8.87 (d, J = 5.0 Hz, 1H), 8.08 – 8.00 (m, 2H), 7.93 (s, J = 0.7 Hz, 
1H), 7.61 – 7.40 (m, 4H). 13C NMR (126 MHz, CDCl3) δ 158.79, 150.61, 138.97 (q, J = 33.8 Hz), 
138.03, 129.82, 128.95, 127.01, 122.94 (q, J = 273.1 Hz), 117.49 (q, J = 3.5 Hz), 116.00 (q, J = 
3.6 Hz). 19F NMR (470 MHz, CDCl3) δ -64.85 (m). 




2-chloropyrimidine (50 mmol, 5.7g), phenyl boronic acid (60 mmol, 7.26 g), Pd(PPh3)4 (0.5 mmol, 
578  mg), K2CO3 (100 mmol, 13.8 g) were reacted together in EtOH (100 mL) according to the 
general procedure to afford the title compound as a white crystalline solid (7.02 g, 90%).  
1H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 4.9 Hz, 1H), 8.53 – 8.42 (m, 2H), 7.58 – 7.45 (m, 3H), 
7.13 (t, J = 4.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 164.73, 157.22, 137.63, 130.80, 128.62, 
128.19, 119.08. MP 37-39 oC 






2-chloro,4-methylpyrimidine (30 mmol, 3.84g), phenyl boronic acid (36 mmol, 4.35 g), Pd(PPh3)4 
(0.3 mmol, 346  mg), K2CO3 (60 mmol, 8.3 g) were reacted together in EtOH (100 mL) according 
to the general procedure to afford the title compound as a colourless oil (5.4 g, 92%).  
1H NMR (400 MHz, CDCl3) δ 8.67 (d, J = 5.0 Hz, 1H), 8.51 – 8.43 (m, 2H), 7.55 – 7.46 (m, 3H), 
7.07 (d, J = 5.1 Hz, 1H), 2.61 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 167.27, 164.43, 156.81, 
137.87, 130.53, 128.53, 128.18, 118.59, 24.42. 
Data conforms to literature.12 
5-ethyl-2-phenylpyrimidine (5c) 
 
2-chloro,5-ethylpyrimidine (36 mmol, 5.11g), phenyl boronic acid (43 mmol, 5.2 g), Pd(PPh3)4 
(0.36 mmol, 415  mg), K2CO3 (72 mmol, 10 g) were reacted together in EtOH (100 mL) according 
to the general procedure to afford the title compound as a colourless oil (5.5 g, 83%).  
1H NMR (400 MHz, CDCl3) δ 8.62 (s, 2H), 8.53 – 8.32 (m, 2H), 7.56 – 7.40 (m, 3H), 2.61 (q, J = 
7.6 Hz, 2H), 1.26 (t, J = 7.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 162.62, 156.62, 137.73, 134.12, 
130.32, 128.54, 127.91, 23.36, 14.89. 





    
2-chloropyrimidine (50 mmol, 5.7g), 4-methoxyphenyl boronic acid (60 mmol, 9 g), Pd(PPh3)4 (0.5 
mmol, 578  mg), K2CO3 (100 mmol, 13.8 g) were reacted together in EtOH (100 mL) according to 
the general procedure to afford the title compound as a white crystalline solid (7.44 g, 80%).  
1H NMR (500 MHz, CDCl3) δ 8.73 (d, J = 4.8 Hz, 2H), 8.40 (d, J = 9.0 Hz, 2H), 7.09 (t, J = 4.8 Hz, 
1H), 7.02 – 6.96 (m, 2H), 3.86 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 164.60, 162.02, 157.23, 
130.32, 129.88, 118.43, 114.04, 77.16, 55.45, 11.37. MP 52-56 oC 








To an oven dried, argon purged carousel tube equipped with magnetic stirrer was added [RuCl2(p-
cymene)]2 (15 mg, 0.025 mmol), a carboxylate ligand (0.015 mmol), K2CO3 (1 mmol, 138 mg), a 
co-catalyst / co-ligand the substrate molecule (0.5 mmol), ethyl bromoacetate (0.17 mL, 1.5 
mmol), and 1,4-Dioxane (2 mL). The carousel tube was then sealed and refluxed on a carousel 
at 120 °C for 15h. After cooling to room temperature the reaction mixture was dry loaded onto 
silica and a mixed fraction collected by silica gel column chromatography (Hexane / EtOAc).  
Ortho / meta ratio calculated using the corresponding benzyl peaks: ortho δ 3.82 ppm (s, 2H) 
meta δ 3.70 ppm (s, 2H). Major product consistent with meta substituted product and is fully 
characterised in section below. Minor isomer consistent with ortho substituted product.13 Example 







General procedure for synthesis of meta substituted compounds 
 
 
To an oven dried, argon purged carousel tube equipped with magnetic stirrer was added [RuCl2(p-
cymene)]2 (15 mg, 0.025 mmol), 2,4,6 trimethylbenzoic acid (25 mg, 0.015 mmol), *Pd(PPh3)4 (57 
mg, 0.05 mmol), K2CO3 (1 mmol, 138 mg), the substrate molecule (0.5 mmol), 1,4-Dioxane (2 
mL) and the corresponding coupling partner (1.5 mmol). The carousel tube was then sealed and 
refluxed on a carousel at 120 °C for 15 h. After cooling to room temperature the reaction mixture 
was dry loaded onto silica and purified by silica gel column chromatography (Hexane / EtOAc).  
*Certain reactions did not require the addition of Pd(PPh3)4 please refer to individual 
preparations. 




ethyl 2-(3-(pyridin-2-yl)phenyl)acetate (3aa) 
 
2-phenylpyridine (0.5 mmol, 0.07 mL), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (69 mg, 58%). 
1H NMR (500 MHz, CDCl3) δ 8.68 (dt, J = 4.9, 1.2 Hz, 1H), 7.93 (s, 1H), 7.87 (d, J = 7.8 Hz, 1H), 
7.75 – 7.69 (m, 2H), 7.43 (t, J = 7.7 Hz, 1H), 7.35 (d, J = 7.7 Hz, 1H), 7.21 (ddd, J = 5.4, 5.0, 2.8 
Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.70 (s, 2H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 171.56, 157.25, 149.72, 139.77, 136.80, 134.77, 129.92, 129.02, 128.00, 125.70, 122.25, 
120.71, 60.96, 41.50, 14.27. HR-MS (ESI) m/z: calculated for C15H15NO2 [M+Na]+ 264.100048, 





ethyl 2-(3-(4-methoxypyridin-2-yl)phenyl)acetate (3ba) 
 
 4-methoxy-2-phenylpyridine (0.5 mmol, 93 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (49mg, 36%). 
1H NMR (500 MHz, CDCl3) δ 8.51 (d, J = 5.7 Hz, 1H), 7.89 (t, J = 1.4 Hz, 1H), 7.86 – 7.81 (m, 
1H), 7.42 (t, J = 7.7 Hz, 1H), 7.39 – 7.31 (m, 1H), 7.22 (d, J = 2.4 Hz, 1H), 6.77 (dd, J = 5.7, 2.4 
Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.90 (s, 3H), 3.70 (s, 2H), 1.25 (t, J = 7.1 Hz, 3H).13C NMR (126 
MHz, CDCl3) δ 171.63, 166.53, 159.10, 151.00, 139.88, 134.75, 130.03, 129.01, 128.13, 125.81, 
108.35, 107.07, 61.02, 55.32, 41.55, 14.32. HR-MS (ESI) m/z: calculated for C16H17NO3 [M+Na]+ 




ethyl 2-(3-(4-methylpyridin-2-yl)phenyl)acetate (3ca) 
 
4-methyl-2-phenylpyridine (0.5 mmol, 85 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (80 mg, 63%). 
1H NMR (500 MHz, CDCl3) δ 8.53 (d, J = 4.9 Hz, 1H), 7.91 (t, J = 1.4 Hz, 1H), 7.88 – 7.84 (m, 
1H), 7.57 – 7.50 (m, 1H), 7.42 (t, J = 7.6 Hz, 1H), 7.36 – 7.30 (m, 1H), 7.08 – 7.02 (m, 1H), 4.16 
(q, J = 7.1 Hz, 2H), 3.70 (s, 2H), 2.40 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) 
δ 171.65, 157.17, 149.48, 147.85, 139.91, 134.69, 129.80, 128.98, 128.04, 125.75, 123.31, 
121.71, 60.98, 41.53, 21.31, 14.29. HR-MS (ESI) m/z: calculated for C16H17NO2 [M+Na]+ 
278.115698, found: 278.117900 νmax (neat) / cm-1: 2980, 1731 (C=O), 1601  
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ethyl 2-(3-(4-fluoropyridin-2-yl)phenyl)acetate (3da) 
 
4-fluoro-2-phenylpyridine (0.5 mmol, 87 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (80 mg, 62%). 
1H NMR (500 MHz, CDCl3) δ 8.62 (dd, J = 8.8, 5.6 Hz, 1H), 7.92 (s, 1H), 7.85 (d, J = 7.7 Hz, 1H), 
7.45 – 7.40 (m, 2H), 7.37 (d, J = 7.6 Hz, 1H), 6.95 (ddd, J = 6.4, 5.7, 2.2 Hz, 1H), 4.15 (q, J = 7.1 
Hz, 2H), 3.69 (s, 2H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.44, 169.43 (d, J 
= 261.3 Hz), 160.43 (d, J = 6.9 Hz), 151.98 (d, J = 7.2 Hz), 138.64 (d, J = 3.5 Hz), 134.92, 130.61, 
129.11, 128.03, 125.72, 110.08 (d, J = 16.4 Hz), 108.27 (d, J = 17.6 Hz), 61.00, 41.39, 14.25.19F 
NMR (470 MHz, CDCl3) δ -102.49 – -102.61 (m). HR-MS (ESI) m/z: calculated for C15H14NO2F 




ethyl 2-(3-(4-chloropyridin-2-yl)phenyl)acetate (3ea) 
 
4-chloro-2-phenylpyridine (0.5 mmol, 95 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (62 mg, 45%). 
1H NMR (500 MHz, CDCl3) δ 8.57 (dd, J = 5.2, 0.5 Hz, 1H), 7.91 (t, J = 1.8 Hz, 1H), 7.88 – 7.84 
(m, 1H), 7.73 (dd, J = 1.9, 0.6 Hz, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.39 – 7.35 (m, 1H), 7.24 (dd, J = 
5.3, 1.9 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.70 (s, 2H), 1.26 (t, J = 7.1 Hz, 3H).13C NMR (126 
MHz, CDCl3) δ 171.52, 158.87, 150.61, 144.89, 138.57, 135.00, 130.66, 129.21, 128.13, 125.85, 
122.51, 121.08, 61.09, 41.49, 14.32.HR-MS (ESI) m/z: calculated for C15H14NO2Cl [M+Na]+ 
276.079131, found: 276.079800. νmax (neat) / cm-1: 2981, 1730 (C=O), 1571, 1560  
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methyl 2-(3-(2-ethoxy-2-oxoethyl)phenyl)isonicotinate (3fa) 
 
methyl 2-phenylisonicotinate (0.5 mmol, 107 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (46 mg, 31%). 
1H NMR (500 MHz, CDCl3) δ 8.83 (dd, J = 5.0, 0.9 Hz, 1H), 8.29 (dd, J = 1.5, 0.9 Hz, 1H), 7.99 (t, 
J = 1.8 Hz, 1H), 7.97 – 7.93 (m, 1H), 7.78 (dd, J = 5.0, 1.5 Hz, 1H), 7.46 (t, J = 7.6 Hz, 1H), 7.41 
– 7.37 (m, 1H), 4.17 (q, J = 7.1 Hz, 2H), 4.00 (s, 3H), 3.72 (s, 2H), 1.27 (t, J = 7.1 Hz, 3H).13C 
NMR (126 MHz, CDCl3) δ 171.59, 165.92, 158.35, 150.58, 138.95, 138.34, 135.02, 130.56, 
129.25, 128.15, 125.90, 121.38, 119.95, 61.11, 52.91, 41.56, 14.34. HR-MS (ESI) m/z: calculated 





ethyl 2-(3-(5-methylpyridin-2-yl)phenyl)acetate (3ga) 
 
5-methyl-2-phenylpyridine (0.5 mmol, 85 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15z 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (65 mg, 51%). 
1H NMR (500 MHz, CDCl3) δ 8.50 (s, 1H), 7.90 (s, 1H), 7.84 (d, J = 6.8 Hz, 1H), 7.61 (d, J = 8.0 
Hz, 1H), 7.53 (dd, J = 4.4, 3.6 Hz, 1H), 7.41 (dt, J = 7.7, 3.6 Hz, 1H), 7.35 – 7.29 (m, 1H), 4.15 
(q, J = 7.1 Hz, 2H), 3.69 (s, 2H), 2.35 (s, J = 3.1 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H).13C NMR (126 
MHz, CDCl3) δ 171.63, 154.60, 150.13, 139.78, 137.37, 134.70, 131.77, 129.56, 128.97, 127.78, 
125.49, 120.20, 60.95, 41.52, 18.24, 14.28.HR-MS (ESI) m/z: calculated for C16H17NO2 [M+H]+ 




ethyl 2-(3-(5-fluoropyridin-2-yl)phenyl)acetate (3ha) 
 
5-fluoro-2-phenylpyridine (0.5 mmol, 87 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (65 mg, 50%). 
1H NMR (500 MHz, CDCl3) δ 8.54 (d, J = 2.9 Hz, 1H), 7.88 (t, J = 1.5 Hz, 1H), 7.84 – 7.79 (m, 
1H), 7.72 (ddd, J = 8.8, 4.2, 0.4 Hz, 1H), 7.49 – 7.45 (m, 1H), 7.43 (t, J = 7.5 Hz, 1H), 4.17 (q, J 
= 7.1 Hz, 2H), 3.70 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.62, 159.02 
(d, J = 256.2 Hz), 153.66 (d, J = 3.9 Hz), 138.87, 137.90 (d, J = 23.5 Hz), 134.93, 129.95, 129.17, 
127.95, 125.65, 123.66 (d, J = 18.5 Hz), 121.57 (d, J = 4.3 Hz), 61.09, 41.54, 14.35. 19F NMR 
(470 MHz, CDCl3) δ -129.64 – -129.69 (m). HR-MS (ESI) m/z: calculated for C15H14NO2F [M+H]+ 
260.108682, found: 260.108500. νmax (neat) / cm-1: 2981, 1733 (C=O), 1580 
ethyl 2-(3-(1H-pyrazol-1-yl)phenyl)acetate (4aa) 
 
1-phenyl-1H-pyrazole (0.5 mmol, 0.67 mL), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (60 mg, 52%). 
1H NMR (300 MHz, CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 1.5 Hz, 1H), 7.66 (t, J = 1.6 Hz, 
1H), 7.58 (dd, J = 8.1, 1.2 Hz, 1H), 7.40 (t, J = 7.8 Hz, 1H), 7.21 (d, J = 7.7 Hz, 1H), 6.47 – 6.43 
(m, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.67 (s, 2H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3) 
δ 171.26, 141.20, 140.41, 135.75, 129.67, 127.45, 126.90, 120.29, 117.90, 107.74, 61.14, 41.33, 
14.28. HR-MS (ESI) m/z: calculated for C13H14N2O2 [M+Na]+ 253.095297, found: 253.096000. 
νmax (neat) / cm-1: 2981, 1729 (C=O), 1609, 1594  
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ethyl 2-(3-(pyrimidin-2-yl)phenyl)acetate (5aa) 
 
2-phenylpyrimidine (0.5 mmol, 78 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (80 mg, 66%). 
1H NMR (500 MHz, CDCl3) δ 8.79 (d, J = 4.8 Hz, 2H), 8.37 (d, J = 0.5 Hz, 1H), 8.35 (ddd, J = 7.4, 
1.6 Hz, 1H), 7.48 – 7.41 (m, 2H), 7.17 (t, J = 4.8 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.71 (s, 2H), 
1.24 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.57, 164.61, 157.32, 137.95, 134.69, 
131.79, 129.21, 128.95, 127.02, 119.26, 60.99, 41.46, 14.29. HR-MS (ESI) m/z: calculated for 
C14H14N2O2 [M+H]+ 243.113353, found: 243.112100 νmax (neat) / cm-1: 2981, 1730 (C=O), 1568, 
1556 
ethyl 2-(3-(4-methylpyrimidin-2-yl)phenyl)acetate (5ba) 
 
4-methyl-2-phenylpyrimidine (0.5 mmol, 85 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (95 mg, 74%). 
1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 5.1 Hz, 1H), 8.37 – 8.36 (m, 1H), 8.34 (ddd, J = 7.4, 1.6 
Hz, 1H), 7.47 – 7.39 (m, 2H), 7.02 (d, J = 5.2 Hz, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.71 (s, 2H), 2.56 
(s, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.59, 167.32, 164.18, 156.84, 
138.21, 134.53, 131.50, 129.18, 128.83, 127.02, 118.74, 60.94, 41.47, 24.46, 14.27. HR-MS (ESI) 
m/z: calculated for C15H16N2O2 [M+Na]+ 279.110947, found: 279.110100. νmax (neat) / cm-1: 2981, 
1731 (C=O), 1573, 1554  
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ethyl 2-(3-(5-ethylpyrimidin-2-yl)phenyl)acetate (5ca) 
 
5-ethyl-2-phenylpyrimidine (0.5 mmol, 92 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (80 mg, 59%). 
1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 3.5 Hz, 2H), 8.34 – 8.32 (m, J = 1.5 Hz, 1H), 8.31 (ddd, 
J = 7.6, 1.5 Hz, 1H), 7.44 (t, J = 7.6 Hz, 1H), 7.39 (ddd, J = 7.6, 1.5 Hz, 1H), 4.15 (q, J = 7.1 Hz, 
2H), 3.70 (s, 2H), 2.65 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.6 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 171.56, 162.49, 156.71, 138.02, 134.60, 134.33, 131.31, 128.92, 
128.87, 126.71, 60.93, 41.46, 23.49, 15.03, 14.27. HR-MS (ESI) m/z: calculated for C16H18N2O2 
[M+Na]+ 293.126598, found: 293.127600. νmax (neat) / cm-1: 2971, 1731 (C=O), 1586, 1544 
ethyl 2-(benzo[h]quinolin-7-yl)acetate (6aa) 
 
benzo[h]quinoline (0.5 mmol, 90 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a white solid (60 mg, 45%). 
Recrystallization using dichloromethane and 60:40 petroleum ether afforded crystals suitable for 
X-Ray analysis.  
1H NMR (500 MHz, CDCl3) δ 9.33 (d, J = 8.2 Hz, 1H), 9.01 (dd, J = 4.4, 1.8 Hz, 1H), 8.17 (dd, J 
= 8.0, 1.8 Hz, 1H), 8.02 (d, J = 9.1 Hz, 1H), 7.74 (d, J = 9.2 Hz, 1H), 7.70 (dd, J = 8.2, 7.2 Hz, 
1H), 7.63 (dd, J = 7.1, 1.2 Hz, 1H), 7.52 (dd, J = 8.0, 4.4 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 4.13 
(s, 2H), 1.22 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.59, 149.11, 146.83, 135.83, 
132.34, 132.20, 130.87, 130.54, 126.82, 126.01, 125.83, 124.34, 123.60, 122.01, 77.16, 61.16, 
39.64, 14.29. HR-MS (ESI) m/z: calculated for C17H15NO2 [M+H]+ 266.118104, found: 
266.117500. νmax (neat) / cm-1: 2985, 1725 (C=O), 1590. MP: (from CH2Cl2) 95-96 oC  
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ethyl 2-(2-methoxy-5-(pyridin-2-yl)phenyl)acetate (3ka)  
 
2-(4-methoxyphenyl)pyridine (0.5 mmol, 93 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (56 mg, 41%).  
1H NMR (500 MHz, CDCl3) δ 8.64 (ddd, J = 4.8, 1.8, 1.1 Hz, 1H), 7.90 (dd, J = 8.5, 2.4 Hz, 1H), 
7.87 (d, J = 2.3 Hz, 1H), 7.72 – 7.66 (m, 2H), 7.16 (ddd, J = 7.1, 4.8, 1.5 Hz, 1H), 6.96 (d, J = 8.5 
Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.70 (s, 2H), 1.25 (t, J = 7.1 Hz, 3H).13C NMR (126 
MHz, CDCl3) δ 171.82, 158.64, 157.15, 149.63, 136.74, 131.92, 129.76, 127.25, 123.72, 121.54, 
119.99, 110.71, 60.75, 55.75, 36.39, 14.38. HR-MS (ESI) m/z: calculated for C16H17NO3 [M+Na]+ 
294.110613, found: 294.112700. νmax (neat) / cm-1: 2978, 1732 (C=O), 1610, 1564 
ethyl 2-(2-methoxy-5-(4-methylpyridin-2-yl)phenyl)acetate (3la) 
 
2-(4-methoxyphenyl)-4-methylpyridine (0.5 mmol, 100 mg), ethyl bromoacetate (1.5 mmol, 0.17 
mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic 
acid (0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 
mL) according to general procedure to afford the title compound as a colourless oil (70 mg, 49%).  
1H NMR (500 MHz, CDCl3) δ 8.49 (d, J = 5.0 Hz, 1H), 7.89 (dd, J = 8.5, 2.3 Hz, 1H), 7.85 (d, J = 
2.3 Hz, 1H), 7.52 – 7.46 (m, 1H), 6.99 (dd, J = 5.0, 0.8 Hz, 1H), 6.95 (d, J = 8.6 Hz, 1H), 4.16 (q, 
J = 7.1 Hz, 2H), 3.87 (s, 3H), 3.69 (s, 2H), 2.39 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (126 
MHz, CDCl3) δ 171.85, 158.52, 157.01, 149.37, 147.69, 132.01, 129.76, 127.24, 123.61, 122.61, 
120.92, 110.66, 60.74, 55.74, 36.38, 21.35, 14.37. HR-MS (ESI) m/z: calculated for C17H19NO3 
[M+H]+ 308.126263, found: 308.125900. νmax (neat) / cm-1: 2978, 1733 (C=O), 1604, 1559  
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ethyl 2-(2-methoxy-5-(pyrimidin-2-yl)phenyl)acetate (5da) 
 
2-(4-methoxyphenyl)pyrimidine (0.5 mmol, 93 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (75 mg, 55%).  
1H NMR (500 MHz, CDCl3) δ 8.73 (d, J = 4.8 Hz, 2H), 8.37 (dd, J = 8.6, 2.3 Hz, 1H), 8.29 (d, J = 
2.2 Hz, 1H), 7.09 (t, J = 4.8 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H), 4.16 (q, J = 7.1 Hz, 2H), 3.88 (s, 
3H), 3.70 (s, 2H), 1.24 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.67, 164.45, 160.04, 
157.17, 131.08, 130.02, 128.99, 123.53, 118.43, 110.40, 60.68, 55.70, 36.34, 14.31. HR-MS (ESI) 
m/z: calculated for C15H16N2O3 [M+H]+ 273.123917, found: 273.122300. νmax (neat) / cm-1: 2978, 
1730 (C=O), 1608, 1591 
ethyl 2-(2-methoxy-5-(pyridin-2-yl)phenyl)-2-methylpropanoate (3kb) 
 
2-(4-methoxyphenyl)pyridine (0.5 mmol, 93 mg), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 
0.22 mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) 
and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general 
procedure to afford the title compound as a colourless oil (120 mg, 80%).  
1H NMR (500 MHz, CDCl3) δ 8.66 (ddd, J = 4.9, 1.6, 1.0 Hz, 1H), 7.99 (d, J = 2.2 Hz, 1H), 7.85 
(dd, J = 8.5, 2.3 Hz, 1H), 7.74 – 7.70 (m, 1H), 7.68 (ddd, J = 8.0, 1.2 Hz, 1H), 7.17 (ddd, J = 7.0, 
4.9, 1.4 Hz, 1H), 6.93 (d, J = 8.5 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.81 (s, 3H), 1.59 (s, 6H), 1.15 
(t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.86, 157.76, 157.57, 149.62, 136.69, 134.63, 
131.97, 126.57, 124.61, 121.46, 120.08, 110.92, 60.40, 55.34, 44.55, 25.75, 14.30.  





2-Phenylpyridine (0.5 mmol, 0.07 mL), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 0.22 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (95 mg, 71%).  
1H NMR (500 MHz, CDCl3) δ 8.69 (ddd, J = 4.9, 1.7, 1.0 Hz, 1H), 7.99 (dd, J = 1.9 Hz, 1H), 7.86 
– 7.83 (m, 1H), 7.77 – 7.74 (m, 1H), 7.71 (ddd, J = 8.0, 1.1 Hz, 1H), 7.43 (dd, J = 7.7 Hz, 1H), 
7.40 – 7.37 (m, 1H), 7.23 (ddd, J = 7.3, 4.9, 1.3 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 1.64 (s, 6H), 
1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.80, 157.50, 149.54, 145.50, 139.34, 
137.05, 128.87, 126.72, 125.45, 124.36, 122.27, 120.92, 60.96, 46.73, 26.70, 14.18. HR-MS (ESI) 
m/z: calculated for C17H19NO2 [M+H]+ 270.149404, found: 270.150600. νmax (neat) / cm-1: 2978, 
1723 (C=O), 1585, 1566 




ethyl 2-(1-ethoxy-2-methyl-1-oxopropan-2-yl)-4-(pyridin-2-yl)benzoate (3pb) 
 
ethyl 4-(pyridin-2-yl)benzoate (0.5 mmol, 114 mg), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 
0.22 mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) 
and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general 
procedure to afford the title compound as a colourless oil (39 mg, 23%).  
1H NMR (500 MHz, CDCl3) δ 8.74 – 8.72 (m, 1H), 8.22 (d, J = 1.7 Hz, 1H), 7.98 (d, J = 8.1 Hz, 
1H), 7.87 (dd, J = 8.1, 1.7 Hz, 1H), 7.81 – 7.74 (m, 2H), 7.30 – 7.26 (m, 1H), 4.31 (q, J = 7.1 Hz, 
2H), 4.11 (q, J = 7.1 Hz, 2H), 1.72 (s, 6H), 1.38 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H). 13C 
NMR (126 MHz, CDCl3) δ 177.01, 168.20, 156.65, 149.98, 146.04, 142.42, 136.96, 131.63, 
130.52, 125.62, 124.81, 122.84, 121.13, 61.25, 60.65, 47.24, 28.07, 14.29, 14.13. HR-MS (ESI) 
m/z: calculated for C20H23NO4 [M+H]+ 342.170533, found: 342.170800. νmax (neat) / cm-1: 2980, 
1720 (C=O), 1608, 1587  
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ethyl 2-methyl-2-(3-(pyrimidin-2-yl)phenyl)propanoate (5ab) 
 
2-phenylpyrimidine (0.5 mmol, 78 mg), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 0.22 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (80 mg, 59%).  
1H NMR (500 MHz, CDCl3) δ 8.80 (d, J = 4.8 Hz, 2H), 8.51 – 8.46 (m, 1H), 8.32 (ddd, J = 6.3, 2.4, 
1.7 Hz, 1H), 7.49 – 7.40 (m, 2H), 7.18 (t, J = 4.8 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 1.66 (s, 6H), 
1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.83, 164.86, 157.34, 145.45, 137.78, 
128.74, 128.54, 126.65, 125.50, 119.21, 60.97, 46.79, 26.74, 14.19. HR-MS (ESI) m/z: calculated 





ethyl 2-(3-(4-(dimethylamino)pyridin-2-yl)phenyl)-2-methylpropanoate (3vb) 
 
N,N-dimethyl-2-phenylpyridin-4-amine (0.5 mmol, 99 mg), ethyl 2-bromo-2-methylpropanoate 
(1.5 mmol, 0.22 mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (87 mg, 56%).  
1H NMR (500 MHz, CDCl3) δ 8.32 (d, J = 6.0 Hz, 1H), 7.91 (dd, J = 1.8 Hz, 1H), 7.75 (ddd, J = 
7.4, 1.5 Hz, 1H), 7.39 (dd, J = 7.6 Hz, 1H), 7.36 – 7.33 (m, 1H), 6.85 (d, J = 2.5 Hz, 1H), 6.47 (dd, 
J = 6.0, 2.6 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.04 (s, 6H), 1.63 (s, 6H), 1.18 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 176.91, 158.19, 155.14, 149.64, 145.18, 140.90, 128.54, 126.16, 
125.55, 124.46, 105.53, 103.93, 60.87, 46.72, 39.33, 26.71, 14.17. HR-MS (ESI) m/z: calculated 




ethyl 2-methyl-2-(3-(4-methylpyridin-2-yl)phenyl)propanoate (3cb) 
 
4-methyl-2-phenylpyridine (0.5 mmol, 85 mg), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 0.22 
mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and 
K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general 
procedure to afford the title compound as a colourless oil (106 mg, 56%).  
1H NMR (500 MHz, CDCl3) δ 8.54 (d, J = 5.0 Hz, 1H), 7.96 (s, 1H), 7.83 (d, J = 7.4 Hz, 1H), 7.51 
(s, 1H), 7.44 – 7.35 (m, 2H), 7.05 (d, J = 4.9 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 2.41 (s, 3H), 1.64 
(s, 6H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.85, 157.58, 149.53, 147.79, 
145.36, 139.78, 128.76, 126.44, 125.45, 124.34, 123.24, 121.76, 60.93, 46.73, 26.71, 21.33, 
14.17. HR-MS (ESI) m/z: calculated for C18H21NO2 [M+Na]+ 306.146999, found: 306.146900. νmax 




methyl 2-(3-(1-ethoxy-2-methyl-1-oxopropan-2-yl)phenyl)isonicotinate (3fb) 
 
4-methyl-2-phenylpyridine (0.5 mmol, 107 mg), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 
0.22 mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) 
and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general 
procedure to afford the title compound as a colourless oil (90 mg, 55%).  
1H NMR (500 MHz, CDCl3) δ 8.79 (d, J = 5.0 Hz, 1H), 8.23 (s, 1H), 8.04 (s, J = 1.8 Hz, 1H), 7.87 
(ddd, J = 6.9, 1.9 Hz, 1H), 7.72 (dd, J = 5.0, 1.4 Hz, 1H), 7.44 – 7.36 (m, 2H), 4.12 (q, J = 7.1 Hz, 
2H), 3.94 (s, 3H), 1.63 (s, 6H), 1.16 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.56, 
165.72, 158.47, 150.43, 145.57, 138.63, 138.14, 128.85, 127.03, 125.38, 124.32, 121.13, 119.74, 
77.16, 60.87, 52.70, 46.65, 26.61, 14.07. HR-MS (ESI) m/z: calculated for C19H21NO4 [M+H]+ 
328.154883, found: 328.154800. νmax (neat) / cm-1: 2978, 1726 (C=O), 1597, 1558  
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ethyl 2-methyl-2-(3-(4-(trifluoromethyl)pyridin-2-yl)phenyl)propanoate (3wb) 
 
2-phenyl-4-(trifluoromethyl)pyridine (0.5 mmol, 112 mg), ethyl 2-bromo-2-methylpropanoate (1.5 
mmol, 0.22 mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 
25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to 
general procedure to afford the title compound as a colourless oil (67 mg, 40%).  
1H NMR (500 MHz, CDCl3) δ 8.86 (d, J = 5.0 Hz, 1H), 8.06 – 8.04 (m, 1H), 7.90 – 7.89 (m, 1H), 
7.87 (ddd, J = 5.6, 3.5, 1.8 Hz, 1H), 7.49 – 7.42 (m, 3H), 4.15 (q, J = 7.1 Hz, 2H), 1.66 (s, 6H), 
1.19 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 176.63, 158.97, 150.75, 145.87, 139.20 (q, 
J = 33.9 Hz) 138.29, 129.06, 127.52, 125.50, 124.53, 123.07 (q, J = 273.3 Hz), 117.63 (q, J = 3.4 
Hz), 116.21 (q, J = 3.7 Hz), 61.02, 46.76, 26.69, 14.16. 19F NMR (470 MHz, CDCl3) δ -64.84 (s). 
HR-MS (ESI) m/z: calculated for C18H18NO2F3 [M+H]+ 338.136788, found: 338.136897. νmax 




ethyl 2-methyl-2-(3-(5-methylpyridin-2-yl)phenyl)propanoate (3gb) 
  
5-methyl-2-phenylpyridine (0.5 mmol, 85 mg), ethyl 2-bromo-2-methylpropanoate (1.5 mmol, 0.22 
mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and 
K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general 
procedure to afford the title compound as a colourless oil (76 mg, 54%).  
1H NMR (500 MHz, CDCl3) δ 8.52 (dd, J = 1.4, 0.7 Hz, 1H), 7.96 (dd, J = 1.8 Hz, 1H), 7.84 – 7.79 
(m, 1H), 7.60 (d, J = 7.9 Hz, 1H), 7.57 – 7.52 (m, 1H), 7.41 (dd, J = 7.7 Hz, 1H), 7.36 (ddd, J = 
7.8, 1.8, 1.3 Hz, 1H), 4.13 (q, J = 7.1 Hz, 3H), 2.37 (s, 3H), 1.64 (s, 6H), 1.18 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 176.89, 155.04, 150.22, 145.42, 139.69, 137.37, 131.72, 128.80, 
126.26, 125.22, 124.13, 120.30, 60.96, 46.77, 26.74, 18.30, 14.21. HR-MS (ESI) m/z: calculated 
for C18H21NO2 [M+Na]+ 306.146999, found: 306.146000. νmax (neat) / cm-1: 2977, 1725 (C=O), 
1600, 1566  
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ethyl 2-(2-methoxy-5-(pyridin-2-yl)phenyl)propanoate (3kc) 
  
2-(4-methoxyphenyl)pyridine (0.5 mmol, 93 mg), ethyl 2-bromopropanoate (1.5 mmol, 0.22 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (83 mg, 58%).  
1H NMR (500 MHz, CDCl3) δ 8.63 (d, J = 4.3 Hz, 1H), 7.89 (dd, J = 8.4, 2.3 Hz, 1H), 7.88 (d, J = 
2.2 Hz, 1H), 7.71 – 7.67 (m, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.15 (ddd, J = 7.0, 4.9, 1.3 Hz, 1H), 
6.94 (d, J = 8.4 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 4.04 (q, J = 7.2 Hz, 1H), 3.84 (s, 3H), 1.51 (d, J 
= 7.2 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 175.01, 157.88, 157.13, 
149.42, 136.95, 130.13, 127.07, 126.93, 121.56, 120.13, 110.91, 60.64, 55.71, 40.04, 17.36, 
14.35. HR-MS (ESI) m/z: calculated for C17H19NO3 [M+Na]+ 308.126263, found: 308.128100. νmax 




ethyl 2-(3-(pyridin-2-yl)phenyl)propanoate (3ac) 
  
2-Phenylpyridine (0.5 mmol, 0.07 mL), ethyl 2-bromopropanoate (1.5 mmol, 0.22 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 (1 mmol, 
138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure to afford 
the title compound as a colourless oil (70 mg, 55%).  
1H NMR (500 MHz, CDCl3) δ 8.67 (dd, J = 4.6, 1.2 Hz, 1H), 7.93 (s, 1H), 7.85 (dd, J = 7.6, 1.4 Hz, 
1H), 7.75 – 7.68 (m, 2H), 7.41 (dd, J = 7.6 Hz, 1H), 7.36 (dd, J = 7.6, 1.1 Hz, 1H), 7.22 – 7.17 (m, 
1H), 4.18 – 4.03 (m, 3H), 3.79 (q, J = 7.1 Hz, 1H), 1.54 (dd, J = 7.2, 1.0 Hz, 3H), 1.18 (td, J = 7.1, 
1.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.51, 157.29, 149.68, 141.29, 139.76, 136.76, 
129.05, 128.00, 126.35, 125.72, 122.20, 120.69, 60.80, 45.69, 18.77, 14.17. HR-MS (ESI) m/z: 
calculated for C16H17NO2 [M+Na]+ 278.115698, found: 278.116500. νmax (neat) / cm-1: 2980, 1727 
(C=O), 1584, 1566  
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ethyl 2-(1-ethoxy-1-oxopropan-2-yl)-4-(pyridin-2-yl)benzoate (3pc) 
 
ethyl 4-(pyridin-2-yl)benzoate (0.5 mmol, 114 mg), ethyl 2-bromopropanoate (1.5 mmol, 0.22 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford the title compound as a colourless oil (72 mg, 44%).  
1H NMR (500 MHz, CDCl3) δ 8.73 – 8.70 (m, 1H), 8.02 (dd, J = 4.9, 3.1 Hz, 2H), 7.94 (dd, J = 8.2, 
1.8 Hz, 1H), 7.80 – 7.73 (m, 2H), 7.29 – 7.25 (m, 1H), 4.69 (q, J = 7.2 Hz, 1H), 4.38 (qd, J = 7.1, 
0.6 Hz, 2H), 4.21 – 4.05 (m, 2H), 1.62 (d, J = 7.2 Hz, 3H), 1.41 (t, J = 7.2 Hz, 3H), 1.19 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.64, 167.46, 156.26, 150.00, 142.87, 142.65, 136.97, 
131.40, 130.05, 127.25, 125.27, 122.95, 121.13, 61.28, 60.86, 42.55, 18.49, 14.40, 14.27. HR-
MS (ESI) m/z: calculated for C19H21NO4 [M+H]+ 328.154883, found: 328.156100. νmax (neat) / cm-




 ethyl 2-(3-(1H-pyrazol-1-yl)phenyl)propanoate (4ac) 
 
1-phenyl-1H-pyrazole (0.5 mmol, 0.67 mL), ethyl 2-bromopropanoate (1.5 mmol, 0.22 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (55 mg, 45%).  
1H NMR (500 MHz, CDCl3) δ 7.92 (dd, J = 2.5, 0.5 Hz, 1H), 7.71 (d, J = 1.4 Hz, 1H), 7.67 (t, J = 
1.9 Hz, 1H), 7.57 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.25 – 7.21 (m, 1H), 6.46 
(dd, J = 2.4, 1.8 Hz, 1H), 4.18 – 4.07 (m, 2H), 3.77 (q, J = 7.2 Hz, 1H), 1.54 (d, J = 7.2 Hz, 3H), 
1.21 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.22, 142.39, 141.20, 140.52, 129.73, 
126.94, 125.65, 118.74, 118.01, 107.72, 77.16, 61.02, 45.66, 18.70, 14.25. HR-MS (ESI) m/z: 
calculated for C14H16N2O2 [M+H]+ 245.129003, found: 245.126900. νmax (neat) / cm-1: 2980, 1727 
(C=O), 1608, 1593 
ethyl 2-(3-(4-methylpyrimidin-2-yl)phenyl)propanoate (5bc) 
 
4-methyl-2-phenylpyrimidine (0.5 mmol, 85 mg), ethyl 2-bromopropanoate (1.5 mmol, 0.22 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (50 mg, 37%).  
1H NMR (500 MHz, CDCl3) δ 8.62 (d, J = 5.0 Hz, 1H), 8.38 (s, 1H), 8.34 – 8.30 (m, 1H), 7.43 (dd, 
J = 3.8, 1.5 Hz, 2H), 7.02 (d, J = 5.1 Hz, 1H), 4.21 – 4.00 (m, 2H), 3.82 (q, J = 7.2 Hz, 1H), 2.57 
(s, 4H), 1.55 (d, J = 7.2 Hz, 4H), 1.19 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 174.58, 
167.33, 164.27, 156.85, 141.13, 138.25, 129.58, 128.89, 127.65, 127.07, 118.73, 77.16, 60.82, 
45.73, 24.48, 18.78, 14.21. HR-MS (ESI) m/z: calculated for C16H18N2O2 [M+H]+ 271.144653, 
found: 271.142900. νmax (neat) / cm-1: 2980, 1728 (C=O), 1572, 1555 
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tert-butyl 2-(3-(pyridin-2-yl)phenyl)propanoate (3ad) 
 
2-Phenylpyridine (0.5 mmol, 0.07 mL), tert-butyl 2-bromopropanoate (1.5 mmol, 0.28 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (58 mg, 41%).  
1H NMR (500 MHz, CDCl3) δ 8.67 (ddd, J = 4.7, 1.3 Hz, 1H), 7.92 (dd, J = 1.8 Hz, 1H), 7.86 (ddd, 
J = 7.6, 1.4 Hz, 1H), 7.73 – 7.68 (m, 2H), 7.41 (dd, J = 7.6 Hz, 1H), 7.38 – 7.34 (m, 1H), 7.21 – 
7.17 (m, 1H), 3.71 (q, J = 7.2 Hz, 1H), 1.50 (d, J = 7.2 Hz, 3H), 1.39 (s, 9H). 13C NMR (126 MHz, 
CDCl3) δ 173.88, 157.50, 149.75, 141.84, 139.69, 136.80, 129.00, 128.01, 126.39, 125.58, 
122.20, 120.72, 80.64, 46.70, 28.07, 18.84. HR-MS (ESI) m/z: calculated for C18H21NO2 [M+H]+ 






2-Phenylpyridine (0.5 mmol, 0.07 mL), 2-bromo-1-phenylpropan-1-one (1.5 mmol, 0.23 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (59 mg, 41%).  
1H NMR (500 MHz, CDCl3) δ 8.71 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 8.00 – 7.99 (m, 1H), 7.98 – 7.96 
(m, 2H), 7.81 (ddd, J = 7.7, 1.7, 1.2 Hz, 1H), 7.74 (ddd, J = 7.8, 7.4, 1.8 Hz, 1H), 7.69 (ddd, J = 
8.0, 1.1 Hz, 1H), 7.48 – 7.44 (m, 1H), 7.42 – 7.35 (m, 3H), 7.34 – 7.32 (m, 1H), 7.23 (ddd, J = 7.3, 
4.8, 1.3 Hz, 1H), 4.80 (q, J = 6.9 Hz, 1H), 1.59 (d, J = 6.9 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 
200.42, 157.25, 149.69, 142.19, 140.13, 136.97, 136.56, 133.04, 132.94, 130.11, 129.51, 128.92, 
128.63, 128.41, 128.38, 126.66, 125.69, 122.39, 120.95, 77.16, 48.09, 19.76. HR-MS (ESI) m/z: 
calculated for C20H17NO [M+H]+ 288.138839, found: 288.141000. νmax (neat) / cm-1: 2974, 1678 




ethyl 4,4,4-trifluoro-2-(3-(pyridin-2-yl)phenyl)butanoate (3ai) 
 
2-Phenylpyridine (0.5 mmol, 0.07 mL), ethyl 2-bromo-4,4,4-trifluorobutanoate (1.5 mmol, 332 mg), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (65 mg, 40%).  
1H NMR (500 MHz, CDCl3) δ 8.70 (dd, J = 4.8, 0.7 Hz, 1H), 7.96 (s, 1H), 7.91 (d, J = 7.7 Hz, 1H), 
7.78 – 7.73 (m, 1H), 7.72 (d, J = 7.8 Hz, 1H), 7.46 (dd, J = 7.8 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 
7.25 – 7.22 (m, 1H), 4.25 – 4.16 (m, 1H), 4.14 – 4.06 (m, 1H), 3.99 (dd, J = 9.2, 4.7 Hz, 1H), 3.26 
– 3.09 (m, 1H), 2.61 – 2.46 (m, 1H), 1.21 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 172.00, 
156.91, 149.88, 140.35, 137.87, 136.94, 129.53, 128.08, 126.65, 126.47, 126.16 (q, J = 277.2 
Hz), 122.54, 120.79, 61.72, 45.60 (q, J = 2.8 Hz), 37.57 (q, J = 28.8 Hz), 14.10. 19F NMR (470 
MHz, CDCl3) δ -65.35 (t, J = 10.4 Hz). HR-MS (ESI) m/z: calculated for C20H17NO [M+Na]+ 
346.103083, found: 346.104300. νmax (neat) / cm-1: 2986, 1732 (C=O), 1585, 1567  
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ethyl 3-phenyl-2-(3-(pyridin-2-yl)phenyl)propanoate (3aj) 
 
2-Phenylpyridine (0.5 mmol, 0.07 mL), ethyl 2-bromo-3-phenylpropanoate (1.5 mmol, 384 mg), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 
(1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure 
to afford the title compound as a colourless oil (74 mg, 45%).  
1H NMR (500 MHz, CDCl3) δ 8.70 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.96 (dd, J = 1.6 Hz, 1H), 7.90 
(ddd, J = 7.2, 1.8 Hz, 1H), 7.77 – 7.72 (m, 1H), 7.70 (ddd, J = 8.0, 1.1 Hz, 1H), 7.46 – 7.38 (m, 
2H), 7.27 – 7.21 (m, 3H), 7.20 – 7.15 (m, 3H), 4.14 – 4.00 (m, 2H), 3.96 (dd, J = 9.3, 6.3 Hz, 1H), 
3.47 (dd, J = 13.7, 9.3 Hz, 1H), 3.09 (dd, J = 13.7, 6.3 Hz, 1H), 1.12 (t, J = 7.1 Hz, 3H). 13C NMR 
(126 MHz, CDCl3) δ 173.41, 157.35, 149.80, 139.89, 139.49, 139.19, 136.85, 129.16, 129.13, 
128.57, 128.45, 126.80, 126.50, 126.09, 122.31, 120.81, 77.16, 60.92, 53.91, 40.14, 14.18. HR-
MS (ESI) m/z: calculated for C22H21NO2 [M+Na]+ 354.146999, found: 354.147500. νmax (neat) / 




Determination of regioisomeric by-products  
Compounds 3ka-3ua contained significant amount of regioisomeric by-products. These reactions 
were conducted as per the general procedure and a mixed fraction was collected by column 
chromatography. The ratio between the major and minor isomer was determined by suitable 
signals in the 1H or 19F NMR spectra where available. The minor product was identified by 
literature reference where possible and when unavailable the regioselectivity is not stated. The 
major product in most cases could be further purified and are characterised below. 
 
Reaction with 2-(p-tolyl)pyridine 
 
2-(p-tolyl)pyridine (0.5 mmol, 85 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford a mixed fraction of title compound and a regioisomeric 
by-product (40 mg, 31%) major:minor 10:1 (determined from 1H spectra below). The major isomer 
was purified further by column chromatography and is characterised below. The minor isomer is 




ethyl 2-(2-methyl-5-(pyridin-2-yl)phenyl)acetate (3ma) 
 
1H NMR (500 MHz, CDCl3) δ 8.70 – 8.65 (m, 1H), 7.86 (d, J = 1.9 Hz, 1H), 7.80 (dd, J = 7.9, 2.0 
Hz, 1H), 7.76 – 7.67 (m, 2H), 7.28 (d, J = 7.9 Hz, 1H), 7.23 – 7.17 (m, 1H), 4.16 (q, J = 7.1 Hz, 
2H), 3.72 (s, 2H), 2.37 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 171.51, 
157.34, 149.73, 138.13, 137.46, 136.80, 133.53, 130.94, 128.93, 125.89, 122.03, 120.47, 60.99, 
39.62, 19.61, 14.36. HR-MS (ESI) m/z: calculated for C16H17NO2 [M+Na]+ 278.115698, found: 




Reaction with 2-(4-fluorophenyl)pyridine 
 
2-(4-fluorophenyl)pyridine (0.5 mmol, 87 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford a mixed fraction of title compound and a regioisomeric 
by-product (75 mg, 58%) major:minor 6:1 (determined from 1H and 19F spectra shown below). The 





ethyl 2-(2-fluoro-5-(pyridin-2-yl)phenyl)acetate (3na) 
 
1H NMR (500 MHz, CDCl3) δ 8.67 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.94 (dd, J = 7.2, 2.3 Hz, 1H), 
7.88 (ddd, J = 8.5, 5.0, 2.4 Hz, 1H), 7.76 – 7.71 (m, 1H), 7.68 (ddd, J = 8.0, 1.1 Hz, 1H), 7.22 
(ddd, J = 7.4, 4.8, 1.2 Hz, 1H), 7.18 – 7.13 (m, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.74 (d, J = 0.8 Hz, 
2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 170.70, 161.97 (d, J = 249.4 Hz), 
156.43, 149.79, 136.95, 135.72 (d, J = 3.4 Hz), 130.42 (d, J = 4.5 Hz), 127.76 (d, J = 8.6 Hz), 
122.23, 122.05 (d, J = 16.4 Hz), 120.44, 115.83 (d, J = 22.4 Hz), 61.24, 34.95 (d, J = 2.7 Hz), 
14.31. 19F NMR (470 MHz, CDCl3) δ -116.97 – -117.30 (m). HR-MS (ESI) m/z: calculated for 





Reaction with 2-(4-fluorophenyl)pyridine 
 
2-(4-fluorophenyl)-4-methylpyridine (0.5 mmol, 94 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford a mixed fraction of title compound and a regioisomeric 
by-product (90 mg, 66%) major:minor 5:1 (determined from 1H and 19F spectra shown below). The 





ethyl 2-(2-fluoro-5-(4-methylpyridin-2-yl)phenyl)acetate (3oa) 
 
1H NMR (500 MHz, CDCl3) δ 8.51 (d, J = 5.0 Hz, 1H), 7.92 (dd, J = 7.2, 2.3 Hz, 1H), 7.87 (ddd, 
J = 7.9, 5.0, 2.4 Hz, 1H), 7.50 (s, 1H), 7.14 (t, J = 9.0 Hz, 1H), 7.05 (dd, J = 5.0, 0.6 Hz, 1H), 
4.18 (q, J = 7.1 Hz, 2H), 3.74 (s, 2H), 2.40 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (126 MHz, 
CDCl3) δ 170.72, 161.89 (d, J = 248.9 Hz), 156.26, 149.44, 148.08, 130.42 (d, J = 4.5 Hz), 
127.78 (d, J = 8.5 Hz), 121.95 (d, J = 16.5 Hz), 118.11 (d, J = 22.0 Hz), 115.76 (d, J = 22.4 Hz), 
61.21, 34.93 (d, J = 2.6 Hz), 21.36, 14.30. 19F NMR (470 MHz, CDCl3) δ -115.47 – -119.82 (m). 
HR-MS (ESI) m/z: calculated for C16H16NO2 F [M+Na]+ 296.106277, found: 296.106700. νmax 




Reaction with 2-(4-fluorophenyl)pyridine 
 
 
ethyl 4-(pyridin-2-yl)benzoate (0.5 mmol, 114 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), 
[RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid 
(0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford a mixed fraction of title compound and a regioisomeric 
by-product (91 mg, 58%) major:minor 10:1 (determined from 1H spectra below). The major isomer 
was purified further by column chromatography and is characterised below. The minor isomer is 





ethyl 2-(2-ethoxy-2-oxoethyl)-4-(pyridin-2-yl)benzoate (3pa) 
 
1H NMR (500 MHz, CDCl3) δ 8.71 (ddd, J = 4.8, 1.4 Hz, 1H), 8.12 (d, J = 8.1 Hz, 1H), 7.95 (dd, J 
= 8.1, 1.9 Hz, 1H), 7.93 – 7.92 (m, 1H), 7.78 – 7.76 (m, 2H), 7.27 (ddd, J = 4.0, 3.5 Hz, 1H), 4.35 
(q, J = 7.1 Hz, 2H), 4.16 (q, J = 7.1 Hz, 2H), 4.11 (s, 2H), 1.39 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.1 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 171.51, 167.06, 156.05, 149.95, 142.79, 136.99, 136.61, 
131.65, 130.84, 130.45, 125.65, 122.98, 121.11, 61.15, 60.86, 41.08, 14.36, 14.32. HR-MS (ESI) 
m/z: calculated for C18H19NO4 [M+H]+ 314.139233, found: 314.141000. νmax (neat) / cm-1: 2982, 




Reaction with 2-(4-chlorophenyl)pyridine 
 
2-(4-chlorophenyl)pyridine (0.5 mmol, 95 mg), ethyl bromoacetate (1.5 mmol, 0.17 mL), [RuCl2(p-
cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic acid (0.15 
mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 mL) 
according to general procedure to afford a mixed fraction of title compound and a regioisomeric 
by-product (76 mg, 55%) major:minor 5:1 (determined from 1H spectra shown below). The major 






ethyl 2-(2-chloro-5-(pyridin-2-yl)phenyl)acetate (3qa) 
 
1H NMR (500 MHz, CDCl3) δ 8.68 (ddd, J = 4.8, 1.8, 1.0 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.84 
(dd, J = 8.3, 2.2 Hz, 1H), 7.77 – 7.73 (m, 1H), 7.71 (ddd, J = 8.0, 1.2 Hz, 1H), 7.48 (d, J = 8.3 Hz, 
1H), 7.24 (ddd, J = 7.3, 4.8, 1.3 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.85 (s, 2H), 1.27 (t, J = 7.1 Hz, 
3H). 13C NMR (126 MHz, CDCl3) δ 170.59, 156.18, 149.86, 138.31, 136.98, 135.61, 133.07, 
130.13, 129.93, 127.09, 122.55, 120.55, 61.21, 39.53, 14.32. HR-MS (ESI) m/z: calculated for 




Reaction with 2-(4-(trifluoromethyl)phenyl)pyridine 
 
2-(4-(trifluoromethyl)phenyl)pyridine (0.5 mmol, 112 mg), ethyl bromoacetate (1.5 mmol, 0.17 
mL), [RuCl2(p-cymene)]2 (5 mol%, 15 mg), Pd(PPh3)4 (10 mol%, 57 mg), 2,4,6-Trimethylbenzoic 
acid (0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-Dioxane (2 
mL) according to general procedure to afford a mixed fraction of title compound and a 
regioisomeric by-product (85 mg, 55%) major:minor 2.5:1 (determined from 1H and 19F spectra 






ethyl 2-(5-(pyridin-2-yl)-2-(trifluoromethyl)phenyl)acetate (3ra) 
 
1H NMR (500 MHz, CDCl3) δ 8.72 (ddd, J = 4.8, 1.7, 1.1 Hz, 1H), 8.05 (s, 1H), 7.99 (dd, J = 8.2, 
0.8 Hz, 1H), 7.82 – 7.73 (m, 3H), 7.30 (ddd, J = 6.7, 4.8, 2.0 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 
3.91 (d, J = 0.9 Hz, 2H), 1.25 (t, J = 7.1 Hz, 3H). 19F NMR (470 MHz, CDCl3) δ -59.91 (s). HR-MS 
(ESI) m/z: calculated for C18H18NO2F3 [M+H]+ 310.1055, found: 310.1097. νmax (neat) /        cm-1: 





Synthesis of complex A 
 
 
To an oven-dried, argon-purged Schlenk tube was added [Ru(p-cymene)Cl2]2 (612 mg, 1 mmol, 
MesCOOK (889 mg, 4.4 mmol) and DCM (50 mL). The vessel was then sealed and the reaction 
mixture was stirred at room temperature for 16 h. The reaction mixture was then filtered through 
a sinter funnel and eluted with DCM. The solvent was removed under vacuum to yield complex 
as a yellow solid (1.1 g, 95 % yield). 
1H NMR (500 MHz, CDCl3) δ 6.68 (s, 4H), 6.00 (d, J = 5.0 Hz, 2H), 5.79 (d, J = 5.2 Hz, 2H), 2.96 
(dt, J = 13.8, 6.9 Hz, 1H), 2.35 (s, 3H), 2.18 (s, 6H), 2.16 (s, 12H), 1.42 (d, J = 6.9 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 183.10, 137.43, 135.28, 134.56, 128.73, 127.91, 98.11, 79.01, 
78.20, 31.68, 22.74, 21.15, 19.96, 19.00. 
Reactions with ABCN 
 
2-Phenylpyridine (0.5 mmol, 0.07 mL), 1,1′-Azobis(cyclohexanecarbonitrile) (1 mmol, 244 mg), 
K2CO3 (1 mmol, 138 mg) and a catalyst were reacted together in 1,4-Dioxane (2 mL) in the 
amounts specified in a carousel tube. The carousel tube was then sealed and refluxed on a 
carousel at 120 °C for 15h. After cooling to room temperature the reaction mixture was dry loaded 






2-Phenylpyridine (0.5 mmol, 0.07 mL), 1,1′-Azobis(cyclohexanecarbonitrile) (1 mmol, 244 mg), 
Complex A (0.25mmol 141 mg), and K2CO3 (1 mmol, 138 mg) were reacted together in 1,4-
Dioxane (2 mL) according to general procedure to afford the title compound as a colourless oil 
(34 mg, 26%).  
1H NMR (500 MHz, CDCl3) δ 8.70 (d, J = 4.7 Hz, 1H), 8.14 (s, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.80 
– 7.72 (m, 2H), 7.57 (d, J = 7.9 Hz, 1H), 7.50 (dd, J = 7.8 Hz, 1H), 7.28 – 7.23 (m, 1H), 2.26 – 
2.17 (m, 2H), 1.94 – 1.81 (m, 8H). 13C NMR (126 MHz, CDCl3) δ 157.09, 149.90, 142.23, 140.28, 
136.98, 129.43, 126.51, 126.47, 124.30, 122.86, 122.55, 120.89, 77.16, 44.68, 37.54, 25.12, 
23.77. HR-MS (ESI) m/z: calculated for C18H18N2 [M+H]+ 263.154824, found: 263.156900. νmax 
(neat) / cm-1: 2934, 2229 (CN), 1584, 1566 
Reactions with primary alkyl halide n-Hex-Br 
 
2-Phenylpyridine (0.5 mmol, 0.07 mL), 1-bromohexane (210 µL, 1.5 mmol) [Ru(p-cymene)Cl2]2 
(15.0 mg, 0.025 mmol) 2,4,6-Trimethylbenzoic acid (0.15 mmol, 25 mg) and K2CO3 (1 mmol, 138 
mg) were reacted together in 1,4-Dioxane (2 mL) according to general procedure. After cooling 
to room temperature the reaction mixture was dry loaded onto silica and purified by silica gel 







1H NMR: (500 MHz, CDCl3) δ 8.69 (d, J = 4.2 Hz, 1H), 7.75 (t, J = 7.6 Hz, 1H), 7.41 – 7.23 (m, 
6H), 2.73 – 2.66 (m, 2H), 1.49 – 1.40 (m, 2H), 1.26 – 1.09 (m, 6H), 0.82 (t, J = 6.9 Hz, 2H). 13C 
NMR: (126 MHz, CDCl3) δ 160.32, 149.11, 140.77, 140.32, 136.03, 129.71, 129.69, 128.24, 
125.70, 124.08, 121.57, 32.92, 31.48, 31.23, 29.10, 22.48, 14.05. 
 





Computational Details / Methodology 
DFT calculations were run with Gaussian 09 (Revision D.01).14 Ru centers were described with 
the Stuttgart RECPs and associated basis sets,15 and 6-31G** basis sets were used for all other 
atoms.16,17Initial BP8618,19optimizations were performed using the ‘grid = ultrafine’ option, with all 
stationary points being fully characterized via analytical frequency calculations as minima (all 
positive eigenvalues). All energies were recomputed with a larger basis set featuring cc-pVTZ on 
Ru and 6-311++G** on all other atoms. Corrections for the effect of 1,4-dioxane (ε = 2.2099) 
solvent were run using the polarizable continuum model and BS1.20Single-point dispersion 
corrections to the BP86 results employed Grimme’s D3 parameter set with Becke-Johnson 
damping as implemented in Gaussian.21 Natural Bond Orbital (NBO) analysis calculations were 
also computed with Gaussian 09.  
 
Relative Fukui Index 
Relative nucleophilicity Fukui numbers were calculated by optimising the neutral molecule, and 
then performing NBO computations (nbo=npa, natural population analysis) on the neutral and 
cationic radical. For each atomic nucleophilicty Fukui number (𝑓𝐴
−) the NBO charge of the cationic 
calculation (𝑃𝐴(𝑁 − 1)) is subtracted from the neutral NBO charge value (𝑃𝐴(𝑁)) (see Eq. 1), 
before the values are scaled relative to the largest positive value of the molecule, which is 
normalised and equal to 1.00. This determines the nucleophilicty of atom A in molecule M (of N 
electrons), where P stands for the population of atom A in molecule M.  
𝑓𝐴
− = 𝑃𝐴(𝑁) − 𝑃𝐴(𝑁 − 1) (Eq. 1) 
N.B. N is the number of electrons of the original molecule / ion. The equilibrium geometry of the 
original molecule is used for the cationic radical calculation. We also note that using the total 
atomic charge values gives positive Fukui values, whilst using the local atomic charge values 


















C1 5.7782 5.8032 0.0249 0.179 
C3 5.9417 5.9865 0.0448 0.322 
C4 6.1694 6.2869 0.1175 0.844 
C5 6.2030 6.2137 0.0107 0.077 
C6 6.1815 6.2608 0.0793 0.570 
C7 5.9844 6.0783 0.0939 0.675 
C8 6.1544 6.2077 0.0533 0.383 
C9 6.2241 6.2432 0.0191 0.137 
C10 6.0996 6.2387 0.1391 1.000 
C11 6.2092 6.2445 0.0352 0.253 























C1 5.7730 5.7674 -0.0056 -0.109 
C3 5.9637 5.9667 0.0030 0.058 
C4 6.2629 6.2857 0.0228 0.441 
C5 6.1906 6.2117 0.0212 0.410 
C6 6.2343 6.2483 0.0141 0.272 
C7 6.0865 6.1169 0.0304 0.588 
C8 5.9875 5.9913 0.0038 0.073 
C9 6.2431 6.2608 0.0177 0.343 
C10 6.2141 6.2246 0.0106 0.205 
C11 6.2115 6.2632 0.0517 1.000 





















C1 5.7995 5.8020 0.0025 0.025 
C3 5.9540 5.9865 0.0325 0.329 
C4 6.1937 6.2924 0.0987 1.000 
C5 6.2036 6.2143 0.0107 0.108 
C6 6.1990 6.2636 0.0647 0.655 
C7 5.9953 6.1043 0.1090 1.104 
C8 6.1533 6.1904 0.0371 0.376 
C9 6.2831 6.3289 0.0458 0.464 
C10 5.6168 5.6853 0.0685 0.694 
C11 6.2227 6.2826 0.0599 0.607 























C1 5.7762 5.7685 -0.0076 -0.134 
C3 5.9629 5.9665 0.0036 0.063 
C4 6.2631 6.2910 0.0279 0.489 
C5 6.1933 6.2124 0.0191 0.335 
C6 6.2348 6.2521 0.0173 0.304 
C7 6.0864 6.1339 0.0474 0.831 
C8 5.9848 5.9863 0.0015 0.026 
C9 6.2985 6.3038 0.0053 0.093 
C10 5.6558 5.6706 0.0149 0.260 
C11 6.2873 6.3444 0.0570 1.000 






















C1 5.7837 5.8035 0.0198 0.173 
C3 5.9425 5.9855 0.0429 0.375 
C4 6.1730 6.2875 0.1145 1.000 
C5 6.2026 6.2129 0.0103 0.090 
C6 6.1858 6.2618 0.0760 0.664 
C7 5.9936 6.0934 0.0997 0.871 
C8 6.1555 6.1964 0.0409 0.358 
C9 6.2746 6.3133 0.0387 0.338 
C10 5.4850 5.5838 0.0988 0.863 
C11 6.2666 6.3149 0.0483 0.422 
























C1 5.7740 5.7679 -0.0061 -0.117 
C3 5.9632 5.9662 0.0030 0.058 
C4 6.2629 6.2871 0.0243 0.467 
C5 6.1906 6.2109 0.0203 0.391 
C6 6.2350 6.2500 0.0150 0.288 
C7 6.0931 6.1290 0.0359 0.690 
C8 5.9835 5.9843 0.0008 0.015 
C9 6.3215 6.3326 0.0111 0.214 
C10 5.5590 5.5710 0.0119 0.230 
C11 6.2798 6.3318 0.0520 1.000 


















C1 5.7761 5.8076 0.0315 0.272 
C3 5.9386 5.9846 0.0460 0.397 
C4 6.1658 6.2815 0.1157 1.000 
C5 6.2012 6.2119 0.0107 0.092 
C6 6.1791 6.2574 0.0783 0.676 
C7 5.9854 6.0644 0.0791 0.683 
C8 6.1497 6.2024 0.0527 0.456 
C9 6.2018 6.2178 0.0159 0.138 
C10 6.0397 6.1683 0.1286 1.111 
C11 6.1901 6.2191 0.0290 0.251 
























C1 5.7745 5.7699 -0.0046 -0.101 
C3 5.9632 5.9657 0.0025 0.055 
C4 6.2607 6.2811 0.0205 0.452 
C5 6.1895 6.2106 0.0211 0.467 
C6 6.2327 6.2452 0.0125 0.276 
C7 6.0800 6.1053 0.0253 0.559 
C8 5.9903 5.9898 -0.0004 -0.009 
C9 6.2180 6.2330 0.0150 0.331 
C10 6.1433 6.1565 0.0132 0.291 
C11 6.1959 6.2412 0.0453 1.000 
C12 6.2041 6.2106 0.0065 0.144 
 
 
Cartesian Coordinates and Computed Energies (in Hartrees)  
Substrates (1x) 
1a (X = H) 
SCF (BP86) Energy = -479.337880828 
Enthalpy 0K = -479.173092 
Enthalpy 298K = -479.163055 
Free Energy 298K = -479.208178 
Lowest Frequency = 40.4788 cm-1 
Second Frequency = 91.3214 cm-1 
 
C  -2.82035 -1.22021 -0.17267 
C  -1.42052 -1.18871 -0.16232 
C  -0.72639  0.03150  0.00415 
C  -1.47865  1.21540  0.17687 
C  -2.88013  1.18211  0.16868 
C  -3.55762 -0.03489 -0.01029 
H  -3.34010 -2.17463 -0.30931 
H  -0.83155 -2.10242 -0.28030 
H  -0.97109  2.17066  0.34550 
H  -3.44471  2.10971  0.31090 
H  -4.65241 -0.05969 -0.01750 
C   0.76442  0.03286 -0.00013 
C   1.51734  1.21497 -0.19225 
C   2.91522  1.14948 -0.17420 
H   1.01709  2.17021 -0.37488 
C   2.71056 -1.21703  0.18185 
C   3.53611 -0.09242  0.02285 
H   3.51132  2.05634 -0.32171 
H   3.15301 -2.21220  0.32554 
H   4.62554 -0.19184  0.04418 
N   1.36757 -1.17207  0.17462 
 
 
1k (X = OMe) 
SCF (BP86) Energy = -593.863940782 
Enthalpy 0K = -593.667613 
Enthalpy 298K = -593.654912 
Free Energy 298K = -593.706377 
Lowest Frequency = 29.8744 cm-1 
Second Frequency = 57.4225 cm-1 
 
C   2.01418 -0.98160  0.09028 
C   0.61450 -1.02948  0.09002 
C  -0.16895  0.14003 -0.01269 
C   0.51046  1.37743 -0.13072 
C   1.90359  1.44261 -0.13441 
C   2.66962  0.26201 -0.02003 
H   2.58242 -1.91111  0.17780 
H   0.09410 -1.98798  0.16942 
H  -0.05230  2.30950 -0.24307 
H   2.42732  2.39798 -0.23289 
C  -1.65226  0.03615 -0.00037 
C  -2.49219  1.16593  0.15249 
C  -3.88098  0.99759  0.14465 
H  -2.06637  2.16339  0.29298 
C  -3.50574 -1.35749 -0.12953 
C  -4.41188 -0.29247 -0.00391 
H  -4.54066  1.86419  0.26135 
H  -3.87438 -2.38700 -0.23689 
H  -5.49117 -0.47166 -0.01523 
N  -2.16995 -1.21480 -0.13193 
O   4.02982  0.43422 -0.03098 
C   4.84221 -0.73707  0.07178 
H   5.88307 -0.38375  0.04111 
H   4.66671 -1.27405  1.02343 
H   4.66688 -1.43130 -0.772037 
1n (X = F) 
SCF (BP86) Energy = -578.572206709 
Enthalpy 0K = -578.415442 
Enthalpy 298K = -578.404536 
Free Energy 298K = -578.451895 
Lowest Frequency = 36.9301 cm-1 
Second Frequency = 70.8050 cm-1 
 
C   2.38679 -1.21663  0.14979 
C   0.98861 -1.17753  0.14133 
C   0.28935  0.04353 -0.00427 
C   1.04079  1.23093 -0.15838 
C   2.44141  1.20964 -0.15412 
C   3.09545 -0.01759  0.00432 
H   2.93311 -2.15646  0.26826 
H   0.40298 -2.09482  0.24515 
H   0.53542  2.18988 -0.30831 
H   3.02826  2.12337 -0.28033 
C  -1.20029  0.03781  0.00079 
1r (X = CF3) 
SCF (BP86) Energy = -816.373644785 
Enthalpy 0K = -816.204505 
Enthalpy 298K = -816.190700 
Free Energy 298K = -816.246328 
Lowest Frequency = 16.2999 cm-1 
Second Frequency = 40.1890 cm-1 
 
C   1.28342 -1.19370  0.11775 
C  -0.11405 -1.16842  0.12296 
C  -0.81887  0.04814 -0.02443 
C  -0.07593  1.23758 -0.19770 
C   1.32337  1.21670 -0.20530 
C   2.00937  0.00061 -0.04341 
H   1.81752 -2.14133  0.23131 
H  -0.69378 -2.08824  0.23579 
H  -0.58826  2.19135 -0.35614 
H   1.88705  2.14181 -0.35372 
C  -2.30983  0.03721 -0.00476 
 211 
 
C  -1.96223  1.21761  0.17220 
C  -3.35949  1.14099  0.15496 
H  -1.47142  2.18093  0.33712 
C  -3.13777 -1.22952 -0.16018 
C  -3.97171 -0.10871 -0.02027 
H  -3.96205  2.04607  0.28607 
H  -3.57229 -2.23041 -0.28680 
H  -5.06032 -0.21634 -0.03976 
N  -1.79519 -1.17404 -0.15404 
F   4.45191 -0.04523  0.01110 
 
C  -3.07061  1.21342  0.18653 
C  -4.46827  1.13266  0.18511 
H  -2.57938  2.17580  0.35527 
C  -4.24242 -1.23508 -0.15840 
C  -5.07719 -0.11720  0.00326 
H  -5.07245  2.03394  0.33262 
H  -4.67574 -2.23538 -0.29157 
H  -6.16561 -0.22810 -0.00519 
N  -2.90020 -1.17529 -0.16526 
C   3.51753 -0.01598  0.01272 
F   4.03125 -1.18693 -0.46120 
F   3.97343  0.12619  1.29330 
F   4.06565  0.99868 -0.71627 
 
 




SCF (BP86) Energy = -1501.49589663 
Enthalpy 0K = -1500.950642 
Enthalpy 298K = -1500.914203 
Free Energy 298K = -1501.019014 
Lowest Frequency = 15.0912 cm-1 
Second Frequency = 22.6119 cm-1 
 
Ru  1.09279 -0.58811 -0.23800 
O  -0.99310 -0.33503 -0.37229 
C  -1.83608 -0.85993  0.49544 
C   1.70311 -2.33692 -1.68337 
C   2.77852 -1.43861 -1.35879 
C   3.24098 -1.22200 -0.01410 
C   0.92173 -2.88360 -0.63331 
O  -1.54666 -1.64375  1.42173 
C   4.52745 -0.44065  0.23171 
H   4.56150  0.36096 -0.53289 
C   1.12380  2.20706  0.73101 
C   1.13624  3.29468  1.63481 
C   1.00271  0.85992  1.19185 
C   0.99734  3.06267  3.00657 
H   1.24007  4.32273  1.26818 
C   0.81795  0.66161  2.57779 
C   0.82095  1.74474  3.47283 
H   1.00642  3.90163  3.70972 
H   0.64412 -0.34955  2.95958 
H   0.68044  1.56159  4.54449 
N   1.08333  1.14902 -1.39298 
C   1.14732  2.35084 -0.72097 
C   2.43118 -1.79546  1.02688 
C   1.28572 -2.59500  0.73584 
H   0.63398 -2.93360  1.54239 
H   2.65958 -1.56710  2.07180 
H   3.30310 -0.92524 -2.17433 
H   1.42460 -2.51419 -2.72621 
C   5.74570 -1.36727 -0.00596 
Ak 
SCF (BP86) Energy = -1616.02247516 
Enthalpy 0K = -1615.445770 
Enthalpy 298K = -1615.406604 
Free Energy 298K = -1615.517575 
Lowest Frequency = 16.0708 cm-1 
Second Frequency = 19.0663 cm-1 
 
Ru -1.03514 -0.90512 -0.02131 
O   1.05146 -0.71808  0.20241 
C   1.87741 -0.58850 -0.81650 
C  -1.59432 -3.18634  0.00441 
C  -2.68472 -2.30692  0.33350 
C  -3.18059 -1.30231 -0.56770 
C  -0.83461 -2.93472 -1.16580 
O   1.57899 -0.67199 -2.02481 
C  -4.48247 -0.57289 -0.25273 
H  -4.51308 -0.44008  0.84714 
C  -1.12536  1.85884  1.02853 
C  -1.16905  3.26879  1.02030 
C  -1.01196  1.12550 -0.19800 
C  -1.07621  3.98262 -0.17907 
H  -1.26297  3.82916  1.95805 
C  -0.87946  1.85416 -1.38866 
C  -0.91446  3.26754 -1.38885 
H  -1.11184  5.07410 -0.16530 
H  -0.71910  1.35059 -2.34670 
N  -1.00009 -0.30904  1.97965 
C  -1.09731  1.04367  2.23254 
C  -2.39008 -1.07381 -1.74792 
C  -1.23193 -1.85351 -2.04054 
H  -0.59608 -1.59406 -2.88801 
H  -2.64380 -0.24190 -2.41116 
H  -3.19353 -2.43300  1.29735 
H  -1.29039 -3.97555  0.69831 
C  -5.68226 -1.46833 -0.65021 
H  -6.63558 -0.98461 -0.37504 
H  -5.69332 -1.64345 -1.74063 
H  -5.64056 -2.45155 -0.15160 
 212 
 
H   6.68871 -0.80480  0.10687 
H   5.75469 -2.19449  0.72572 
H   5.73038 -1.81103 -1.01588 
C   4.61020  0.22471  1.61672 
H   3.73282  0.86055  1.81495 
H   4.68226 -0.52752  2.42262 
H   5.51614  0.85116  1.67876 
C  -0.28582 -3.73965 -0.91545 
H  -0.67059 -3.57640 -1.93442 
H  -0.01864 -4.80783 -0.81432 
H  -1.08125 -3.51597 -0.18874 
C   1.17536  3.56172 -1.44496 
H   1.22932  4.50815 -0.90041 
C   1.11720  3.54964 -2.83994 
H   1.13958  4.48831 -3.40234 
C   1.01036  2.31627 -3.50725 
H   0.93735  2.25568 -4.59619 
C   0.98983  1.14602 -2.74583 
H   0.89190  0.16018 -3.20725 
C  -3.27846 -0.43146  0.26098 
C  -4.30465 -1.41625  0.22431 
C  -3.61805  0.94256  0.13605 
C  -5.63702 -1.00955  0.03410 
C  -4.96974  1.30007 -0.02961 
C  -5.99545  0.34338 -0.09737 
H  -6.42040 -1.77769 -0.00059 
H  -5.22506  2.36493 -0.10613 
C  -4.01061 -2.89446  0.38023 
H  -3.37949 -3.27053 -0.44561 
H  -3.46117 -3.08688  1.31455 
H  -4.94492 -3.47956  0.37662 
C  -7.43627  0.75156 -0.32092 
H  -7.70325  0.71430 -1.39391 
H  -8.13441  0.08103  0.20857 
H  -7.62331  1.78183  0.02532 
C  -2.58174  2.04548  0.20195 
H  -1.89065  1.91305  1.05025 
H  -1.95807  2.05955 -0.70697 
H  -3.07232  3.02790  0.30567 
 
 
C  -4.60249  0.81825 -0.89955 
H  -3.73644  1.45409 -0.65683 
H  -4.68175  0.74706 -1.99917 
H  -5.51720  1.32088 -0.54195 
C   0.38334 -3.75490 -1.50443 
H   0.78583 -4.26908 -0.61740 
H   0.12100 -4.52072 -2.25770 
H   1.16274 -3.10652 -1.93214 
C  -1.11227  1.50864  3.56680 
H  -1.19381  2.58224  3.75700 
C  -1.00763  0.60860  4.62770 
H  -1.01945  0.96940  5.66106 
C  -0.86860 -0.76384  4.34931 
H  -0.75919 -1.50482  5.14530 
C  -0.86318 -1.17385  3.01493 
H  -0.74213 -2.22366  2.73598 
C   3.31713 -0.33434 -0.38885 
C   4.36227 -1.12187 -0.94632 
C   3.63312  0.71583  0.51401 
C   5.69121 -0.86328 -0.56707 
C   4.98151  0.94974  0.84504 
C   6.02676  0.16655  0.32920 
H   6.48975 -1.48188 -0.99678 
H   5.21822  1.77484  1.52936 
C   4.09010 -2.23502 -1.93751 
H   3.47705 -3.03688 -1.48719 
H   3.52978 -1.85500 -2.80576 
H   5.03352 -2.69050 -2.28079 
C   7.46479  0.41016  0.73605 
H   7.76320 -0.24757  1.57412 
H   8.16132  0.20851 -0.09563 
H   7.62074  1.45047  1.06742 
C   2.57273  1.61483  1.11529 
H   1.87157  1.99306  0.35329 
H   1.96196  1.07041  1.85383 
H   3.03997  2.47999  1.61515 
O  -0.78829  3.85801 -2.61950 
C  -0.78211  5.28570 -2.67592 
H  -0.65165  5.54282 -3.73707 
H  -1.73531  5.71476 -2.31160 
H   0.05434  5.71347 -2.09127 
 
An 
SCF (BP86) Energy = -1600.73161489 
Enthalpy 0K = -1600.194438 
Enthalpy 298K = -1600.157053 
Free Energy 298K = -1600.264277 
Lowest Frequency = 13.4396 cm-1 
Second Frequency = 20.9685 cm-1 
 
Ru -1.06752  0.69798 -0.24615 
O   1.01889  0.46121 -0.40328 
C   1.85223  0.80909  0.55826 
C  -1.66737  2.70179 -1.31196 
C  -2.74884  1.76274 -1.17482 
Ar 
SCF (BP86) Energy = -1838.53275869 
Enthalpy 0K = -1837.983312 
Enthalpy 298K = -1837.942943 
Free Energy 298K = -1838.058889 
Lowest Frequency = 10.5599 cm-1 
Second Frequency = 15.7328 cm-1 
 
Ru -0.91919 -1.12082 -0.27695 
O   1.16011 -0.92752 -0.01908 
C   1.92919 -0.30218 -0.89102 
C  -1.32671 -3.25110 -1.17486 
C  -2.46067 -2.67301 -0.50624 
 213 
 
C  -3.21436  1.28463  0.09847 
C  -0.88739  3.02733 -0.17343 
O   1.55325  1.41028  1.60942 
C  -4.50669  0.47918  0.18297 
H  -4.54745 -0.15020 -0.72830 
C  -1.11861 -2.23803  0.10990 
C  -1.14151 -3.49016  0.76601 
C  -1.00022 -1.01708  0.84737 
C  -1.02139 -3.56190  2.15623 
H  -1.24091 -4.41972  0.19404 
C  -0.83580 -1.10708  2.24458 
C  -0.85476 -2.36130  2.86613 
H  -1.03436 -4.51421  2.69195 
H  -0.66563 -0.21751  2.85727 
N  -1.04860 -0.75735 -1.74193 
C  -1.12343 -2.07340 -1.33802 
C  -2.40365  1.63495  1.23404 
C  -1.25502  2.47154  1.10987 
H  -0.60373  2.63979  1.96849 
H  -2.63597  1.20458  2.21235 
H  -3.27384  1.42538 -2.07715 
H  -1.38642  3.08233 -2.29831 
C  -5.71695  1.44509  0.14088 
H  -6.66463  0.87925  0.13972 
H  -5.71832  2.10684  1.02505 
H  -5.69844  2.08406 -0.75823 
C  -4.59529 -0.45276  1.40426 
H  -3.72426 -1.12415  1.46681 
H  -4.65938  0.12007  2.34666 
H  -5.50718 -1.07014  1.33979 
C   0.32202  3.91985 -0.27778 
H   0.71025  3.95886 -1.30770 
H   0.05513  4.94789  0.02965 
H   1.11441  3.55702  0.39387 
C  -1.14704 -3.10466 -2.30189 
H  -1.20986 -4.14467 -1.97076 
C  -1.07421 -2.79892 -3.66186 
H  -1.09310 -3.59813 -4.40938 
C  -0.95764 -1.45304 -4.05396 
H  -0.87350 -1.16498 -5.10496 
C  -0.94170 -0.46995 -3.06286 
H  -0.83648  0.59051 -3.30514 
C   3.29505  0.41851  0.26809 
C   4.32598  1.38767  0.41489 
C   3.62931 -0.91526 -0.08937 
C   5.65862  1.01106  0.17209 
C   4.98103 -1.24792 -0.29951 
C   6.01206 -0.30096 -0.18834 
H   6.44608  1.76800  0.28062 
H   5.23224 -2.28512 -0.55645 
C   4.03586  2.81773  0.82281 
H   3.41703  3.33608  0.06770 
H   3.47570  2.84714  1.77010 
H   4.97227  3.38883  0.93300 
C   7.45352 -0.67444 -0.46253 
C  -3.06074 -1.43079 -0.91191 
C  -0.63688 -2.48551 -2.15033 
O   1.56802  0.14562 -1.99721 
C  -4.39283 -0.99613 -0.31018 
H  -4.39010 -1.33773  0.74417 
C  -1.11696  1.00038  1.77458 
C  -1.24632  2.29264  2.33145 
C  -1.00624  0.80735  0.36300 
C  -1.24518  3.41586  1.50157 
H  -1.33510  2.42888  3.41518 
C  -0.95538  1.96011 -0.44733 
C  -1.08282  3.24455  0.11163 
H  -1.34241  4.42031  1.92079 
H  -0.78470  1.86356 -1.52312 
N  -0.85227 -1.35733  1.79409 
C  -1.00740 -0.22443  2.56301 
C  -2.33916 -0.68086 -1.90402 
C  -1.14512 -1.18019 -2.50527 
H  -0.56890 -0.55101 -3.18503 
H  -2.67964  0.32392 -2.17018 
H  -2.91988 -3.22095  0.32602 
H  -0.93945 -4.22647 -0.86657 
C  -5.54701 -1.72964 -1.03781 
H  -6.51763 -1.47751 -0.57690 
H  -5.58894 -1.43227 -2.10052 
H  -5.42343 -2.82521 -0.99881 
C  -4.62469  0.52501 -0.31299 
H  -3.79585  1.06279  0.17397 
H  -4.73518  0.91693 -1.33970 
H  -5.55774  0.76360  0.22482 
C   0.62000 -2.99644 -2.80539 
H   1.10009 -3.78457 -2.20443 
H   0.37777 -3.41840 -3.79825 
H   1.33032 -2.16860 -2.94979 
C  -0.99801 -0.31776  3.96992 
H  -1.12560  0.58888  4.56728 
C  -0.81053 -1.55461  4.59114 
H  -0.80343 -1.62988  5.68286 
C  -0.61267 -2.69437  3.79208 
H  -0.43795 -3.68031  4.23049 
C  -0.63408 -2.54913  2.40330 
H  -0.46974 -3.39623  1.73285 
C   3.37513 -0.17692 -0.43205 
C   4.42575 -0.53082 -1.32425 
C   3.68932  0.34451  0.85190 
C   5.75905 -0.38539 -0.90275 
C   5.04074  0.49215  1.21779 
C   6.09307  0.12254  0.36478 
H   6.56199 -0.66802 -1.59568 
H   5.27416  0.91418  2.20380 
C   4.15848 -1.06338 -2.71734 
H   3.62480 -2.03080 -2.68538 
H   3.52383 -0.36719 -3.28679 
H   5.10445 -1.22451 -3.25984 
C   7.53783  0.25178  0.79854 
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H   7.73306 -0.45737 -1.51073 
H   8.14839 -0.10805  0.18060 
H   7.63182 -1.74971 -0.29426 
C   2.58632 -2.00530 -0.22528 
H   1.89316 -2.02175  0.63169 
H   1.96602 -1.85282 -1.12365 
H   3.07016 -2.99386 -0.29644 
F  -0.71098 -2.42663  4.21507 
H   7.92065 -0.70061  1.21120 
H   8.19222  0.52278 -0.04742 
H   7.65776  1.01819  1.58235 
C   2.62404  0.77980  1.83714 
H   1.86092  1.41818  1.36273 
H   2.08857 -0.08867  2.25458 
H   3.07784  1.34502  2.66841 
C  -1.12166  4.44665 -0.80147 
F  -0.75323  5.59357 -0.16011 
F  -0.30453  4.29915 -1.88038 
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